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Abstract 
Abstract 
Amyloid fibrils are a type of protein nanofibres that form when a normally soluble protein 
aggregates in a regular fashion via self-association. Their organised and repetitive β-sheet 
structure is thought to be a generic property of all proteins, depending on the environmental 
conditions. The nanometre size and high stability of these protein nanofibres are attractive 
features to exploit in bionanomaterials.  
 
This thesis aimed to manipulate insulin amyloid fibrils, as a model protein nanofibre system, 
through investigating the effect of chemical modification on insulin fibril formation in 
heterogeneous mixtures. Using acetylation, reduction carboxymethylation, reduction 
pyridylethylation, trypsin digestion and chymotrypsin digestion, it was shown that 
nanofibres can form in heterogeneous mixtures of modified insulin at variable rates to 
produce fibrils of distinct morphologies. Distinctively well defined, long, unbranched 
nanofibres were observed in the crude reduced carboxymethylated insulin mixture after 
incubation at 60°C (pH 7.4), which formed at a faster rate than native insulin. The crude 
reduced pyridylethylated insulin revealed the formation of “wavy” fibrils when exposed to 
60°C and pH 1.6, compared to the straight native insulin amyloid fibrils. Although, the 
trypsin digestion inhibited nanofibre formation at 60°C and pH 1.6, chymotrypsin digestion 
of insulin produced a mixture of long and short nanofibres under the same conditons. Thus 
chemical modification provides a simple means of manipulating protein nanofibre assembly 
for use in bionanotechnology. 
 
Protein nanofibres were incorporated into a model polymer polyvinylalcohol (PVOH) film in 
order to assess the impact on material properties. A systematic study involving both insulin 
and a crude source of crystallin proteins derived from bovine eye lens was undertaken. A 
protein nanofibre-PVOH nanocomposite was successfully fabricated by a procedure of 
solution mixing and casting. Dynamic mechanical analysis showed that the addition of 
insulin fibrils did not change the stiffness of the PVOH. However, an increase in the 
stiffness of the PVOH-crude bovine eye lens composites was found. Both insulin and 
bovine eye lens nanofibres reduced the damping properties of the polymer, which 
suggested a reduction in molecular mobility/slipping.  
 
The results revealed that protein nanofibre formation can be controlled through the 
modification of the protein and that nanofibres may alter polymer properties in a protein 
specific manner. Employing these findings in the development of novel bionanomaterials 
that use the protein nanofibres as a form of natural scaffolding offers a fruitful avenue of 
future research. 
 xvi
Chapter 1 Introduction 
 
 
Introduction 
 
This thesis aims to explore the self-assembly of amyloid fibrils from a model 
protein (bovine insulin) with the long term aim of using amyloid fibrils made from 
cheap, readily available proteins. The nanosized structure of fibrils, together 
with their strength and chemical functionality, inspired this study for their 
potential use in bionanomaterials. 
Amyloid fibrils are formed when a normally soluble protein self associates into 
an insoluble β-sheet aggregate. Studies have shown that these structures are 
highly ordered and generic to most, if not all, proteins. Although amyloid fibrils 
have been of wide interest from the medical perspective, their potential as 
bionanomaterials is less well explored. This chapter will provide a background 
on the ability of proteins to form amyloid fibrils and the factors affecting their 
formation. It will also highlight the current prospects of fibrils in the development 
of bionanomaterials.  
1.1 What are Amyloid Fibrils? 
 
Amyloid fibrils are highly ordered, insoluble aggregates of proteins or 
polypeptides that arise when the proteins’ or polypeptides’ normally soluble, 
native structures are partially denatured and the denatured species self-
assemble into structured nanofibres (Chiti and Dobson 2006). They have been 
reviewed in detail in a number of papers due to their association with a growing 
number of human diseases, including Alzheimer's disease, Parkinson's disease, 
Huntington's disease, prion diseases, and numerous others (Chiti and Dobson 
2006, Pedersen and Otzen 2008, Sipe and Cohen 2000). However, in the early 
days, the term "amyloid" was used to describe histological deposits, as it was 
thought that they were composed of starch (Cohen and Calkins 1959, Sipe and 
Cohen 2000). Today, it is known that protein constitutes the main component of 
 1
Chapter 1 Introduction 
amyloid deposits. The term amyloid is now assigned to aggregates that have a 
highly ordered molecular assembly and satisfy other criteria, including the ability 
to bind and shift the spectral properties of certain hydrophobic dyes  (Eisert et 
al. 2006, Krebs et al. 2005, Nilsson 2004) and a strong scattering of X-rays at 
an angle corresponding to a 4.7 Å molecular spacing along the same direction 
as the fibre and a more diffuse reflection at 10 Å perpendicular to the fibre 
direction (Sunde et al. 1997), being diagnostic for ordered β-sheet structure 
(Makin and Serpell 2005, Nelson and Eisenberg 2006). The X-ray diffraction 
patterns for amyloid fibrils can be visualised by clear arcs at the two different 
angles. A model of amyloid fibril structure, as a protein or peptide cross-β core 
with β-strands stacked in β-sheets along the fibril axis and adjacent β-sheets 
stacked perpendicular to the fibril axis was first proposed in the 1950s (Cohen 
and Calkins 1959). 
 
Other than the cross β-sheet structure, amyloid fibrils have been proposed to 
have structures including β-helices and concentric cylinders (Perutz et al. 2002, 
Wille et al. 2002), which are water filled. In contrast, a recent review has 
suggested that there is no difference in the hydrated and dried fibril structures 
from transthyretin (TTR) and lysozyme (Squires et al. 2006). This suggests that 
hydrated fibril structures do not contain water within the fibril core and are 
unlikely to be hollow nanotubes, hence being referred to as nanofibres (Gras 
2007a). A review by Makin and Serpell (2005) discussed amyloid structure in 
detail adding further support for the cross-β fibril structure (section 1.4). 
In addition to over 25 different proteins associated with different amyloid 
pathologies (Krishnan and Lindquist 2005) many other nonpathogenic proteins 
can be induced to form the amyloid structure in vitro (Stefani and Dobson 
2003). These attributes make the amyloid structure broadly interesting, not only 
from the point of view of human disease but also in terms of fundamental 
aspects of protein folding and function. The formation of these “non-native” 
protein structures has long been the subject of much research in the biomedical 
arena, given the manifestation of amyloid fibrils with the diseases of protein 
misfolding (Krishnan and Lindquist 2005, Westermark et al. 2005). Thus there is 
considerable literature on protein fibril formation in vivo, and some well 
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characterised examples of proteins from which fibrils can be formed. Other than 
their association with disease, amyloid fibrils have been found to play useful 
biological roles in spider silk (Kenney et al. 2002), moth silk (Iconomidou et al. 
2000), curli protein in bacteria (Chapman et al. 2002), SUP35 protein in yeast 
(King et al. 1997), bacterial inclusion bodies (Carrio et al. 2005) and recently in 
melanosomes of humans (Dantzker 2005, Fowler et al. 2006) and fungal spores 
(Kwan et al. 2006). 
 
Among the proteins that form well defined fibrils is the 84-residue SH3 domain 
of the p85a subunit of bovine phosphatidylinositol-3׳-kinase, which forms 
amyloid fibrils at low pHs (Chiti et al. 1999, Guijarro et al. 1998). An example of 
a molecular model of an amyloid fibril derived from cryo-EM analysis of fibrils 
grown from a SH3 domain is shown in Figure 1.1. The fibril consists of four 
‘protofilaments’ that twist around one another to form a hollow fibre with a 
diameter of approximately 60 Å (Jiménez et al. 1999). This particular model 
represents one way in which regions of the polypeptide chain involved in β-
sheet structure could be assembled within the fibrils (Dobson 1999). 
Cryoelectron microscopy characterisation of insulin fibrils on the other hand 
have revealed two, four, or six protofilaments per insulin fibril, with the cross β-
sheet structure composed of relatively flat β-sheets (Jiménez et al. 2002). The 
structural features of amyloid fibril are further described in section 1.4. 
 
Other proteins that are not known to form fibrils in disease or nature but can be 
induced to form fibrils in vitro, include bovine insulin (Nielsen et al. 2001c), 
bovine crystallins (Garvey et al. 2008), wheat proteins (Mackintosh et al. 2008), 
hen egg lysozyme (Krebs et al. 2000), α-lactoglobulin (Graveland-Bikker and de 
Kruif 2006), milk proteins (Thorn et al. 2005), ovalbumin and bovine serum 
albumin (Pearce et al. 2007). Of the several proteins available, bovine insulin 
was selected to be the model protein in this thesis because it has been well 
characterised from the fibril forming perspective (Brange et al. 1997a, Brange et 
al. 1997b, Jiménez et al. 2002, Nielsen et al. 1999, Nielsen et al. 2001a, 
Nielsen et al. 2001b, Nielsen et al. 2001c) and was available at reasonable 
cost. 
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In most cases, fibrils are obtained by altering conditions such as pH or 
temperature, or by altering salt or metal ion concentrations, or by using solvents 
and chaotropic agents, which suggests fibril formation in vitro is dependent on 
conformational stability of the protein (Aggeli et al. 2001, Calamai et al. 2005, 
Chiti et al. 1999, Ramirez-Alvarado et al. 2000, Smith et al. 2003). Thus it is 
becoming apparent that the formation of amyloid fibrils may be a generic feature 
of proteins that can be induced given the appropriate physical and chemical 
conditions (Dobson and Karplus 1999, Fändrich et al. 2001, Fändrich et al. 
2003, Guijarro et al. 1998). 
 
 
 
Figure 1.1 Molecular model of an amyloid fibril derived from cryo-EM analysis of fibrils 
grown from an SH3 domain showing one way in which regions of the polypeptide chain 
involved in β-sheet structure is assembled within the fibrils, from (Dobson 1999). 
 
Although amyloid fibrils can be formed from a diverse group of proteins either 
as complete peptides or cleaved peptide fragments, the final conformation of 
the amyloid structure remains morphologically very similar, regardless of the 
protein source (Makin and Serpell 2002, Sunde et al. 1997). The ability to form 
amyloid is dependent on the common feature among all proteins, the 
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polypeptide chain backbone, but the propensity to form amyloid fibrils depends 
on sequence (Esteras-Chopo et al. 2005, Fändrich and Dobson 2002, Lopez de 
la Paz and Serrano 2004) which has allowed the design of de novo sequences 
which readily form fibrils (Lopez de la Paz et al. 2002, Lopez de la Paz and 
Serrano 2004). Prediction algorithms have been published attempting to predict 
amyloidogenic regions in protein sequences (Galzitskaya et al. 2006, Pawar et 
al. 2005, Thompson et al. 2006); these will be discussed further in section 1.5. 
 
1.2 Protein Folding and Misfolding 
 
Proteins have to leave a disorganised state and enter a highly organised state 
to be able to function (Dobson 2003). This process, known as protein folding, is 
of vital importance because proteins enable or control essentially every 
chemical process that takes place in all living organisms. Given that the amyloid 
state may represent a primitive ground state of protein folding and assembly 
reactions, research into the specific features of polypeptides that ensure folding 
to the correct, functional native state has increased tremendously (Chen et al. 
2008, Dobson 2003, Dobson 2004b, Harrison et al. 2007, Jahn and Radford 
2008).  
 
Figure 1.2 illustrates the various states that can be attained by a protein once it 
is synthesised on the ribosome. Depending on the details of the external 
conditions (temperature, pH, solution composition) different conformational 
changes may lead to different aggregation pathways, resulting in structurally 
different supramolecular aggregates, such as amorphous aggregates or 
amyloid fibrils (Hamada and Dobson 2002). 
 
In living systems, transitions between the different states are highly regulated by 
the environment and by the presence of molecular chaperones, proteolytic 
enzymes and other factors (Dobson 2003). In vitro, these constraints are 
relaxed, and the potential to increase the yield of the amyloid form is released. 
Amyloid fibrils are just one of the types of aggregate that can be formed by 
proteins, although a significant feature of amyloid is that its highly organised 
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hydrogen-bonded structure is likely to give it unique kinetic and/or 
thermodynamic stability. Thus, once formed, such aggregates can persist for 
long periods. Henceforth, in this thesis, all aggregates other than amyloid will be 
referred to as amorphous aggregates. 
 
 
 
 
Figure 1.2 Schematic mechanism showing states a protein molecule can access. I, 
intermediate; N, native; U, unfolded, from (Dobson 2003). 
 
 
The folding process provides proteins with access to several conformational 
states under given conditions. To illustrate this, energy landscapes have been 
proposed that describe protein folding as an entropically driven process (Jahn 
and Radford 2005, Radford 2000). They show the advancement of the unfolded 
polypeptide chains along an energy landscape towards the folded native 
structure. The simple sloping funnel-like nature of the energy landscape directs 
the folding polypeptide towards the energetically stable native state via a rough 
surface, while the intermolecular associations lead to aggregation via a more 
rugged energy landscape (as depicted in Figure 1.3). The landscape may be 
funnel-like for small proteins to fold rapidly and reliably towards a native state 
(Watters et al. 2007). Larger polypeptide sequences may have a rougher 
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energy landscapes, allowing partially folded species that may be on- or off-
pathway to the native state (Brockwell and Radford 2007, Vendruscolo et al. 
2003). However, the ruggedness of the energy surface is affected by factors like 
protein sequence and conditions under which protein folding or misfolding 
occurs. 
 
 
 
Figure 1.3 “Illustration of a combined energy landscape for protein folding and 
aggregation. (a) The surface illustrates the roughness of the protein energy landscape, 
showing the multitude of conformational states available to a polypeptide chain. While 
rather simple folding funnels (light grey) can describe the conformational search of a 
single polypeptide chain to a functional monomer, intermolecular protein association 
dramatically increases ruggedness (dark grey). (b) Proposed pathways linking the 
conformational states shown in (a) populated on the combined folding and aggregation 
energy landscape. N, native; I, intermediate; U, unfolded; OA, ordered aggregate; AA, 
amorphous aggregate; F, fibril ” from (Jahn and Radford 2008). 
 
 
Modifying the conditions under which a protein folds in vivo or in vitro alters the 
nature of the folding landscape. Different routes might be populated and/or 
different intermediates and transition states are observed as a consequence of 
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small alterations in the energy profile. Changes may result in local energy 
minima, which may become populated with partially folded intermediate protein 
structures. Under normal protein folding conditions, these minima are populated 
by transient intermediate structures. However, if an intermediate structure is 
stable enough, an energy barrier will be created which delays native folding. 
The increasing population of the long lived stable intermediate structures may 
lead to their self association. Such protein misfolding results in protein 
aggregation, including amyloid formation (Jahn and Radford 2008). 
 
1.3 Mechanism for Amyloid Formation 
 
1.3.1 Amyloid fibril formation in vitro 
The generic nature of the aggregation process has enabled extensive studies of 
the transition between soluble precursor states and insoluble amyloid fibrils in 
vitro (Uversky and Fink 2004). The native conformation of globular proteins 
must usually be destabilised to allow protein amyloid aggregation to occur on a 
viable timescale (McParland et al. 2000). Specific protein destabilisation results 
in an increased population of partially folded conformations, with exposed 
aggregation-prone regions that enhance the probability of intermolecular 
interactions (Figure 1.4). In the case of lysozyme, the aggregation of which is 
involved in hereditary systemic amyloidosis, a single point mutation in the 
lysozyme gene is associated with fibril deposition in several tissues (Selkoe 
2003). Partially structured folding intermediates are believed to play a key role 
in fibril formation by many amyloidogenic proteins (Wiseman et al. 2005). 
However, other assembly mechanisms have been suggested, including 
aggregation from a fully denatured state (Ferguson et al. 2006) or from the 
partially destabilised and predominantly native state (Plakoutsi et al. 2005) 
(Figure 1.4). In the absence of strong denaturants, the non-native oligomeric 
forms of the native proteins may play the role of promoting amyloid formation. 
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Figure 1.4 “Proposed mechanisms of protein aggregation. Amyloid fibril formation for 
many proteins proceeds from intermediate partially folded states that are formed via 
partial unfolding of the native structure or via the partial structuring of unfolded 
polypeptides. Ordered aggregates associate via mechanisms such as domain 
swapping (ds), strand association (sa), edge-edge-association (ee) or β-strand stacking 
(bs). Self-association of these early oligomeric species, possibly involving further 
conformational changes, then leads to the formation of amyloid fibrils. The generic 
principles that govern this self-association process and the structure of the final 
amyloid fibril may depend critically on the polypeptide sequence and the solution 
conditions. In some proteins, association of native-like monomers or non-specific self-
association into disordered aggregates has been observed as the initial step in amyloid 
assembly, in the latter route the polypeptide adopts an ordered β-sheet structure within 
the initially disordered aggregate before amyloid fibril formation proceeds” from (Jahn 
and Radford 2008). 
 
 
1.3.2 Intermolecular association pathways 
Although several models for amyloid fibril formation have been suggested 
based on monitoring fibrillogenesis via microscopy, spectroscopic techniques 
and/or the binding of amyloid-specific dyes (Scheibel et al. 2004), it is generally 
agreed that amyloid fibrils are formed in a nucleation-dependent manner, in 
which the protein monomer is converted into a fibril structure via a transiently 
populated aggregation nucleus (Chiti and Dobson 2006, Dobson 2004a, Harper 
and Lansbury 1997). After the rate-limiting step of nucleus formation, aggregate 
growth proceeds rapidly by further addition of monomers or other assembly-
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competent species. Even though the formation of the nucleus is 
thermodynamically unfavourable, its subsequent elongation is highly favourable 
and proceeds rapidly to the ultimate fibril structure (O'Nuallain et al. 2005).  
 
In the initial lag phase of growth, the partially unfolded intermediate structures 
accumulate and form pre-fibrillar aggregates (Chiti and Dobson 2006). The 
association of the intermediate structures continues until a critical number 
associate to form an oligomeric structure known as the fibril nucleus (labelled 
‘prefibrillar species’ in Figure 1.2). At this point, the slow lag phase ends and an 
exponential amyloid growth phase commences. In the growth phase, the 
oligomeric nucleating species and additional intermediates are thought to 
associate further into structures known as protofibrils. The protofibrils then 
associate to form longer filaments and growth continues with the addition of 
subsequent intermediate structural units, until the mature amyloid fibril is formed 
(Pedersen and Otzen 2008).  
 
The fibril formation mechanism has been likened to the crystallisation process 
(Sawaya et al. 2007). There is a wealth of evidence in support of a nucleation-
polymerisation mechanism, with aggregation being dependent on both protein 
concentration and time (Ahmad et al. 2005, Powers and Powers 2008). 
Nucleation is dependent on the monomer (or equivalent intermediate species) 
concentration exceeding a threshold value, known as the critical concentration, 
with the formation of the nucleus considered the rate-limiting step (Jarrett and 
Lansbury 1993, Powers and Powers 2008). High protein concentrations can 
therefore often accelerate nucleation, but may also result in formation of both 
on- and off-pathway oligomeric intermediates (Ahmad et al. 2005). The seeding 
of a supersaturated protein solution results in a greatly reduced lag time, 
supporting the formation of the nucleus as a limiting step (Powers and Powers 
2008). The existence of the rate limiting step suggests that the formation of 
amyloid nuclei may be a heavily regulated step in biological systems, as a 
means of avoiding amyloid growth. Knowledge of the rate limiting step also 
provides a potential means to accelerate the process in vitro. Pathways of fibril 
formation, fibril morphologies and stability of protofibrillar intermediates are 
influenced strongly by experimental conditions (e.g. protein concentration, pH 
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and ionic strength) (Jahn et al. 2006), and elongation rates can depend on the 
stability of aggregation prone folding intermediates (Gosal et al. 2005).  
 
As studies involving amyloidogenic proteins have advanced, it has been 
discovered that not all proteins conform to this model, but may instead involve 
pathways with additional or alternative rate-limiting steps. The assembly of 
spherical oligomers and other prefibrillar forms occurs with nucleation-
independent kinetics, and results in the formation of spherical particles or 
“worm-like” fibrils (Smith et al. 2006a). Such routes towards fibrillation do not 
have a lag phase (Jahn and Radford 2008). In some cases, oligomeric species 
have been suggested to be the direct precursors of long-straight amyloid fibrils, 
whilst in other cases, an off-pathway role has been proposed (Necula et al. 
2007) where the changes in intrinsic β-aggregation propensity affect the 
accessibility of parallel routes of aggregation (Pellarin et al. 2007). However, the 
primary protein used in this study, bovine insulin, conforms to the nucleation-
polymerisation model, which will be described in more detail in chapter 2.  
 
1.4 Fibril Structure 
 
An enormous amount of research has been done to gain an in depth knowledge 
of amyloid structure. Of the many models for amyloid structure that have been 
postulated (section 1.1), the cross-β structure has attained most support (Makin 
et al. 2005, Nelson et al. 2005). 
 
1.4.1 Amyloid macromolecular structure 
Transmission electron microscopy (TEM) and atomic force microscopy (AFM) 
have revealed much about the macromolecular structure of amyloid. Under the 
TEM, amyloid fibrils typically appear as relatively straight, unbranched strands 
of 8–30 nm in width and highly variable lengths, up to several μm, consistent 
with a substructure of bundled protofilaments of 2–3 nm in diameter (Shirahama 
and Cohen 1967, Sipe and Cohen 2000, Vestergaard et al. 2007). Amyloid 
fibrils are comprised of protofilaments which are the fibrillar subunits that are 
clearly visible in micrographs, even before image processing (Makin and Serpell 
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2004). AFM imaging studies found that the protofilaments have a uniform height 
which vary when they reach the protofibril and fibril stage (Khurana et al. 2003). 
This signifies the intertwining of  protofilaments in the fibrils (Serpell et al. 2000), 
as shown in Figure 1.1 where the SH3 domain forms twisted fibrils in which four 
protofilaments twist slowly around one another (Jiménez et al. 1999). Differing 
numbers and arrangements of protofilaments may be present under the same 
experimental conditions (Makin and Serpell 2004). The 3D reconstruction of 
insulin fibrils depict fibrils formed with two, four and six protofilaments in Figure 
1.5 (Jiménez et al. 2002). The 4 protofilaments twisted around each other to 
form a fibril in Figure 1.5 (b) is analogous to the SH3 fibril depicted in Figure 
1.1.  
 
 
                                           a         b          c           d 
Figure 1.5 Surface representation of 3D maps of the four insulin fibril structures (a) 
Structure of the fibril with a pair of protofilaments twisting around each other, (b) The 
four-protofilament compact fibril, (c) The six-protofilament fibril, (d) The twisted ribbon, 
from (Jiménez et al. 2002). 
 
 
Cryo-EM images of ex vivo amyloid fibrils of Asp67His variant lysozyme showed 
wavy fibrils, and image analysis indicated the presence of six protofilaments 
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(Jiménez et al. 2001). Chapter 3 will provide further details on the association of 
protofibrils to form insulin fibrils. 
Microscopy studies on amyloid fibril morphology has been supplemented by X-
ray fibre diffraction (Makin and Serpell 2005) to derive structural information on 
amyloid fibrils, which will be discussed in the following sections.  
 
1.4.2 Internal structure of amyloid 
At the molecular level, the secondary structure of amyloid fibrils appears to 
have cross β-sheet structure as revealed by X-ray fibre diffraction (Jiménez et 
al. 1999, Sawaya et al. 2007, Sunde and Blake 1997, Sunde et al. 1997). The 
β-strands are arranged perpendicular to the axis of the fibril (approximately 4.7 
Å apart) and the β-sheets run parallel to it (approximately 10 Å apart) (Makin et 
al. 2005, Makin and Serpell 2005, Serpell 2000). The signals at 4.7 Å arise from 
the spacing between hydrogen bonded strands within a sheet and those at 10 Å 
are indicative of the intersheet spacing. Both of these signals are characteristic 
of a cross β structure. The backbone hydrogen atoms of the β-sheet provide 
extensive hydrogen bonding network which, in turn, gives the structure 
outstanding strength.  The "stacks" of β-sheet are short and the amyloid fibril is 
built up of aligned strands (Makin and Serpell 2005) (Figure 1.6). 
 
 
 
Figure 1.6 Amyloid fibrils as self-assembling nanostructures, from (Jaskólski 2001). 
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1.4.3 High resolution amyloid structural studies 
In the last few years, X-ray crystallography and solid-state nuclear magnetic 
resonance spectroscopy (ssNMR) has been applied to gain insights into the 
secondary structure of amyloid fibrils (Ritter et al. 2005). Crystals prepared from 
small peptide fragments, with amyloid characteristics, have allowed studies to 
determine the molecular packing in the cross-β spine (Makin and Serpell 2005, 
Nelson et al. 2005). One example of a well studied peptide is the fragment 
(GNNQQNY) of the yeast prion protein Sup35p. Its X-ray crystal structure 
shows that it consists of pairs of parallel β-sheets and each individual peptide 
molecule contributes to a single β-strand (Figure 1.7 a) (Nelson et al. 2005). 
The region in between the β-sheets is dry, in contrast to the hydration 
externally. This tight molecular interaction between the pair of β-sheets results 
from interaction between the side chains of the two sheets to form a 'steric 
zipper' structure (Figure 1.7 b). The side chain interdigitation within the dry 
interface is suggested to be the underlying support for the cross-β spine found 
in amyloid fibrils (Eisenberg et al. 2006, Sawaya et al. 2007). However, the 
'steric zipper' may vary depending on the protein sequence, side-chains, 
alignment of adjacent strands (parallel/antiparallel) and the separation of the 
sheets, which subsequently may cause the variations found in the structures of 
fibrils (Eisenberg et al. 2006, Fändrich and Dobson 2002, Sawaya et al. 2007). 
The continued elucidation of amyloid structure at a molecular level reveals that 
a structural diversity within the cross-β amyloid architecture exists. However, 
presence of stable β-sheet structures in all amyloid fibrils seems certain. It is 
possible that proteins with high β-sheet content, may also fall within the amyloid 
categorisation, hence a collective analysis by X-ray diffraction, ssNMR and EM 
(electron microscopy), is needed to grasp further understanding of the amyloid 
core structure (Kajava et al. 2005, Kajava et al. 2004). 
 
 14
Chapter 1 Introduction 
 
 
Figure 1.7 Structure of GNNQQNY. a) “Shows a pair-of-sheets, with the backbone of 
each β-strand as an arrow with side chains protruding. The dry interface is between the 
two sheets, and the wet interfaces are on the outside surfaces. Side chains Asn2, 
Gln4, and Asn6 point inward, forming the dry interface. The 21 screw axis of the crystal 
is shown as the vertical line. It rotates one of the strands of the near sheet 180°C about 
the axis and moves it up ½ x 4.87 Å so that it is superimposed on one of the strands of 
the far sheet. b) Shows the steric zipper viewed edge on (down the a-axis). The vertical 
shift of one sheet, relative to the other, allows interdigitation of the side chains 
emanating from each sheet. The amide stacks of the dry interface (grey) is at the 
centre, and those of the wet interface are (pale red) on either side”, from (Nelson et al. 
2005). 
 
1.5 Factors Affecting Protein Amyloid Formation 
 
The process of fibril assembly is driven by non-covalent interactions and is 
responsive to environmental conditions, which can lead to formation of fibrils 
with markedly different characteristics, as introduced in section 1.1. For 
example, glucagon fibrils formed at high concentrations appeared as thin 
flexible fibrils, in contrast to fibrils formed at low concentrations, which appeared 
thicker and bundled (Pedersen and Otzen 2008). The environmental conditions 
 15
Chapter 1 Introduction 
affect both fibril nucleation and fibril growth rates and it is the fibrils with the 
highest growth rate that are observed at the end of fibrillation trials (Pedersen 
and Otzen 2008). 
 
This process of amyloid formation in vitro, from some peptides and proteins, 
can be rapid, occurring within a few hours for protein sequences with a high 
tendency to aggregate. For example, insulin forms fibrils in few hours, at acidic 
pHs (pH 1.6) and at elevated temperatures (60°C) (Nielsen et al. 2001c), and 
will be discussed in detail in chapters 2 and 3.  
 
1.5.1 Sequence determines protein aggregation propensity 
Although all proteins can, in theory, form amyloid, the process itself can be 
affected by various factors. Intrinsic factors which influence the aggregation 
propensity of proteins include: the β-sheet propensity, the hydrophobicity, the 
net charge and the presence of aromatic residues within the protein sequence 
(Chiti et al. 2003, DuBay et al. 2004, Lopez de la Paz and Serrano 2004, Pawar 
et al. 2005). The polypeptide 17-H-6 provides an example of a system in which 
aggregation was controlled by pH adjustment, charge−charge repulsion to 
obtain distinct nanofibres (Lin et al. 2008).  
 
Although a large part of the polypeptide chain may be involved in the fibril 
structure, it is clear that some amino acid sequences are more prone to 
aggregation than others, as shown by a variety of studies of peptide assembly 
into amyloid fibrils in vitro (Lopez de la Paz and Serrano 2004). From a 
systematic analysis of more than 50 protein variants, Chiti et al. rationalized the 
propensities of some sequences to aggregate more rapidly than others, based 
on the physicochemical characteristics of the polypeptide chain (Chiti et al. 
2003). 
 
The correlations between amyloid and amorphous aggregation (Chiti et al. 
2003) (section 1.2), prompted the development of computer algorithms that 
identify aggregation-prone regions in the amino acid sequence of proteins such 
as the prion protein, lysozyme, β-microglobulin, α-synuclein and tau 
(Fernandez-Escamilla et al. 2004, Pawar et al. 2005). Two examples of the 
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algorithms which have been developed are Zyggreggator  (Pawar et al. 2005) 
and TANGO (Fernandez-Escamilla et al. 2004), and attempts were made to 
characterise the amyloid aggregation propensity of chemically modified proteins 
in this thesis using the Zyggregator algorithm (chapter 3, section 3.8.2). 
 
1.5.2 Predicting amyloid fibril formation using the algorithm, Zyggregator  
The Zyggregator algorithm of Dobson and his co-workers (Pawar et al. 2005) 
identifies aggregation-prone sequences by comparing the aggregation 
propensity score of a given amino acid sequence with an average propensity 
calculated for a set of sequences of similar length. Single amino acid mutations 
in the aggregation prone regions can change the aggregation rates 
dramatically, while similar changes in other regions may have relatively little 
effect (Chiti et al. 2002, Pawar et al. 2005). More specifically, DuBay and co-
workers used a seven parameter formula which includes the intrinsic properties 
of the polypeptide chain (hydrophobicity, charge and the patterns of alternating 
hydrophobic–hydrophilic residues) and extrinsic factors related to the 
environment (peptide concentration, pH value and ionic strength of the solution) 
(DuBay et al. 2004). The algorithm takes into consideration both the intrinsic 
and extrinsic factors of the protein and provides a numeric score of the β–sheet 
aggregation propensity. This analysis has provided supplementary data for the 
discussion on the impact of protein sequence modification in chapter 3 which 
aims to assess the impact of chemical modification on insulin fibril propensity. 
 
1.6 Amyloid Fibrils as Components of Bionanomaterials 
 
Nanotechnology is the study and control of matter at dimensions of 1-100 nm 
which involves design, fabrication and application of nanomaterials (Koo 2006). 
Protein aggregates have been of interest in nanotechnology fields through 
bottom-up approaches for the assembly of fibrils employed in hydrogels and 
device applications (Hamada et al. 2004). Examples include self-assembly of 
fibrils to construct nanowires (Reches and Gazit 2003, Scheibel et al. 2003) and 
the use of fibrils to promote cell adhesion (Kasai et al. 2004). A more recent 
paper suggests that “an amyloid of a particular protein appears to be an 
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unusual plastic in some respects, such as in the homogeneous chain lengths of 
the monomers, the complexity and homogeneity of the side chain sequences, 
and the amphipathic nature of many polypeptides. Such unique features, 
combined with our ever-increasing abilities to dissect amyloid structure and the 
molecular basis of amyloid stability, may provide a level of control over the final 
product unprecedented in the synthetic plastics field and encourage practical 
uses of amyloid fibrils in material science and nanotechnology” (Wetzel et al. 
2007). 
 
Thus, in vitro polypeptide association and aggregation can offer attractive 
avenues for designing desirable structures for material science applications 
(Arnold 2008, Cherny and Gazit 2008, Gras 2007a, Gras 2007b, Gras et al. 
2006, Gras et al. 2008, Kar et al. 2006, Mesquida et al. 2006, Petka et al. 1998, 
Qu et al. 2000, Waterhouse and Gerrard 2004). A recent analysis 
summarising/assessing the potential of fibrils led to the construction of a tree 
diagram (Figure 1.8) (Meade et al. 2007). Of the various potential uses for self-
assembled protein shown in the tree, one branch depicts the reinforcing 
properties of fibrils in films, which are the subject of this study. The use of 
protein fibrils in bionanomaterials is reliant on the nature and properties of fibrils 
and is discussed in detail in the following sub-sections. 
 
1.6.1 Strength and stability 
In addition to their nanometre size and varying structural topographies, 
discussed in section 1.4.4, amyloids are attractive for their strength and stability. 
The organisation within the β-sheet structure of amyloid fibrils (Dirix et al. 2005, 
Knowles et al. 2006) confers stability at extremes of pH, temperature, or 
pressure (Dirix et al. 2005) and fibril structure is typically preserved in both 
aqueous and organic solvents. Amyloid fibrils are also resistant to proteolysis 
(Zurdo et al. 2001) and dehydration (Squires et al. 2006) making these 
structures suitable for more extreme conditions than native proteins. The 
mechanical properties displayed by amyloid fibrils show that fibril strength  (~0.6 
GPa) is equivalent to steel and the stiffness of fibrils (~3.3 GPa) is equivalent to 
the natural β-sheet protein silk (Smith et al. 2006b) indicating that fibrils are 
flexible. Additionally, the strength of fibrils under a tensile axial load (Fukuma et 
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al. 2006) has led to the suggestion that fibrils may contribute to the strength of 
natural adhesives including those utilised by terrestrial algae (Mostaert et al. 
2006). These properties make fibrils promising candidate for the development of 
new materials. 
 
 
Figure 1.8 A tree diagram showing the various potential for amyloid fibrils, adapted 
from (Meade et al. 2007). 
 
1.6.2 Sequence versatility 
Amyloid fibrils may be constructed from any combination of amino acids so the 
choice of amino acid sequence included within the fibril core or displayed on the 
fibril surface can (in theory) be used to manufacture fibrils with desired physical 
and chemical characteristics (Gras 2007a, Gras 2007b, Gras et al. 2008). 
Selective choice of amino acid side chains may introduce additional functionality 
to fibrillar materials, such as bioactive groups and enzymes, or for the covalent 
immobilization of other non-protein groups (Gras et al. 2006, Hartgerink 2004). 
The possibility of making amyloid fibrils composed of two distinct peptides, 
where the fibril itself assembles from unrelated peptides or proteins (MacPhee 
 19
Chapter 1 Introduction 
and Dobson 2000), implies that more than one type of functional group can be 
incorporated on an amyloid fibril at a time (Gras 2007a). 
 
1.6.3 Exploiting proteins in bionanomaterials 
The favourable properties of amyloid fibrils including their increasingly 
recognised use in nature (section 1.1), a size and structure comparable to 
manmade nano-scale structures such as carbon nanotubes (CNTs) and 
buckyballs (Katz and Willner 2004) suggest that these structures hold great 
potential for a number of applications (Donald 2007, Gras 2007b, Gras et al. 
2006, Gras et al. 2008, Hamada et al. 2004, Knowles et al. 2007, Maji et al. 
2008, Waterhouse and Gerrard 2004). The use of proteins with their diverse 
array of biological functionality in composite materials may confer distinct 
advantages over using non-biological origin analogues, such as CNTs, in such 
materials. For example, CNTs are difficult to functionalise and may, in 
themselves, constitute a significant potential environmental hazard (Donaldson 
et al. 2006, Lam et al. 2006).  
 
Moreover, the self-association of proteins into β-sheet fibrils has drawn attention 
for the development of supramolecular structures and functional materials with 
improved mechanical properties (Hamada et al. 2004, Tycko 2004, Zhang 
2003). Recent successes include the production of nanowires based on 
controlled amyloid self-assembly (Scheibel et al. 2003). These metal wires were 
produced using a genetically modified variant of the prion determinant of the 
yeasts Saccharomyces cerevisiae Sup35p. In the first step, the self-assembly of 
high concentrations of NM fibrils acted as seeds to rapidly induce fibril growth. 
The exposed cysteine residues of the NM fibrils were derivatised with colloidal 
gold particles, which were subsequently coated with silver and then gold-
enhanced to produce an unbroken network of conductive material spanning the 
length of fibril. In another study, conductive silver nanowires were produced 
after casting ionic silver inside the amyloid fibrils formed from a small synthetic 
peptide (Reches and Gazit 2003). Lindquist and her colleagues (Lindquist et al. 
2005) claim applications relating to conducting and semi-conducting nano-wires 
built by controlled self-assembly of amyloid fibrils and selective deposition of 
metals and semi-conducting materials on these fibres. These achievements 
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show how the self-assembly process can be controlled to be used to conduct 
circuit devices on the nanometre scale.  
 
Much discussion around the potential for the use of proteins in materials has 
originated from work on biological-origin materials. The strength and toughness 
of natural adhesives, fibres and composites was discussed by Smith and his co-
workers in relation to the numbers of sacrificial inter-chain bonds holding a 
cross-linked multi-chain protein matrix together (Smith et al. 1999). The 
toughness of natural composite materials such as nacre (a composite of 
calcium carbonate and organic matter comprising protein) was discussed by 
Smith et al. (1999) and later studies (Fukuma et al. 2006, Mostaert et al. 2006, 
Mostaert and Jarvis 2007) concluded that the inherent strength of natural 
adhesives of terrestrial algae were due to the presence of amyloid fibril 
structures.  More specifically, linear protein structures are believed to make stiff 
and strong fibres, which can be woven or knitted or embedded in a matrix, 
resulting in strong materials, for example acting as a barrier against crack 
propagation (Viney 2004). 
 
The development of amyloid fibrils for hydrogels has also been described, 
based on the conjugation of specific peptide sequences to synthetic polymers. 
This technology opens up potential future biomedical applications, using 
hydrogels as biocompatible and/or biodegradable materials with readily 
controllable physical states (Goeden-Wood et al. 2003, Rösler et al. 2003). A 
hydrogel scaffold was designed with chemical and mechanical responsiveness, 
based on a synthetic peptide designed to undergo intramolecular folding to the 
β-structure in response to pH (Schneider et al. 2002). The folding process 
promotes self-assembly which allows the gel to respond to shear pressure, 
while the hydrogel can readily be dissolved by again altering the pH of the 
environment. 
 
In the nanomaterials related patent literature, Veerman (2006) cites examples of 
using globular protein fibrils as thickening and foaming agents in food products 
and has included claims, relating to the use of these products and properties in 
non-foods such as paints, cosmetics, deodorants and toothpaste (Veerman 
 21
Chapter 1 Introduction 
2006). β-Lactoglobulin forms gels, due to its ability to denature and aggregate. 
Under differing conditions of pH and ionic strength, β-lactoglobulin solutions can 
form either densely packed particulate gels (Clark et al. 2001) or fine-stranded 
(fibrillar) gels (Euston et al. 2007, Langton and Hermansson 1992). Globular 
aggregates of whey protein isolate and fibril aggregates of ovalbumin from egg 
white as gels for controlling food properties were found to be promising 
(Chojnicka et al. 2008). 
 
1.6.4 Concerns on the application of amyloid nanofibres 
A concern with protein amyloid fibril in bionanomaterials design may be the 
compatibility and potential toxicity of these materials. Although fibrils are 
typically associated with amyloid disease in vivo, there is evidence that the 
soluble oligomeric intermediates, not the insoluble well-ordered fibrils, are 
responsible for cellular toxicity (Bucciantini et al. 2002, Hardy and Selkoe 2002, 
Kayed et al. 2003). Mature fibrils may even serve as a rescue mechanism to 
remove cytotoxic species (Hardy and Selkoe 2002). Recently, it has been found 
that amyloids can act as a long-acting drug because they are stable depots that 
ensure a controlled release of the active peptide drug, gonadotropin-releasing 
hormone, from the amyloid termini (Maji et al. 2008). 
 
Furthermore, it has been hypothesised recently that the α-sheet may be the 
toxic conformer in amyloid diseases (Daggett 2006). The existence of fibrils with 
natural functions in vivo also suggests that controlled interactions between 
fibrils and cells may be favourable (Fowler et al. 2006). These studies further 
support the thesis aim to investigate the potential of protein amyloid fibrils in 
bionanomaterials. However, any bionanomaterial developed will need to 
undergo safety testing prior to its commercial release. 
 
1.6.5 Sources of protein for amyloid fibril 
To enable the use of amyloid fibrils in bionanotechnological applications, a 
ready supply of fibrils is required. However, the vast majority of literature 
available on the formation of amyloid describes the behaviour of pure proteins 
in vitro. For industrial production of fibrils, there will be a need to source large 
amounts of amyloid fibrils, which may be prohibitively expensive and make it an 
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impractical option for material use. With a view to sourcing inexpensive proteins 
for amyloid forming propensity, fibrils have been formed from inexpensive 
precursor materials such as crude wheat proteins (Mackintosh et al. 2008) and 
crude bovine eye lens proteins (Garvey et al. 2008), potentially decreasing the 
cost of producing fibrillar materials on a large scale (Larsen et al. 2005). This 
research aims to develop the use of such amyloid fibrils, from crude sources of 
waste protein, for potential industrial use. In this thesis, methods are developed 
using insulin as a model protein. 
 
1.7 Lessons from the Development of other β-Sheet Systems 
 
The development of protein based fibrils for bionanomaterials can be informed 
from work with other β-sheet rich fibre-forming systems, which also offer 
considerable potential as new materials (Zhang et al. 2002). Relevant examples 
include the short repeating peptide sequences, arginine-alanine-aspartate 
(RAD) that have been used to produce β-sheet rich scaffolds (Holmes et al. 
2000). These structures form hydrated gels under physiological conditions, 
which promote cell differentiation (Kisiday et al. 2002) and have been further 
functionalised incorporating bioactive sequences from laminin and collagen to 
enhance cell interactions (Genove et al. 2005). In addition, self-assembling 
peptides designed to resemble the chemical properties of the joint lubricant 
haluronic acid have favourable rheological properties, indicating a potential use 
as a therapeutic lubricant to assist in osteoarthritis (Bell et al. 2006).  Nanofibres 
formed from simple homo-aromatic dipeptide motifs also demonstrate 
remarkable properties, such as chemical and thermal stability (Adler-
Abramovich et al. 2006) at temperatures up to 150°C (Sedman et al. 2006) 
suggesting that these fibrils may be used for nanotechnology applications such 
as scaffolds and drug delivery. In addition, aromatic side chains may be 
chemically modified, resulting in different fibril morphologies (Reches and Gazit 
2006).  
 
The potential to control amyloid fibril morphology by chemical modification 
provides scope for the development of nanofibres since fibril structure (straight, 
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curly, ribbon) may affect fibril strength. Chapters 2 and 3 provide a discussion 
on the chemical modification of bovine insulin and its impact on controlling the 
structure of insulin nanofibres.    
 
1.8 Film Nanocomposites 
 
The basic physical, chemical, and biological properties of materials are 
remarkably altered as the size of their constituent grains decreases to a 
nanometre scale (Wan and Bai 2006). Nanomaterials that contain nanoparticles 
from a biological source, like protein fibrils, will be referred to as 
bionanomaterials in this thesis. Nanocomposites are multiphase materials 
where at least one of the constituent phases has one dimension less than 100 
nm (Ajayan et al. 2003, Manocha 2006). The promise of nanocomposites lies in 
their multifunctionality and the feasibility of obtaining unique combinations of 
properties unachievable with traditional materials (Koo 2006).  
 
1.8.1 Polymer nanocomposites 
Polymer nanocomposites consist of a polymeric material and a reinforcing 
nanoscale material and show improvements in mechanical properties of the 
polymer, depending on factors such as the polymer matrix, nanocomposite 
morphology and the type of nanoparticle (Koo 2006).  There are different types 
of commercially available nanoparticles, of which CNTs are attracting 
considerable interest as reinforcing materials in polymer nanocomposites 
(Calvert 1999). The driving force for the development of polymer 
nanocomposites is to control properties of nanomaterials with the introduction of 
nanometre sized structures, without changing the material chemical 
composition (Koo 2006). 
 
This thesis investigated the incorporation of amyloid fibrils into a film matrix 
based on polyvinyl alcohol (PVOH). Nanometre sized fibres can strengthen a 
polymer matrix and the vast majority of studies have been carried out on CNTs 
(Bhattacharyya et al. 2006, Bhattacharyya et al. 2005, Calvert 1999, Coleman 
 24
Chapter 1 Introduction 
2006). The background literature available on CNTs, protein and polymer 
nanocomposites were utilised as a platform for investigations in this thesis. 
 
1.8.2 Carbon nanotubes and their functionalisation for nanocomposites 
CNTs can be described as a nano-sized tube made up of a graphite sheet 
(Nepal and Geckeler 2006). Their stiff and robust structure is owed to the 
carbon-carbon bonds in their graphite-like structures, which are some of the 
strongest in nature (Thostensona et al. 2001). Of the wide spectrum of potential 
applications, CNTs are attracting considerable interest as reinforcing materials 
in polymer composites due to their superior structural and transport properties 
(high strength and flexibility, high thermal and electrical conductivity, and low 
density) (Calvert 1999, Koo 2006). Mechanical reinforcement of polymers by 
CNTs requires good interfacial bonding to ensure efficient stress transfer from 
the polymer matrix to the nanotube lattice. Unlike proteins, CNTs don’t 
intrinsically have any side chain groups on the surface of their walls, to be able 
interact with a matrix. Studies supporting the modification and functionalisation 
of CNTs with amino acids and peptides (Figure 1.9) have become important for 
the bottom-up design of nanotubes (Lin et al. 2004). Furthermore, solubilisation 
via chemical modification and functionalisation is effective in imparting 
biocompatibility to CNTs, especially for the stable conjugation of CNTs with a 
variety of biological and bioactive molecules like  proteins (Lin et al. 2004).  
 
 
 
 
Figure 1.9 An example of functionalising CNTs with biological molecules like protein 
from (Lin et al. 2004). 
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Unlike CNTs, the protein side chains of amyloid are an intrinsic part of their 
structure and can be functionalised with additional peptide and protein groups 
or entities such as fluorophores and metalloporphyrins (Baldwin et al. 2006, 
MacPhee and Dobson 2000) allowing fibrils to interact with their environment or 
living cells. Preliminary studies into bilayered nanotubular structures suggested 
that hollow tubular arrangements of amyloid can be formed of uniform 
dimensions with charged curve surfaces representing scaffolds highly 
accessible for modification (Lu et al. 2003). This feature imparts a significant 
advantage over CNTs, which are limited by the lack of reactivity along their 
sidewalls (Lin et al. 2003). 
 
1.8.3 Polyvinyl alcohol 
Polymer nanocomposites have a polymer as the matrix, which will be PVOH in 
this study, and the nanoparticles, dispersed within it, in this case protein 
amyloid fibrils. PVOH is a nontoxic, water-soluble, biocompatible, and 
biodegradable synthetic polymer, which can be widely used in biochemical and 
biomedical materials. It has good film-forming properties, highly hydrophilic 
properties, and high mechanical strength, and has been studied as a membrane 
(Lin et al. 2006, Shang and Peng 2007). PVOH is a semicrystalline polymer with 
hydroxyl groups that give rise to intermolecular and intramolecular hydrogen 
bonds. PVOH films have a high tensile strength and oxygen barrier properties, 
comparable to many other polymers (Kim et al. 2007). In addition, since PVOH 
is biocompatible and nontoxic, and exhibits minimal cell adhesion and protein 
absorption, PVOH membranes have been developed for biomedical 
applications (Choi et al. 2007, Chuang et al. 1999, Kobayashi et al. 2005, 
Koyano et al. 2000, Oh et al. 2004, Qi et al. 2004). For instance, PVOH/ 
polyvinylpyrrolidone/chitosan hydrogels were studied for wound dressing 
application in rats (Huang and Yang 2008).  
 
PVOH was selected as the model polymer to determine the potential of fibrils as 
nanocomposite components in this thesis, and the large amount of work done 
on PVOH provides support for its use as a model in a film forming system. More 
specifically, the selection of PVOH for investigating the impact of protein fibrils 
on the mechanical properties of the polymer was motivated by PVOH/protein 
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based film studies, such as PVOH/wheat (Dicharry et al. 2006), PVOH/collagen 
hydrolysate (Alexy et al. 2003), and PVOH/gelatin (Bergo et al. 2006, Darder et 
al. 2006, Ma et al. 2006, Mendieta-Taboada et al. 2008, Su et al. 2007, Wang et 
al. 2005, Yi et al. 2006)), PVOH/soluble egg shell membrane (Yi et al. 2006), 
PVOH/chitosan (Wang et al. 2005), and PVOH/cellulose fibres (Wang and Sain 
2007), PVOH/soy protein  (Su et al. 2007), and PVOH/membrane protein (Ma et 
al. 2006). To improve the mechanical characteristics of protein-based films, 
these proteins are mixed with synthetic polymers (Tharanathan 2003), such as 
PVOH. (Chiellini et al. 2003) have demonstrated biodegradability of protein 
blended PVOH films. 
 
1.8.4 Proteins in films 
Work to date reveals that films can be made from wheat protein, milk protein, 
zein protein and other proteins (Budi Santosa and Padua 1999). The 
biocompatibility, biodegradability, and structural support, plus the availability of 
an industrial supply of proteins  (Aoi et al. 2000, Tharanathan 2003) has led to 
studies on blends of polymers with polypeptides (Takasu 1997) and, more 
recently, the development of protein-based packaging materials (Tharanathan 
2003). In particular, proteins derived from various animal and plant sources 
have successfully been formed into films and/or coatings (Gounga et al. 2007, 
Lee et al. 2008, Naushad and Stading 2007).  
Edible films have been produced by heating sunflower proteins to 85°C and 
solution casting (Meixueir et al. 2000). Film formation in such proteins is through 
intermolecular disulfide bridges and hydrogen bonds, accompanied by surface 
dehydration. Whey protein isolate and milk protein also produce edible film and 
coatings with different functionalities and applications (Gounga et al. 2007, 
Khwaldia et al. 2004, Sothornvit et al. 2007). An example of this type of natural 
polymers is gelatin, a polypeptide derived from the structural protein collagen, 
that is able to form tough films (Park et al. 2008) and transparent, elastic and 
thermoreversible gels (Darder et al. 2006). The various applications of proteins, 
both in the functional and aggregated form, discussed in the sections above 
further support the potential for amyloid fibrils in bionanomaterials (Gras 2007a, 
Gras 2007b, Gras et al. 2006). 
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1.9 Developing Amyloid Fibril Materials 
 
Potential applications for protein-based materials are far-reaching and include 
industrial applications as diverse as medicine, health and nutrition, catalysis, 
electronics, plastics and structural materials (Dobson 2000). As described in 
section 1.6 (Figure 1.8), limited successes have been described in the literature. 
The huge potential of amyloid fibrils in bionanomaterials detailed in theory 
(Arnold 2008, Cherny and Gazit 2008, Gras 2007a, Gras 2007b, Gras et al. 
2006, Gras et al. 2008), signifies a need to carry out investigations to realise the 
application of protein fibrils in bionanotechnology. To this end, this thesis is 
aimed at developing a method for making films, comprising amyloid fibrils in a 
protein-model polymer matrix which may be developed for applications such as 
biodegradable polymers and membranes and filters for bioremediation and air 
purification and sensing systems. Applications might also be envisaged in tissue 
scaffolding (MacPhee and Woolfson 2004). 
 
1.10 Thesis Objectives 
 
A brief overview of the nature of amyloid fibril formation and their properties has 
been provided in this introduction. For bionanomaterial scientists, protein fibril 
self-assembly presents an exciting opportunity to create novel bionanomaterials 
for applications discussed earlier.  
 
The early part of this study proposed to look at protein structures that will form 
amyloid fibrils, focussing on the little studied area of how protein derivatisation 
(lysine group modification, disulfide reduction-alkylation, trypsin treatment, 
chymotrypsin treatment) influences the amyloid fibrils. The goal was to modify 
bovine insulin (a model protein), knowing that it forms fibrils and can be 
characterised readily in vitro. Initial method development for insulin modification 
and characterisation of the modified insulin was carried out to prepare samples 
in milligram quantities for in vitro fibril studies. Derivatisations were limited to 
those potentially applicable on a commercial scale. 
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This thesis then aimed to test the effect of insulin modification on its 
aggregation propensity, in a heterogeneous mixture. It was hypothesised that a 
change in the primary structure of insulin may have an effect on the fibril 
structure, having identified the role of intrinsic factors in determining the 
aggregation propensity of proteins (section 1.5). The heterogeneity of the 
modified insulin was relevant, to provide key information for the later goal of 
forming fibrils from a cheap and crude source of protein.  
 
The ability of a readily available waste protein (crystallins from bovine eye 
lenses) to form amyloid was then considered. Bovine eye lens protein was 
chosen because it was readily available, and possessed many features that 
appeared promising for the successful induction of amyloid from crude protein 
extracts.  Amyloid fibrils were manufactured from this cheap and crude source 
of protein to be utilised in later studies of film composites. 
 
The strength and stability of amyloid fibrils opens up the potential for amyloid 
fibrils to be used as a minor component of a film, and to determine whether the 
inherent physical properties of individual amyloid fibril structures will have any 
effects on the bulk physical properties of the films into which they are 
incorporated. There is scant evidence to date as to what extent changes will be 
observed in the strength of resulting nanocomposites, when they incorporate 
very small amounts of fibrils. Accordingly, it was an objective of this study to 
develop a method to prepare film composite and provide composite materials 
(films) containing protein amyloid fibrils with better mechanical properties, than 
the parent material. A laboratory scale method of making films was developed, 
films were cast with and without fibrils and their strength was measured. The 
advantage of using waste material is that fibrils could be economically produced 
on the scale required for many applications. Worldwide there is as yet no 
significant technological or industrial activity based around the manufacturing or 
film composite processing of amyloid fibrils. A means to manufacture amyloid 
fibrils from waste materials may thus open up new opportunities. 
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1.11 Thesis Overview  
 
Chapter 2 outlines investigations regarding chemical modification of bovine 
insulin and assessment of the extent of modification via mass spectrometry. 
Sufficient quantities are prepared to prepare amyloid fibrils from the modified 
insulin in chapter 3. 
 
Chapter 3 addresses the effect of chemical modification on the aggregation 
propensity of bovine insulin, present in a heterogeneous mixture in vitro and the 
morphology of the fibrils formed. 
 
Chapter 4 details the development of a small scale method for manufacturing 
and characterising films incorporating protein fibrils. 
 
Chapter 5 investigates the mechanical effect of incorporating insulin fibrils and 
crude crystallin fibrils in to PVOH films. 
 
Chapter 6 summarises the major findings of this thesis and future directions to 
be pursued from this work.  
 
Chapter 7 outlines all experimental procedures undertaken during this thesis.  
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Modification and Characterisation of Insulin 
 
This chapter aimed to assess the impact of chemical modification on the ability 
to form amyloid fibrils for a model protein, insulin. The spectrum of possible 
chemical modifications of proteins is wide, and therefore a representative 
selection is considered here. Previous studies on the impact of chemical 
modification on the aggregation propensity of proteins have been, for the most 
part, motivated by the need to understand the impact of protein modification in 
vivo (Dobson 2003, Naiki et al. 1997, Rochet and Lansbury Jr 2000, Uversky 
and Fink 2004). This chapter, presents the results of the modification of a model 
protein, insulin, with a view to accelerating the formation of amyloid fibrils, for 
potential use in bionanomaterials. 
 
2.1 Background 
 
Post-translational phosphorylation (Ecroyd et al. 2007), glycation (Obrenovich 
and Monnier 2004), acetylation, truncation, oxidative stress (Dear et al. 2007) 
and conformational changes (Colon et al. 2007) have all been shown to play a 
role in the series of events leading to fibrillation. The effect of chemical 
modification on protein aggregation in vitro has been part of studies contributing 
towards an understanding of the mechanism of protein aggregation in vivo   
(Ahmad et al. 2003, Ahmad et al. 2004, Arora et al. 2004, Brange et al. 1997a, 
Jansen et al. 2005, Jiménez et al. 2002, Khurana et al. 2003, Sluzky et al. 1991, 
Uversky et al. 2003). For example, α-synuclein aggregation plays a key role in 
the etiology of Parkinson’s disease and in vitro studies reveal that the nitration 
of tyrosine inhibits α-synuclein fibrillation at neutral pH (Uversky et al. 2005). 
Similarly, the phosphorylation of αβ-crystallin regulates its chaperone activity in 
vitro, which may alleviate the pathogenic effects associated with protein 
conformational diseases (Ecroyd et al. 2007). The impact of glycosylation on 
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the propensity of prion peptides to form fibrils has been shown to depend on the 
site of glycosylation and the nature of the sugar (Chen et al. 2002), the O-linked 
α-GalNAc at Ser-135 suppresses the formation of amyloid fibril formation of the 
prion peptide, whereas the peptide with the same sugar at Ser-132 shows the 
opposite effect. More recently, glycosylation was found to suppress fibrillation of 
chicken cystatin (He et al. 2006). Furthermore, glycation favours the formation 
of β-sheets in albumin (Bouma et al. 2003, Obrenovich and Monnier 2004). 
However, it has been shown that phosphorylation and glycation of tau protein in 
vitro do not promote fibril nucleation but instead favour fibril growth once they 
have been nucleated (Necula and Kuret 2004). Despite a bulky hydrophobic 
group on its C-terminal, prion peptide still formed fibrils, but this derivatisation 
prevented the lateral association of filaments into higher order structures 
(Breydo et al. 2007). These findings suggest that post translational modification 
affects both the kinetic status and thermodynamic stability of fibril formation; it 
may or may not favour the formation of β-structure relative to the native 
conformation. This is consistent with the complicated relationship shown 
between fibril formation and protein sequences (Lopez de la Paz and Serrano 
2004, Pawar et al. 2005). 
 
Chapter 1 detailed the properties of fibrils, and their potential use in 
bionanomaterials. However, a reliance on purified, expensive protein could 
potentially represent a major obstacle for industrial fibril production, as sourcing 
large volumes of pure protein may prove to be costly and hence a nonviable 
option for materials use. The use of fibrils on an industrial scale will require 
large amounts of proteins from inexpensive sources. Amyloid fibril formation 
from crude, and/or partially purified proteins would reduce costs for manufacture 
on a large scale. As such, in this chapter, we were not only interested in 
studying the fibril forming ability of purified modified insulin but the potential of 
fibril formation from modified insulin mixtures, which model the crude starting 
materials in industrial processes using unpurified material as a starting point for 
manufacture.  
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In order to fully assess the potential of chemical modification and sample 
heterogeneity on the propensity of a protein to form amyloid fibrils in vitro, a 
number of areas needed to be addressed, including selection of an appropriate 
protein and development of a range of methods to generate and then 
characterise the derivatised protein. This chapter describes these methods and 
reports on the crude products obtained by a range of chemical modifications of 
insulin. For all the chemical modifications to be discussed in this chapter, bovine 
insulin was modified on a scale to obtain samples in sufficient quantities for fibril 
studies in chapter 3. 
2.2 Bovine Insulin, the Model Protein 
 
2.2.1 Insulin aggregation 
Bovine insulin has been used to study the process of amyloid formation for a 
number of years (reviewed in Brange et al. 1997a) with the most common fibril 
formation conditions involving elevated temperatures and acidic pH. 
Additionally, organic solvents and agitation have been identified as conditions 
that lead to insulin fibril formation (Ahmad et al. 2003, Ahmad et al. 2004, 
Ahmed et al. 2003, Arora et al. 2004, Brange et al. 1997b, Devlin et al. 2006, 
Jansen et al. 2005, Jansen et al. 2004, Jiménez et al. 2002, Khurana et al. 
2003, Nielsen et al. 2001a, Nielsen et al. 2001c, Sluzky et al. 1991, Uversky et 
al. 2003, Waugh 1946, Waugh et al. 1953). A number of compounds added to 
the solution have also been shown to have an influence on the kinetics of 
amyloid fibril formation, with Neilsen et al. (2001c) providing a comprehensive 
review on the effects of a selection of environmental factors. The presence of 
strong denaturants such as guanidine hydrochloride and urea (Ahmad et al. 
2003, Ahmad et al. 2004) also cause insulin to form ordered amyloid-like 
aggregates with distinct staining properties.  
 
Since it was realised that commonly observed insulin fibrils had the generic 
amyloid structure that is associated with many other human diseases (Dische et 
al. 1988, Sluzky et al. 1991, Storkel et al. 1983) several research groups have 
focused their attention on understanding the process of insulin amyloid fibril 
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formation (Brange et al. 1997c, Devlin et al. 2006, Fandrich 2007, Hong et al. 
2006, Hong and Fink 2005, Jiménez et al. 2002, Mauro et al. 2007, Uversky et 
al. 2003, Vestergaard et al. 2007). Insulin fibrils have been studied in 
considerable depth in recent years and there is a substantial body of evidence 
to show that they contain the signature β-sheet structure diagnostic of amyloid 
fibrils (Bouchard et al. 2000, Burke and Rougvie 1972, Devlin et al. 2006, 
Fandrich 2007, Jiménez et al. 2002, Mauro et al. 2007, Nielsen et al. 2001b, Yu 
et al. 1974). Although a lot of work has been done on insulin and its ability to 
fibrillise, the molecular mechanism of the fibrillation is still not fully understood 
(Ahmad et al. 2005, Brange et al. 1997b, Mauro et al. 2007). Early work on 
insulin fibrils prepared from native insulin and modified insulin revealed similar 
X-ray diffraction patterns, suggesting that there is not much difference in the 
structure of fibrils (Koltun et al. 1954). However, this work pre-dated a full 
appreciation of the amyloid form. 
 
2.2.2 Insulin structure  
Bovine insulin is a compact globular protein having a molecular weight of about 
5.7 kDa. It  is composed of two polypeptide chains, the 21 residue A-chain and 
the 30 residue B-chain, linked together by two interchain disulfide bonds and a 
third intramolecular disulfide bridge within the A chain (Baker et al. 1988, 
Blundell et al. 1972, Derewenda et al. 1990) (Figure 2.1). In solution, insulin 
exists as an equilibrium mixture of monomers, dimers, tetramers, hexamers, 
and possibly higher associated states (Nielsen et al. 2001c). It is thought that 
the fibril precursor is an insulin monomer, since conditions that promote 
monomer formation include low pH and high temperatures also promote self-
assembly (Brange et al. 1997a).  
 
 
A chain
B chain
 
 
Figure 2.1 Primary structure of bovine insulin from (Hong and Fink 2005). 
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It is proposed that the critical step in insulin fibrillation involves disruption of the 
native protein contacts (Ahmad et al. 2005, Uversky and Fink 2004). NMR 
studies on the structure of human insulin, when exposed to amyloidogenic 
conditions, show that the N-termini of the A and B chains are separated from 
the core, which leads to the exposure of a hydrophobic surface, which in turn 
may provide the initial interaction surface for aggregation (Hua and Weiss 
2004). Brange and his co-workers (Brange et al. 1997b, Brange et al. 1987) 
showed that the propensity of fibril formation increases with increasing 
truncation of the C-terminal region of the B chain, indicating a region of the B 
chain is critical in the intermolecular association events that lead to insulin fibril 
formation. The removal of residues from the C-terminal region of insulin native 
structure via protein engineering causes exposure of non polar groups normally 
in the core of the protein (Brange et al. 1997b). 
 
In terms of its structure, insulin is constrained by the three disulfide bridges, all 
of which are retained in insulin fibrils (Brange et al. 1997a). As such, these 
constraints limit the conformational space that can be accessed by the protein, 
which, in turn, limits the possible arrangements of the protein in the amyloid 
fibrils (Jiménez et al. 2002).  
 
2.2.3 Insulin chemical modification 
An extensive literature search revealed a substantial body of literature on the 
chemical derivatisation of insulin, carried out for the most part to elucidate 
structure-function relationships of the native fold (Brandenburg et al. 1971, 
Massaglia et al. 1968, Suckau et al. 1992, Zahn et al. 1972). The chemical 
modification of several functional groups, such as carboxyl and amino groups 
and histidine and tyrosine residues, were shown not to prevent fibrillation in 
insulin in early work (Koltun et al. 1954), although the derivatisation of side 
chain amino acids led to a decreased rate of fibrillation (Blundell et al. 1972, 
Koltun et al. 1954). However, Koltun and his co-workers had not characterised 
insulin fibrils as amyloid in those early works. More recently, treatment of bovine 
insulin with cyanogens resulted in crosslinking between Ala-30 and His-5 at 
physiological conditions which caused insulin to form amyloid fibrils (Winters 
2002).  
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The glycosylation of insulin has been shown to stabilise its native structural 
form, by suppressing self-association tendencies (Baudys et al. 1995). Whether 
this also influences the tendency to form amyloid does not appear to have been 
investigated, although other derivatisations, such as the attachment of low 
molecular weight monomethoxypoly(ethylene glycol) derivatives, have 
significantly enhanced insulin's resistance to fibrillation (Hinds and Kim 2002).  
 
For this research, emphasis was placed on establishing how chemical 
modification might influence amyloid fibril formation in insulin molecules. A 
range of modifications was considered, based on various factors including the 
complexity of the methods, availability of reagents and suitability for use on a 
commercial scale. Three approaches were taken to insulin modification: 
i) derivatisation of the single lysine residue with acetic anhydride 
ii) reduction and derivatisation of the disulfide bonds with iodoacetic acid 
(IAA) and 4-vinylpyridine (4-VP). 
iii) treatment with enzymes, specifically trypsin and chymotrypsin 
 
In this chapter, the modification of insulin via each of the three approaches is 
described. The impact of these modifications on the ability to form amyloid fibrils 
is described in chapter 3. 
 
2.2.4 Characterising bovine insulin  
Bovine insulin was obtained commercially and the purity of the batch (Sigma 
Chemicals (Lot 054K1375)) was assessed using Nu polyacrylamide gel 
electrophoresis (NuPAGE) and liquid chromatography-mass spectrometry (LC-
ESI-MS) analysis.   
 
Figure 2.2 compares two purchased batches of insulin including the batch used 
subsequently in this study and shows no difference in the two batches of bovine 
insulin; both batches have an insulin band at about 5.7 kDa. The pH (1.6-8) of 
the insulin solution does not change the position of the insulin bands relative to 
the MW marker, an important consideration for the analysis of different 
modifications which may be soluble at different pHs. 
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Figure 2.2 Bovine insulin SDS-PAGE (non-reducing) analysis on a Bis-Tris 4-12% gel, 
5 µl was loaded at 0.5 mg/ml protein. Lane M = molecular weight marker, (Lanes 1-4 
are bovine insulin from batch Lot no. 103K1440 used for this study, at different pHs), 
Lane 1= 0.025 M HCl with 0.1 M NaCl buffer pH 1.6, Lane 2 = 0.025 M HCl pH 2, Lane 
3 = 50 mM phosphate buffer pH 7, Lane 4 = 50 mM phosphate buffer pH 8, (Lanes 6-9 
are bovine insulin from 5 g batch Lot no. 054K1375 previously used in the laboratory, 
at different pHs), Lane 5 = 0.025 M HCl with 0.1 NaCl buffer pH 1.6, Lane 6 = 0.025 M 
HCl pH 2, Lane 7 = 50 mM phosphate buffer pH 7, Lane 8 = 50 mM phosphate buffer 
pH 8.       
                        
LC-ESI-MS of bovine insulin was carried out to verify purity and molecular 
weight. Figure 2.3 below shows a liquid chromatogram and ESI-MS mass 
spectrum of the insulin monomer. The liquid chromatogram shows a single peak 
for bovine insulin which elutes at 13.05 min with m/z value of 1147.5. Having a 
charge of +5, the experimentally determined molecular mass of insulin is 5732.5 
Da. Thus the commercial sample of insulin was pure and underivatised and the 
molecular mass, with a standard deviation of 2, was consistent with that 
predicted from the amino acid sequence of 5733.5 Da .  
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Figure 2.3 Spectra from LC-ESI-MS analysis of 10 µl injection of 0.1 mg/ml insulin 
solution. a) Insulin was resolved on a Zorbex 2 column with mobile phase A and B (A: 
0.2% formic acid in H2O, B: 0.2% formic acid in acetonitrile) and the eluent was 
introduced to mass spectrometer via electrospray. Ions were scanned over a range of 
800-2000 m/z [M+H]+. b) Full scan mass spectra of the insulin LC peak present in the 
total ion current (TIC) chromatogram, the multiply charged peaks were detected by the 
ESI-MS, manually deconvoluted based on the high resolution mass scans (Zoom scan, 
which provided charge state information). The charge state for insulin peak is shown in 
parentheses. 
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2.3 Amino Group Acetylation of Bovine Insulin 
 
Acetylation has the effect of neutralising the charge of the amino groups at 
neutral pH and charge is one of the intrinsic factors believed to affect 
aggregation propensity. Figure 2.4 shows the possible sites for amino group 
acetylation in bovine insulin, which has 3 available amino groups for acetylation, 
2 on the N-termini (glycine at A1 and phenylalanine at B1) and one on the side 
chain of lysine on B29.  
 
 
 
Figure 2.4 Ribbon representation of the native bovine insulin monomer structure. The 
coordinates are from the crystal structure of the T6 hexameric crystal structure (PDB 
file 2A3G), but only the monomer is shown. The A chain is shown in teal, the B-chain in 
purple with the space filled labelled residues showing the available sites for acetylation 
(lysine-yellow, glycine-green, phenylalanine-red). The intrachain disulfide bond is 
shown in orange and the two interchain disulfide bonds are shown in dark blue. Figure 
was generated using PyMol (DeLano 2002). 
 
Early attempts at non-selective acetylation of insulin amino groups produced a 
mixture of products which had a low resolution by chromatography. As a result, 
selective acetylation of the lysine side chain amino group was thought as a 
better means of insulin amino derivatisation. Acylating agents chosen were 
reported to be specific and react rapidly under mild conditions (Riordan and 
Vallee 1972a). The reactivity of the amino groups to electrophilic attack, 
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depends on the local environment of the residues (Blundell et al. 1972). 
However, the O-acetylation of hydroxyl groups of amino acids such as tyrosine 
is also possible (Riordan and Vallee 1972a, Riordan and Vallee 1972b). This 
section outlines attempts to selectively acetylate the lysine group of bovine 
insulin at B29 and assess the impact on fibrillation. The acetylation of lysine 
with acetic anhydride is well studied and is illustrated in Figure 2.5 (Hermanson 
1996). 
 
 
+R +
Acetic anhydride Amide bond formation Acetate group
Amine containing 
molecule
CH3 O CH3
OO
NH2
CH3NH CH3 O
 -
OO
R
pH 8
 
 
Figure 2.5 Acetic anhydride reacts with amines to form amide bond derivatives, 
adapted from (Hermanson 1996). 
 
 
Amino group acetylation reactions of bovine insulin were carried out as 
described by Zahn et al. (1972) and Blundell et al. (1972). The route, shown in 
Figure 2.6, for acetylation was expected to yield insulin monoacetylated at the 
lysine residue. The modified insulin samples described in Figure 2.6 were 
tested for fibril formation and will be discussed in chapter 3, section 3.4. 
                                                                                                   
2.3.1 Blocking insulin N-terminals with citraconic anhydride 
Citraconic anhydride (2-methylmaleic anhydride) is a reversible acylation agent, 
designed for temporarily masking amine groups. It reacts with amines at 
alkaline pH values (7-8) to form amide linkages with an extending terminal 
carboxylate (Figure 2.7). The amide bonds can be hydrolysed at acidic (pH 3-4) 
pH to release the citraconic acid and liberate the amine (Dixon and Perham 
1968, Habeeb and Atassi 1970). 
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Figure 2.6 Preparation of insulin derivatives modified at B29 ε-amino group, adapted 
from (Zahn et al. 1972).   
 
Deblocking at pH 3.5 
Citraconic anhydride pH 8 
Acetic anhydride pH 8 
Acetylated insulin 
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Figure 2.7 Citraconic anhydride can be used to block amine groups reversibly because 
the amide bond formed is unstable to acidic conditions, from (Hermanson 1996). 
 
With respect to the scheme shown in Figure 2.6, the first step was to block the 
N-terminal amino group with citraconic anhydride, leaving the lysine residue 
free to be acetylated. Insulin was made up to 1 mg/ml concentration with 
potassium phosphate buffer (100 mM) and reacted with a 50 fold molar excess 
(per amino group) of citraconic acid anhydride, according to the method of  
(Havelund et al. 1995) at two pHs, 7 and 8, then characterised by ESI-MS. The 
predicted increase in mass due to the attachment of a citraconic group was 
112.1 Da. 
 
The degree of citraconylation was determined by measuring the increase in MW 
via ESI-MS. The ESI-MS of the citraconylated insulin at pH 7 showed that there 
was some unmodified insulin still present (Figure 2.8) in the sample and that the 
MW of insulin increased by 113.5 (+5 charge state) and 224.2 (+4 charge state) 
(Table 2.1). This indicated that there was a crude mixture of mono and 
dicitraconylated insulin and some unmodified insulin. In contrast, there was no 
indication of any unmodified insulin present in the insulin modified at pH 8 
(Figure 2.9).  
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Figure 2.8 ESI-MS of insulin solution before (a) and after (b) citraconylation was 
performed using an electrospray mass spectrometer operated in positive ion mode. 
Labels in b) show the presence of unmodified insulin. (c) ESI spectrum of 
citraconylated bovine insulin at pH 7 showing mass fragmentation of the parent ion at 
m/z 1170.3. Each of the m/z value is labelled above its corresponding charged states. 
The multiply charged peaks detected by the ESI-MS experiment were manually 
deconvoluted based on the high resolution mass scans (Zoom scan which provided 
charge state information). 
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Figure 2.9 ESI spectrum of citraconylated bovine insulin at pH 8, a) insulin control, b) 
crude citraconylated insulin and c) shows mass fragmentation of the parent ion at m/z 
1222.5 in b). Each of the m/z values labelled above its corresponding charge states.  
 
The reaction went further when citraconylation was carried out at pH 8, with an 
increased mass of 357 (+5 charge state) and 397.2 (+4 charge state) (Table 
2.1). The increase in mass was related to the addition of 3 citraconic groups 
(336 ± 2) plus the Na+ (+23) and K+ (+39) adduct ions, quite common in 
electrospray ionisation (Iavarone et al. 2004). Hence mass fragmentation of the 
parent ions at (M+5H) was carried out and the MW of the fragments lost 
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calculated (Figure 2.8 for pH 7 and Figure 2.9 for pH 8). The fragmentation 
confirmed the attachment of at least one citraconic anhydride to insulin at pH 7 
and pH 8. Future reactions were done at pH 8, to maximise the modification of 
two amino groups and minimise the presence of unmodified insulin in the 
product. 
 
As discussed in the introduction, the heterogeneous nature of the product was 
relevant as a mimic of the crude protein extracts likely to be used in industrial 
production, as sourcing large volumes of pure protein of the required size may 
prove to be costly and hence a nonviable option for materials use. Thus further 
time-consuming attempts to purify the components of the mixture were not 
made.  A reasonable quantity (~20 mg) of acetylated insulin was prepared to 
carry out fibril formation studies in chapter 3. 
 
 
 
Ion 
description 
 
m/z observed 
 
 
MW 
calculated *∆ Mass  
Mass 
fragmented 
from parent 
ion  (M+5H) 
 
Bovine insulin 
pH  7 
 
1147.5  (M+5H) 
1434.3 (M+4H) 
 
5732.5 
5733.2 
0 (±1) 
 
na 
 
Citraconylated 
insulin pH 7 
 
1170.3 (M+5H) 
1490.3 (M+4H) 
 
5846.5 
5957.2 
113.5 
224.2 
 
114 
 
Bovine insulin 
pH  8 
 
956.5 (M+6H) 
1147.5  (M+5H) 
1434.3 (M+4H) 
 
5733.0 
5732.5 
5733.2 
0 (±1) 
 
 
na 
 
Citraconylated 
insulin pH 8 
 
 
1022.7 (M+6H) 
1222.5 (M+5H) 
1523.3 (M+4H) 
 
6130.2 
6107.5 
5957.2 
 
374.5 
356.7 
397.2 
 
112.5 
224.0 
 
Table 2.1 Effect of citraconylation on the MW of insulin at pH 7 and pH 8.* MW of 5733 
for insulin monomer was used to calculate ∆ Mass after modification.  
na = not applicable 
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2.3.2 Acetylating citraconylated bovine insulin and determining the 
extent of amino group acetylation 
Acetylation reactions of the crude citraconylated insulin from section 2.3.1 were 
carried out in 50 mM potassium phosphate buffer with the pH maintained at 8 
(chapter 7, section 7.3) and the extent of acetylation was determined by LC-
ESI-MS analysis. Having selectively citraconylated the two N-termini, the lysine 
was acetylated with a 10-fold molar excess of acetic anhydride. Lysine residues 
are reasonably good nucleophiles at pH 8.0, and therefore react with the 
carbonyl group of the acetic anhydride to form an amide bond with the acetate 
group being the side product (Hermanson 1996). As per Figure 2.10, the 
addition of acetyl is predicted to increase the MW weight by 42 atomic units. 
 
 
 
 
 
Figure 2.10   A schematic representative of the insulin molecule, showing the 
attachment of 2 citraconic groups and 1 acetyl group.  
 
The liquid chromatogram shows a small peak at 6.8 min in the modified insulin 
sample and at 5.3 min in the insulin control (Figure 2.11), it was present in all 
chromatograms obtained during insulin acetylation reactions and will be 
discussed in a later section (2.3.4).  
 
The control sample was put through all the buffer treatments and incubations 
without the derivatising agents, and it will be referred to as the ‘insulin control’ 
throughout chapters 2 and 3 to distinguish it from the insulin standard, which 
was the commercial sample, stored frozen. 
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The analysis also revealed that the crude citraconylated acetylated insulin 
peaks elute after the insulin peak (Figure 2.11). The LC-ESI mass spectrum 
showed a distribution of multiply protonated molecular ions, similar to that of 
unmodified insulin, although the modified insulin had a charged state of +4, 
while that of unmodified insulin was +5, consistent with the loss of an amino 
group. The citraconylated insulin sample, which was acetylated at 10-fold molar 
excess of anhydride per lysine, yielded a mass increase from 42 to 126 atomic 
mass units (Table 2.2), corresponding to one to three acetyl groups. The results 
also show the dicitraconylated insulin detected in the ESI-MS (Table 2.1) was 
absent after acetylation and it is assumed that it was a minor component of the 
citraconylated insulin. Table 2.2 shows the sixth component had a citraconyl 
group as well as 3 acetyl groups attached to it, which may be indicative of the 
O-acetylation of one of the five tyrosine residues present in bovine insulin. 
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Figure 2.11 LC-ESI-MS of (a) non-modified insulin and (b) citraconylated acetylated 
insulin. The m/z corresponds to each LC peak present in the total ion current (TIC) 
chromatogram. The samples were monitored at 280 nm PDA detector on the LC 
system. A: Full ESI-MS, shows a m/z of 1147.73, charge state of +5, molecular weight 
determined as 5734 Da. B: Full ESI-MS of the modified insulin peaks, have a charge 
state of +4. The six most abundant peaks on TIC have been identified in accordance 
with their molecular weights.  
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 m/z MW Change in MW Expected protein peak 
identification 
1 1147.9 5734.5 - Insulin monomer 
2 1156.3 5776.5 42.0 Monoacetyl insulin 
3 1164.7 5818.5 84.0 Diacetyl insulin 
4 1170.3 5846.5 112 Monocitraconyl insulin 
5 1178.8 5889 154.5  (112.5+42.0) Monoacetyl monocitraconyl 
insulin* 
6 1187.2 5931 196.5 (112.5+42.0+42.0) Diacetyl monocitraconyl 
insulin* 
7 1195.6 5973 238.5 
(112.5+42.0+42.0+42.0) 
Triacetyl monocitraconyl 
insulin 
 
Table 2.2 Effect of acetylation on the molecular weight of citraconylated 
insulin.*Indicates MW for components which elute at 2 different retention times on 
liquid chromatography, due to the difference in their sites of modification.   
 
2.3.3 Attempts to identify the unknown peak 
The unknown peak eluting earlier (RT=5.3 min) than the modified insulin peaks 
(RT=12.8-18 min) was present in the liquid chromatography of the unmodified 
and modified insulin sample chromatograms throughout this study (Figure 2.11). 
The intensity of the unknown peak varied relative to the intensity of the modified 
insulin peak. Attempts were made to identify the source of the unknown peak 
via the EI mass spectra. The peak was scanned from 190-350 nm using the 
photo diode array detector (PDA) source on the X-calibur software (Figure 
2.12). The absorbance of the molecule(s) was found to be of a broad range, 
with the maximum at 246 nm. The mass spectrum does not show a single m/z 
score but has a range of signals at a suppressed intensity (Figure 2.13). The 
mass spectra for the unknown peak were inconsistent along the distribution of 
the peak itself. It was assumed that the molecule possibly has m/z below 800, 
suggesting that it cannot be a protein, but phthalates.  
 
A literature search revealed that generally the EI spectra of phthalates lack a 
molecular ion and are characterised by an abundant base peak at m/z 149 
(Ende and Spiteller 1982, Kumar 1999). In addition, low abundance ions in the 
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higher mass range have also been assigned to phthalate esters. Phthalate 
esters tend to migrate from plastic sources into the environment (Williams 2004) 
as they are not chemically bound to the polymer. The possible source of 
contamination in the insulin samples during its amino group acetylation can be 
postulated to be polymeric in nature due to the broad PDA absorbance and its 
low ionisation. The procedure for insulin acetylation involved usage of plastic 
tubing/materials which were part of the autotitrator utilised to carry out the 
reactions (citraconylation followed by acetylation), which may have exclusively 
contributed to this contamination. As expected, this particular peak was absent 
from the insulin standard since it was tested straight from the standard jar 
(Figure 2.5). Attempts to run the modified insulin in negative ion mode on LC-
MS, to analyse the unknown peak were unsuccessful as it still did not ionise. 
The peak was not investigated any further and presumed to be artifactual. 
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Figure 2.12 PDA spectrum (190-350 nm) of the LC-ESI-MS peak at RT 5.3 min, shows 
that it has a maximum absorbance at 246 nm. 
 
 
800 1000 1200 1400 1600 1800 2000
m/z
0
20
40
60
80
100
R
el
at
iv
e 
A
bu
nd
an
ce
1425.31333.4 1951.91012.3 1659.4 1733.71475.6
1121.5952.4 
 
 
 
 
 
Figure 2.13 ESI-MS full mass spectrum of the unknown peak at RT 5.3 min, the 
spectra differed with the retention time variation of 0.01 min. The unknown peak was 
extracted from the LC-ESI-MS data in Figure 2.11. 
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2.3.4 Deprotecting of insulin N-terminals at pH 3.5 (de-citraconylation) 
With reference to the insulin amino group acetylation scheme shown early in 
this chapter (Figure 2.6), insulin was successfully modified to crude 
citraconylated acetylated insulin. The heterogeneous product was composed of 
nine different components modified to different degrees (Table 2.3), of which 
three components had the same MW, but differed in their LC peaks, which 
indicates their different sites of modification. The next step was to deprotect the 
insulin N-termini (Blundell et al. 1972, Zahn et al. 1972) since the citraconylation 
reaction is reversible (Figure 2.7) (Atassi and Habeeb 1972, Brinegar and 
Kinsella 1981). 
 
The lability of the citraconyl blocking group under various conditions was 
explored. Specifically, the effects of time and temperature on de-citraconylation 
of insulin amino groups were determined by treating samples at pH 3.5 in 75 
mM citrate phosphate buffer (Dixon and Perham 1968, Habeeb and Atassi 
1970). The samples were incubated at 20°C and 30°C for 0, 5, 10, 12, 24, 48, 
72, 96 hr and analysed on LC-ESI-MS to determine the change in MW. Loss of 
the citraconic groups was expected. However, the LC-ESI-MS data obtained for 
the samples deprotected at 20°C did not show a decrease in MW (data not 
shown).  
 
The LC-ESI-MS data obtained for the samples deblocked at 30°C were 
analysed and the MW of the sample components were calculated from the m/z 
score of each peak. The sample components were quantified based on the LC 
peak areas. The calculated MW was identified, with the degree of insulin 
modification that was expected. Deblocking of citraconic groups from crude 
citraconylated acetylated insulin was achieved at 30°C after 24 and 48 hr of 
acid (pH 3.5) treatment (Figure 2.14).   
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Figure  2.14  Total ion chromatograms (TIC) of crude citraconylated acetylated insulin 
after de-citraconylation, 48 hr treatment at pH 3.5. LC-MS was performed using an 
electrospray mass spectrometer operated in positive ion mode. Ions were scanned 
over a range of 800-2000 m/z [M+H]+). 
 
The bar graphs at 0 hr in Figure 2.15 show that at the outset of the acid 
treatment, the citraconylated acetylated insulin sample had nine components (a, 
c, d, f, g, h, I, j, k) in the mixture.  Monoacetyl insulin (b,c), and monoacetyl 
monocitraconyl  insulin (g,h) and diacetyl  monocitraconyl (i,j) were graphed 
separately since they differed in their retention times. 
Acid treatment of the sample (Figure 2.17 f, g, h, i, j, k) for 24 and 48 hr led to 
the loss of all citraconic groups in the nine components of the sample. The data 
show that after de-citraconylation, only five components (a, b, c, d, e) remained 
in the mixture of acetylated insulin, the components differing in the degree of 
acetylation (mono, di, tri). Sample component peaks with similar MW but 
different LC peaks were noticed as well. For example, there were two mono 
acetyl insulin peaks (b, c), one eluted at 13.8 min and the other at 14.1 min, 
suggesting different sites of acetylation.  
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Figure 2.15 Removal of citraconyl group from citraconylated acetylated insulin at 30ºC 
over time. Separate bar graphs are labelled with the different components of 
citraconylated acetylated insulin. Peak areas were quantified from LC-MS spectra. MW 
calculated from m/z score for each peak. Error bars show % error of the mean from 
duplicate samples.  
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It was also inferred that over the incubation period there was an increase in the 
peak area of the unmodified insulin present in the modified samples after 
deprotection at 24 and 48 hr of acid treatment. This can be attributed to the loss 
of the citraconyl groups from citraconylated insulin under acidic conditions.  
Deprotected samples at 24 and 48 hr of acid treatment contain mono, di, tri 
acetyl insulin which may differ in their site of acetylation. The results also 
showed that deprotection at 72 hr and beyond caused a decrease in the peak 
areas of the modified insulin fractions, indicating loss of proteins, presumably 
via aggregation.  
 
Citraconylated acetylated insulin required an acid treatment at 30°C for at least 
24-48 hr to remove the citraconic anhydride group and obtain acetylated insulin, 
which was then tested for its aggregation propensity as discussed in the next 
chapter. Quantitative analysis of the LC-ESI-MS peak areas from Figure 2.15 
revealed that 24% of the insulin was unmodified and that the largest proportion 
of the modified insulin was monoacetyl insulin at the retention time of 14.1 min 
(37% of the sample). Samples tested in chapter 3 for fibril formation were crude 
citraconylated acetylated insulin and crude acetylated insulin. 
 
2.3.5 Determination of the site of insulin acetylation   
The crude acetylated insulin, composed largely of mono acetyl insulin, was 
sequenced on LC-ESI-MS/MS to find the site of the acetyl group. Crude 
acetylated insulin was reduced and alkylated prior to trypsin digestion and 
sequencing by LC-ESI-MS/MS. The reduction alkylation was needed to break 
and cap the disulfides, to ensure complete digestion of the protein so that the 
peptide fragments could be identified by MS (Hale et al. 2004).  
 
Trypsin has well defined cleavage specificity at the carboxy terminal side of 
lysine and arginine. It typically yields peptides with an average length of about 
ten amino acid residues (Olsen et al. 2004). Studies in the 1960s on the trypsin 
digestion of bovine insulin (Bromer and Chance 1967, Carpenter 1966, 
Carpenter and Baum 1962, Young and Carpenter 1961) have shown the 
products to be alanine (C-terminus of B chain), a heptapeptide (B chain 
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residues 23-29) and desoctapeptide-insulin.  The expected site of trypsin 
cleavage for bovine insulin is shown in Figure 2.16. 
                                                      
                                             
 
                                                                              Tryptic cleavage sites 
 
Figure 2.16 Insulin amino acid sequence showing the two sites of trypsin cleavage. 
 
 
The mass sequencing of the trypsin-digested crude acetylated insulin was 
predicted to yield insulin B chain with an acetylated lysine. A control sample of 
unmodified insulin was also reduced and alkylated before trypsin digestion and 
then sequenced by LC-ESI-MS/MS.  
 
To observe a fragment ion by mass spectrometry, the parent molecule has to 
be fragmented and the resulting fragments must acquire a positive charge to be 
detected. The spine of a peptide contains three types of bond, C-C, C-N, and N-
C. Any of these bonds may be broken in the mass spectrometer and 2 of the 
ions resulting from the breakage are named B, and Y (Wedd 2007). Figure 2.17 
shows the mechanisms by which the commonly found B and Y ions may 
become charged.  
The acquired MS/MS spectra for each sample were searched using the 
SEQUEST algorithm (under license from the University of Washington, 
(BioWorks Browser© v3.2 EF2, Thermo Electron Corp., CA, USA) against the 
in-house protein database (MacCoss et al. 2002, Moore et al. 2002). BioWorks 
3.2 features the SEQUEST protein search algorithm, which automatically 
identifies peptides by comparing experimental mass spectrometry (MS/MS) 
data with standard protein databases. Searches were performed with trypsin 
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specified as the enzyme with an allowance for missed cleavage of one amino 
acid, for potential hindrance to cleavage of the acetylated lysine B29. Data were 
filtered and scored against SEQUEST database consisting of bovine insulin A 
and B chains and trypsin with the expected variable amino acid modifications of 
alkylation (+58) on cysteine (C) and acetylation (+42) on N-terminal amines and 
lysine (K). Possible peptide combinations were then filtered to show only 
matches with greater than 30% Y and B ion confirmation and a preliminary 
score (Sp) of greater than 200. An explanation of scoring is provided in section 
7.6.3.4 (Novatia 2008).  
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Figure 2.17 Formation and charging of B and Y ions (Wedd 2007). 
 
The ion value gives a measure of the number of experimental ions that matched 
with the theoretical ions for the peptide listed. For example, 8/10 says that the 
LC-MS/MS spectrum contained 8 out of 10 predicted ions for the peptide. 100% 
coverage of the predicted ions is rare, but 70% or 80% coverage is common 
(Joyce, pers. comm.). The scan range limitations or the low mass cut-off feature 
of the ion trap might drop off ions at either end of the spectrum (Joyce, pers. 
comm.). The ion link showed the MS/MS spectrum labeled with the theoretical 
ions from the matched peptides. 
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Combinations of cysteine alkylation with and without N-terminal acetylation 
were identified, but lysine acetylation did not appear to be present. Results are 
summarised in Figure 2.18 and reveal that the glycine on the N-terminus of the 
insulin A chain was acetylated in the crude acetylated insulin.  
 
Insulin B chain fragments 
           
Insulin A chain fragments 
 
 
Figure 2.18 Prominent fragments and modifications for crude acetylated insulin digest. 
Sample was injected in a 10 µl aliquot. Separation was performed on a Zorbax-300SB-
C8, column with a mobile flow rate of 300 µl/min. The mobile phase consisted of water 
(A) and acetonitrile (B) both containing 0.2% formic acid (FA). An elution gradient of 
95% A held for 5 min then switched to 70% A with a linear gradient to 20% A over 45 
min was applied. The column was then re-equilibrated with 95% (A). Eluent was 
dispersed with electrospray ionisation (ESI) in the positive mode for ionisation of the 
peptides into the ion-trap mass analyser from 400-2000 m/z. Full scan normal/zoom 
data were automatically filtered to select M+2H and M+3H peptide states for MS2 
fragmentation to produce fragments suitable for sequence analysis. Any undefined 
charge states were not selected for fragmentation. Note: •Denotes point of enzyme 
cleavage, # Alkylation, *N-terminal acetylation. 
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These findings demonstrate that the glycine on insulin A chain was 
unexpectedly not protected by citraconic group and hence was most susceptible 
to acetylation using this procedure. This is in accordance with the results of 
Lindsay and Shall (1971) who also found that acetylation of insulin with 
hydroxysuccinimide esters increasingly favours reaction at the glycine residue 
on increasing pH. Modifications of the A1 group by acetyl (Zahn et al. 1972), 
acetoacetyl (Lindsay and Shall 1969), have crystal structures which indicate 
that they form hexamers and can have similar structures to insulin but circular 
dichroism indicates that acetylation at A1 may induce conformational changes 
in solution (Blundell et al. 1972, Lindsay and Shall 1971). This is of much 
interest, knowing that a change in the polarity, the secondary structure 
propensity or the net charge of the polypeptide determine a protein’s ability to 
form amyloid (Chiti et al. 2002, Fink 1998, Lopez de la Paz et al. 2002, Lopez 
de la Paz and Serrano 2004). These crude modified insulin samples were 
analysed in fibril trials and are described in chapter 3. 
 
2.4 Reductive Alkylation of Bovine Insulin 
 
This section describes the second approach to derivatise insulin, which was 
reductive alkylation of insulin disulfide bonds. The role of disulfide (S-S) bridges 
in proteins is to add stability in the changing extracellular environment; in 
general, if all the disulfide bonds in a protein are reduced, both the structure and 
the function are lost completely (Thornton 1981). This is true for insulin (Figure 
2.1), where breaking the disulfide linkages of insulin results in an extensive 
unfolding (Markus 1964, Thornton 1981, Waugh 1948), with the conformational 
change accompanying the reduction being the direct consequence of the 
release from the restriction imposed on the native structure by these bonds 
(Fukada and Takahashi 1980, Markus 1964).  
 
Reduction of disulfide bridges is conducive to a greater molecular flexibility and 
a dramatic increase in the exposure of hydrophobic regions. To study the role of 
the disulfide bridges in insulin, all disulfides were reduced with dithioerythritol 
(DTE) and the free cysteines were blocked with IAA and 4-VP. These are 
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frequently used alkylating agents: IAA yielding S-carboxymethyl cysteine and 4-
VP yielding S-pyridylethyl cysteine (Simpson 2003). Iodoacetic introduces a 
hydrophobic moiety to the cysteine while the 4-VP introduces a negative nature 
to the side chain of the protein. The molecular weight change of insulin before 
and after the reduction and alkylation processes was determined by LC-ESI-
MS. The ability of the reduced and alkylated insulin to self-assemble into 
amyloid fibrils was monitored and will be discussed in chapter 3. 
 
2.4.1 Reduction and characterisation of bovine insulin 
Bovine insulin (10 mg/ml) was reduced with DTE at pH 8.0, in 8 M urea using a 
published method (Shechter et al. 1973). DTE  reduces all accessible biological 
disulfides and maintains free thiols in solution even in the presence of oxygen 
(Hermanson 1996) (Figure 2.19). 
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X SH
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HO OH
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Oxidised DTE  
Figure 2.19 DTE reduction of disulfides (Hermanson 1996). 
 
2.4.2 Carboxymethylation and pyridylethylation of reduced insulin 
For the alkylation process, the reduced insulin was further modified by either 
carboxymethylation or pyridylethylation. Figure 2.20 (a) and (b) show the 
carboxymethylation of a reduced cysteine by IAA and pyridylethylation.  
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Figure 2.20 Modification of free SH groups by a) iodoacetic acid b) 4-vinylpyridine 
(Friedman 2001). 
 
2.4.3 Characterising the reduced alkylated insulin 
The reduced insulin samples (before and after carboxymethylation) were gel 
filtered using a Sephadex G-25 column to remove salts. For control purposes, 
the starting material was also gel filtered (insulin control).  
 
The addition of 4-VP to the crude reduced insulin resulted in the formation of a 
white precipitate of reduced pyridylethylated insulin (RPE) which was 
centrifuged at 5000 rpm for 10 min to separate supernatant from the pellet. The 
RPE supernatant was also gel filtered. An example of the gel filtration 
chromatography column profile obtained is shown in Figure 2.21. The protein 
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peaks corresponding to insulin control, reduced insulin, reduced-
carboxymethylated (RCM) insulin and RPE insulin were pooled separately, 
were lyophilised and stored at 4°C. LC-ESI-MS analysis was used to confirm 
the identity of the pooled fractions corresponding to the peaks on the gel 
filtration profile. The RPE pellet was solubilised in HCl (25 mM) at pH 2 for LC-
ESI-MS. After the characterisation of the insulin control and the modified insulin 
on LC-ESI-MS, samples were tested for aggregation propensity, as discussed 
in chapter 3. 
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Figure 2.21 Gel filtration chromatography of soluble derivatised insulin samples on a 
Sephadex G-25 column (2.6 cm x 100 cm) equilibrated in 50 mM ammonium 
bicarbonate pH 7.9. The chromatogram shows peaks corresponding to insulin control 
(green), reduced insulin (blue), RCM insulin (pink) and RPE insulin supernatant (red).   
 
2.4.4 Determining the extent of insulin reduction alkylation 
LC-ESI-MS was used to analyse insulin before and after disulfide reduction as 
well as after S-carboxymethylation and S-pyridylethylation. The mass of the 
insulin increased by ~58 as a result of the introduction of one carboxymethyl 
group for each SH group and by ~106 for the pyridylethylation (Table 2.4). As 
discussed in section 2.2.2 of this chapter, insulin contains three disulfide bonds 
(Figure 2.1); the two interchain bonds are more reactive than the intrachain 
disulfide bond with their reactivities ranging in the order: A7-B7>A20-B17>A6-
A11 (Blundell et al. 1972). 
 
 77
Chapter 2   Modification and characterisation of insulin 
LC-ESI-MS profiles of insulin after reduction, reduction carboxymethylation, and 
reduction pyridylethylation (supernatant and pellet) are shown in Figure 2.22. 
The insulin control was also analysed and Figure 2.22 (a) shows a single peak 
of insulin with m/z score labelled as 1147.7, with the MW calculated to be 
5733.5 Da at a charge of +5. This was expected and shown earlier in section 
2.1. Reduction of insulin disulfides with DTE produced a crude mixture of 
separated insulin chains A and B, including some unmodified insulin (Figure 
2.22 b). Analysis of the LC-ESI-MS data showed the presence of some 
unmodified insulin (5733 Da), insulin A chain (2335 Da) and B chain (3398 Da) 
(Figure 2.22 b). 
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e) Crude reduced pyridylethylated insulin, pellet 
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Figure 2.22 A 10 µl aliquot of modified and unmodified insulin was injected onto the 
Thermofinnigan Micro AS system for LC-ESI-MS. (Thermo-Finnigan LTQ mass 
spectrometer described as a 2D linear quadrupole iontrap, San Jose, CA, USA). A 
triple play (full scan, Zoom scan, CID with 35% collisional energy) data-dependent 
acquisition method with dynamic exclusion was performed using the Xcalibur software. 
Spectra were processed using the base peak ion chromatogram and a seven-point 
Gaussian smoothing function. The multiply charged peaks detected by the ESI-MS 
experiment were manually deconvoluted based on the high resolution mass scans 
(Zoom scan which provided charge state information). Each peak shows its retention 
time and m/z score of the protein component. 
 
 
 
 
 
Figure 2.23 Separate insulin chains (A chain 1-21, B chain 1-30) showing the 
modification of the liberated SH groups with iodoacetic acid.  
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Calculations from the LC-ESI-MS data in Figure 2.22 (c) show that insulin A 
chain has increased in MW from 2338 Da to 2568 Da, confirming the 
attachment of four carboxymethyl groups (58 Da per carboxymethyl) to the four 
cysteine molecules present on the A chain (Table 2.3). Figure 2.22 (c) also 
shows an increment in the MW of the peak representing the insulin B chain 
(MW=3516 Da) which suggests that the two cysteines on the insulin B chain 
have been carboxymethylated (Table 2.3). The unmodified insulin was carried 
over from the reduction step to the RCM insulin mixture, indicated by the peak 
corresponding to MW 5733.4 Da in Figure 2.22 (c).  
 
As discussed earlier, pyridylethylation of the crude reduced insulin led to a 
crude RPE supernatant and pellet. The two fractions were analysed separately 
on LC-ESI-MS for comparison purposes. The RPE pellet was solubilised in HCl 
(25 mM) at pH 2 for LC-ESI-MS. Figure 2.22 (c) and (d), both showed the loss 
of the unmodified insulin peak from the chromatogram. 4-VP produced 
hydrophobic insulin A and B chains, with an elution pattern on LC-ESI-MS 
chromatogram different from that of the unmodified insulin, which was expected. 
The pellet had a mixture of S-pyridylethylated insulin A and B chain and the 
supernatant sample was largely composed of insulin A chain (Figure 2.22 d, e 
and Table 2.3).  
 
There is an increase in the MW of insulin A and B chain which confirms that it 
has 4 and 2 pyridylethyl groups attached to the respective reduced cysteines 
(Table 2.3). The pellet profile has a higher intensity for both S-pyridylethylated 
insulin A and B chain, while the supernatant has a more intense peak for S-
pyridylethylated A chain than the B chain. This reflects the partial separation of 
the two chains: the supernatant mainly contained the A chain, and the pellet 
consists of both the A and B chain.  
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Ion  
description 
MW 
calculated 
 
∆ MW  
 
Sequence 
Insulin  
monomer 
 
5733.4 
 
NA 
 
 
 
 
 
Reduced  
insulin 
5733.4 
2335.3 
3398.3 
3399.9 
10196.9 
NA  
 
 
 
RCM insulin  
(A and  B chain) 
5733.4 
 
 
 
 
2571.6 
 
 
 
3516.1 
 
0.0 
 
 
 
 
236  
(4 x 59) 
 
 
118 
(2 x 59) 
   
 
 
 
 
 
 
 
RPE insulin 
(A and  B chain) 
 
2760.4 
 
 
3610.4 
 
425  
(4 x 106) 
 
212  
(2 X 106) 
 
 
 
Table 2.3 Effect of reduction, reduction S-carboxymethylation, reduction S- 
pyridylethylation on insulin molecular weight. Note:* represents the 
carboxymethyl/pyridylethyl group attached to insulin, with a MW of 58 ±1 Da or 106±1 
Da. MW of insulin A and B chain without any modification is, A chain = 2337.9 Da, B 
chain = 3397.7 Da modification. ∆ MW = MWafter modification – MWbefore modification 
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Overall, the insulin intermolecular and intramolecular disulfide bonds were 
reduced and alkylated (carboxymethylated, pyridylethylated) to obtain crude 
mixtures of RCM and RPE insulin samples for testing aggregation propensity in 
chapter 3. In addition, there was an insulin control sample and reduced insulin, 
which were also tested in aggregation trials. 
 
2.5 Trypsin Digestion of Bovine Insulin  
 
Insulin was digested with trypsin (section 2.3.5, Figure 2.18) on a large scale to 
obtain digests in reasonable quantities (20 mg) for fibril studies in chapter 3. 
Insulin was treated with trypsin at a ratio of 1:50, enzyme to protein ratio at pH 
8.5 (37ºC) for 4 hr (Sigma-Aldrich 2007). Half of the sample digested in the first 
4 hr was retained and the rest was digested sequentially for 12 more hours, with 
4 hr per enzyme addition, to obtain totally digested insulin, without any 
undigested insulin in the mixture. Samples were digested in 500 µl fractions, in 
Eppendorfs. The insulin standard was also treated under the same conditions 
without the enzyme, and will be referred to as the insulin control. LC-ESI-MS 
analysis of the insulin control and trypsin treated insulin is shown in Figure 2.24. 
Mass spectrometry revealed that the intial enzyme digestion (Figure 2.24 b) 
resulted in insulin cleavage to produce 2 peptides with m/z, 859 and 965. Table 
2.4 shows the peptide sequences that were obtained, in addition to the 
undigested insulin present in the trypsin treated sample. 
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Figure 2.24 LC-ESI-MS analysis of (a) insulin control and (b) trypsin treated insulin (4 
hrs, 1:50, enzyme:protein ratio). Labels show the m/z score representing tryptic 
peptides, undigested insulin.  
 
Sequential addition of trypsin to insulin led to the total digestion of insulin to 
produce 3 tryptic peptides with m/z 859, 965, 1133 (Figure 2.24 b). The insulin 
fragments (Table 2.4) produced in a crude mixture from these experiments were 
freeze dried and tested for aggregation propensity in chapter 3. 
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Figure 2.25 LC-ESI-MS analysis of (a) insulin control and (b) trypsin treated insulin (4 
hrs of 4 sequential treatments at 1:50, enzyme:protein ratio). Labels show the m/z 
score representing tryptic peptides.  
 
 
 
Elution 
time 
(min) 
Ion description m/z 
observed 
Sequence 
12.9 Insulin 
monomer 
1147.8  
(M+5H) 
9.5 Tryptic peptide 859.6 (M+H) 
 
12.2 Tryptic peptide 965.3 
(M+5H) 
 
13.1 Tryptic peptide 1133.7 
(M+5H) 
 
Table 2.4 Effect of trypsin digestion on bovine insulin molecular weight and sequence 
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2.6 Chymotrypsin Digestion of Bovine Insulin 
 
This section illustrates the effect of chymotrypsin on insulin cleavage, to obtain 
peptide fragments for fibril studies in chapter 3. Insulin was treated with 
chymotrypsin at a ratio of 1:50, enzyme to protein ratio, at pH 8.5 (37°C) for 4 hr 
(Sigma-Aldrich 2007). Insulin standard was also treated under the same buffer 
conditions without the enzyme (insulin control).  
 
The general strategy to analyse the digested fragments of insulin via LC-MS/MS 
involved the following steps (Yen et al. 2002): (1) chymotrypsin digestion of 
insulin at pH 8.5 to obtain peptides; (2) complete reduction with dithioerythritol  
and alkylation by IAA to label the cysteine residues of the peptides; (3) LC-ESI-
MS/MS analysis of the resulting peptides to identify the fragments. A diagram of 
this scheme is shown in Figure 2.26. Treatment with DTE and IAA was 
necessary because it is more difficult to analyse fragments for disulfide-bonded 
peptides than those completely reduced and alkylated. This step was not 
necessary for the trypsin cleavage of insulin in section 2.5 since the trypsin 
employed specifically cleaved insulin to produce the 3 expected peptide 
fragments, while chymotrypsin cleaved at more than its expected sites of 
cleavage to produce fragments which were difficult to identify prior to the insulin 
reduction and alkylation. 
                        
The acquired MS/MS spectra for insulin control and the chymotryptic digest of 
insulin were searched using the SEQUEST (under license from the University of 
Washington) algorithm on the BioWorks Browser© v3.2 EF2 (Thermo Electron 
Corp., CA, USA) against the in-house insulin database (MacCoss et al. 2002, 
Moore et al. 2002). Searches were performed with chymotrypsin specified as 
the enzyme with an allowance for up to two missed cleavage sites.  
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Figure 2.26 Scheme of the experimental protocol, with modifications from the literature  
(Yen et al. 2002). *carboxymethylated. 
 
LC-ESI-MS ion chromatograms and spectra of the insulin control and 
chymotrypsin treated insulin are shown in Figure 2.27 a. SEQUEST search for 
the insulin control treated with the buffer (without enzyme) showed the presence 
of the separated A and B chains of insulin, with the cysteines 
carboxymethylated (Table 2.5). These data confirm the presence of undigested 
insulin in the insulin control. SEQUEST identified a list of peptide sequences 
(Table 2.5) for the chymotrypsin treated insulin (Figure 2.27 b).  The four 
fragments expected from the chymotryptic digest of insulin (Figure 2.26) were 
present in the sample (Table 2.6). The table also shows that the chymotrypsin, 
had missed cleavages, by one or two amino acids, which led to more than the 
four expected fragments. The presence of separated insulin chain B chain, with 
the cysteines modified (Table 2.6), suggests that undigested insulin B chain is 
present in the chymotrypsin treated sample. 
Fibril trial
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RT 
(min) 
m/z 
(M+nH)n+ 
MW Sequence  Insulin 
chains 
 
36.8 
 
12852+ 
 
2568 
 
GIVEQ*C*CASV*CSLYQLENY*CN 
 
A chain 
 
41.2 
 
8804+ 
11733+ 
17582+ 
 
3516 
 
FVNQHL*CGSHLVEALYLV*CGERGFFYTPKA  
 
B chain 
 
Table 2.5 Major peptide components from insulin reduced and carboxymethylated, A chain 
with the 4 cysteines carboxymethylated, B chain with the two cysteines carbxymethylated. 
RT is retention time.*Indicates carboxymethyl group. 
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Figure 2.27 Total ion chromatograms (TIC) of insulin control (A) and chymotrypsin 
treated insulin (B) Samples were at 1 mg/ml. The m/z score corresponding to each 
peak is labelled. LC-ESI-MS was performed using an electrospray mass spectrometer 
operated in positive ion mode. Ions were scanned over a range of 800-2000 m/z 
[M+H]+).  
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Chymotrypsin digestion of insulin led to the successful preparation of a crude 
mixture of insulin peptide fragments in reasonable quantity for fibril studies in 
chapter 3. The insulin control was also tested.  
 
 
RT, min m/z 
(M+nH)n+ 
Sequence  
10-12 579 YTPKA   
13.17 - 13.70  610 F.VNQHL.C  
20.84 - 20.86  941 
     
Fragment 1 
20.88 - 21.59  666 Y.QLENY.C  
21.61 - 21.78  1166 F.VNQHLC*GSHL.V  
21.81 - 21.87  825 L.VC*GERGF.F  
22.00 - 22.52  757 -.FVNQHL.C  
22.55 - 22.99 726 F.FYTPKA  
25.66 - 25.81  1313 .FVNQHLC*GSHL.V  
25.84 - 26.32  938 
 
Fragment 2 
26.35 - 26.80  594 L.VEALY.L  
29.03 - 29.37 987 L.C*GSHLVEAL.Y  
30.26 - 30.39 1102 L.YLVC*GERGF.F   
30.42 - 30.53 1533 L.VC*GERGFFYTPKA   
30.66 - 30.81  1578 F.VNQHLC*GSHLVEAL.Y  
31.73 - 31.80  972 L.VC*GERGFF.Y   
31.82 - 31.92  1150 L.C*GSHLVEALY.L  
31.98 - 32.13  1150 L.C*GSHLVEALY.L   
32.72 - 32.94  1725 .FVNQHLC*GSHLVEAL.Y   
32.96 - 33.37  1741 
 
Fragment 3 
33.43 - 33.72 1486 -.GIVEQC*C*ASVC*SL.Y  
33.95 - 34.20  1086 Y.LVC*GERGFF.Y   
34.79  1263 L.C*GSHLVEALYL.V   
35.21 - 35.60 1649 
 
Fragment 4 
36.95 - 37.16  1249 L.YLVC*GERGFF.Y   
38.00 - 38.11  1263 L.C*GSHLVEALYL.V  
42.2 880 FVNQHL*CGSHLVEALYLV*CGERGFFYTPKA B chain 
46.5-46.7 986 C*GSHLVEAL  
 
Table 2.6 Peptide matches from insulin chymotrypsin digest. *Indicates the 
carboxymethyl group attached to the cysteines. •Denotes point of enzyme cleavage 
The four peptide components that were expected (Figure 2.28) are labelled.  
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2.7 Summary 
 
Chemical modifications of insulin discussed in this chapter yielded 
heterogeneous mixtures of products in most cases, simulating the sorts of 
mixtures that might be relevant in an industrial process using crude protein 
extracts. The products obtained in sufficient quantities for use in chapter 2 and 
3 are listed below (Figure 2.28): 
 
a)* Crude citraconylated acetylated insulin 
 
 
 
b) Crude acetylated insulin 
 
 
 
c) Crude reduced carboxymethylated insulin 
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d) Crude reduced pyridylethylated insulin (pellet and supernatant) 
 
 
 
 
 
e) Crude tryptic digest of insulin 
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f) Crude chymotryptic digest of insulin  
 
 
Figure 2.28 Structures showing modified insulin products obtained: (a) citraconylated 
acetylated insulin with 1 sites of citraconyl group attachment, (b) glycine acetylated 
insulin, (c) reduced carboxymethylated insulin, (d) reduced pyridylethylated insulin, (e) 
tryptic digest of insulin, (f) chymotryptic digest of insulin. * Note: The site of citraconyl 
group attachment was not confirmed, and has been presumed in the structure shown. 
 
The crude citraconylated acetylated insulin, was largely composed of three 
forms of insulin, in decreasing levels, monoacetyl monocitraconyl insulin > 
monocitraconyl insulin > diacetyl monocitraconyl insulin.  The crude acetylated 
insulin mixture also was composed of three forms of insulin, in decreasing 
levels, monoacetyl insulin > unmodified insulin > diacetyl insulin. Both of these 
mixtures of acetylated insulin were obtained in sufficient quantities and then 
subjected to aggregation trials. 
 
In addition, reduction alkylation of bovine insulin led to the preparation of crude 
reduced carboxymethylated insulin and crude reduced pyridylethylated insulin 
(precipitate and supernatant), including the respective insulin control samples. 
These samples were also tested for aggregation propensity in chapter 3. 
 
Two forms of crude enzymatic digests of insulin were obtained, with trypsin 
digestion and chymotrypsin digestion of insulin. 
 
All of the crude modified insulin samples summarised in this section were tested 
for aggregation propensity in chapter 3 to determine the ability of amyloid fibril 
to form in heterogeneous mixtures of modified insulin. 
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The Impact of Modification on Insulin 
Aggregation and Fibril Formation 
 
As described in chapter 1, there are a range of diagnostic measures for amyloid 
fibrils including their characteristic positive interaction with amyloid detecting 
dyes such as ThT and their morphology, as observed by microscopy 
techniques. In this chapter, ThT binding and TEM are used to assess whether 
the heterogeneous mixtures of modified insulin, characterised in chapter 2, form 
amyloid fibrils when subjected to partially denaturing environmental conditions 
known to fibrillise native insulin. These heterogeneous mixtures are typical of 
crude protein mixtures likely to be available as cheap starting materials for 
industrial fibril production. 
 
 
3.1 Effect of Association States and Oligomerisation on Insulin 
Fibrillation 
 
Several studies have shown that the formation of insulin fibrils is preceded by 
the assembly of partially folded insulin monomers into relatively small oligomers 
(Ahmad et al. 2005, Bouchard et al. 2000, Nettleton et al. 2000). The pathway 
for the formation of insulin fibrils can be described by a simple model 
hexamer? modified monomer? fibrils shown in Figure 3.1 (Ahmad et al. 2003, 
Nielsen et al. 2001a, Nielsen et al. 2001b). 
 
The fully formed insulin fibrils are morphologically distinct and consist of 
between two and six protofilaments interwined into a braided fibrillar structure 
as described in chapter 1, section 1.4.1 (Jiménez et al. 2002). A model for the 
molecular packing of three protofilaments of the insulin molecule within the fibril 
is shown in Figure 3.2 C. 
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Figure 3.1 Model for insulin fibrillation (different shapes represent different 
conformations. The nucleus is shown schematically and consists of a number of 
subunits), adapted from (Nielsen et al. 2001b). 
 
In its native state, insulin is predominantly α-helical (chapter 2, Figure 2.4); the 
monomer self-assembles into dimers, tetramers, and hexamers, depending on 
the concentration and the solvent conditions (Hua and Weiss 2004, Nettleton et 
al. 2000). Insulin exists as a monomer in 20% acetic acid (pH 1.6, 100 mM 
NaCl), a dimer in 25 mM HCl (pH 1.6, 100 mM), a tetramer at pH 3 (20 mM 
formate buffer, 100 mM NaCl) and a hexamer at pH 7.4 (20 mM phosphate 
buffer, 100 mM NaCl) (Nielsen et al. 2001b). Thus, for fibril formation to occur, 
the hexameric or tetrameric associated states of insulin at neutral pH, or the 
dimers at low pH, must initially dissociate into monomeric molecules, which are 
in equilibrium with a partially folded conformation that undergoes 
oligomerisation to form the critical nucleus (Figure 3.1). This step is assumed to 
involve a number of non-native oligomeric precursors, accounting for the lag 
phase observed in the kinetics of fibrillation (Jahn and Radford 2008).  
 
Although one cannot completely exclude the possibility that fibrils may grow by 
addition of individual insulin monomers, the model described in Figure 3.2 
assumes that elongation of protofilaments is directed by insulin oligomer 
association. Figure 3.2 displays a model with a central cavity in which the cross-
section contains eight helical oligomers. Fourteen repeats of the length of these 
eight helical oligomers would form a full turn of one protofilament across three 
fibril repeating units. Two protofilaments presumably intertwine to form the 
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protofibrils, yielding an average protofibril diameter of about 10 nm. Finally, 
three protofibrils intertwine to form the mature insulin fibril.  
 
 
 
Figure 3.2 Model for assembly of the distinct insulin oligomers into protofilaments, 
protofibrils, and fibrils, generated using small-angle x-ray scattering (SAXS): 
(A) Eight helical oligomers (shown in a colour scale from purple through red to light 
yellow) intertwine to form the protofilament. Eight additional precursors in grey nuances 
form the open ends of the model. Side and top views are shown. 
(B) Two protofilaments presumably intertwine to form the protofibrils, with an average 
diameter of 10 nm (top view, intertwining not depicted). An orange ellipse marks the 
outer boundaries of one protofibril.  
(C) Three protofibrils (shown in orange, yellow, and red) intertwine to form the mature 
insulin amyloid fibril ~ 30 nm. Shown are side and front views. An oligomer (blue) is 
superimposed onto the fibril mode , from (Vestergaard et al. 2007). 
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It can be assumed that the helical oligomer is both the structural nucleus and 
the elongating building block of insulin amyloid fibrils. The final morphology of 
the mature fibril is dependent on the conditions under which the fibril was 
formed and can change subtly between treatment conditions (chapter 1, section 
1.5), and even within the same sample (Whittingham et al. 2002).  
 
 
3.2 Standard Insulin Fibril Formation and ThT Assay  
 
ThT, is a fluorescent dye that is frequently used as a specific probe to detect 
amyloid fibril formation in vitro (LeVine 1993, Naiki et al. 1989). Prior to its 
chemical modification, the standard insulin purchased for this study was 
subjected to conditions, low pHs and at high temperatures, known to cause 
fibrillation (Nielsen et al. 2001b, Waterhouse 2003). Fibrils were then 
characterised using the ThT assay on either a spectrofluorometer or a plate 
reader for in situ fibril ThT assays (Nielsen et al. 2001b). Incubations were 
carried out in conditions known to favour the monomeric form of insulin, pH 1.6, 
20% acetic acid solution (Uversky et al. 2003). 
 
3.2.1 Small scale fibril formation and ThT assay 
The spectrofluorometric method involved two separate steps: firstly, to form 
fibrils over time of protein incubation at elevated temperatures and secondly, to 
characterise the rate of fibrillation using the ThT assay. The results obtained 
from this procedure for a standard insulin fibrillation are presented in Figure 3.3. 
The observed ThT fluorescence intensity had a classic sigmoid pattern (Figure 
3.3) (Nielsen et al. 2001b). It also showed the typical fibril formation process, 
with a lag phase of ~1.5 hr. At the end of the lag phase, a sudden increase in 
fibril concentration was observed. Eventually, the process reached saturation 
when most soluble proteins were converted into fibrils. The maximum 
fluorescence intensity observed on the spectrofluorometer was 630 relative 
fluorescence units (Figure 3.3).  
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Figure 3.3 The behaviour of insulin, over time of fibrillation at 5.7 mg/ml, in 20% acetic 
acid, 100 mM NaCl, (pH 1.6) at 60°C. For the ThT assay, samples were assayed in 
triplicate in Tris buffer (pH 7.5) with ThT, final concentration of insulin in the assay was 
0.02 mg/ml. Error bars represent the standard deviation of the mean. The curve was 
fitted according to the method of Nielsen et al. (2001c), the data show a lag time of 1.5 
hr. 
 
3.2.2 In situ fibril formation and ThT assay 
In order to facilitate the rapid screening of many samples over time, a high 
throughput method was developed using 96 well plates. ThT was included in 
the acid and fibril formation monitored in real time. Since ThT may influence the 
amyloid forming process in the in situ method, it was important to compare this 
method to that described above, where the ThT assay was carried out after 
fibrils had formed. 
 
In situ fibril ThT fluorescence measurements were carried out on the 96 well 
plate reader. This procedure was chosen as it allows a relatively large number 
of samples to be assayed using small reaction volumes of 200 µl. Insulin fibrils 
were formed within a few hours of incubation at 60ºC. Fibrillation was monitored 
by measuring fluorescence at 482 nm over time of incubation until maximum 
ThT signal was obtained (Figure 3.4).   
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In situ insulin fibrillation with ThT binding illustrated that the increase in ThT 
fluorescence intensity again followed the classic sigmoidal pattern (Figure 3.4), 
similar to Figure 3.3. From the kinetic analysis of the time course ThT assay, it 
was found that, at 5.7 mg/ml, insulin had a lag phase of 1.7 hr, which is in 
reasonable agreement with the first method.  
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Figure 3.4 Behaviour of insulin at 5.7 mg/ml, at 60ºC in 20% acetic acid (100 mM 
NaCl) only, fibril formed in situ in the plate reader. Samples were analysed in triplicate 
and the curve fitted according to the method of Nielsen et al. (2001c). Fluorescence 
was measured at a final concentration of 5.7 mg/ml insulin and 5-10 µM ThT. The 
maximum fluorescence intensity obtained on the plate reader was 63870, close to the 
maximum reading of the instrument (65000).   
 
3.2.3 Summary of the two methods for ThT fibrillation 
The above results obtained for insulin fibrillation at 5.7 mg/ml, in 20% acetic (pH 
1.6) and 60°C, shows that both methods gave similar lag times (Figure 3.3, 
Figure 3.4).  The in situ method was thus used for rapid screening of the insulin 
samples and allowing more investigations with the limited quantities of modified 
samples available. Since the conditions were different between the two 
methods, direct comparison was not possible. This is because, between the two 
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different methods for ThT assay above, there is also a significant difference in 
the pH at which the ThT assay is carried out. In the small scale fibrillation 
method, the growth of fibrils was carried out at pH 1.6 but the assay was done 
at pH 7.5, the pH at which ThT binding to β-sheets is at its optimum (Nielsen et 
al. 2001b). In contrast, in the plate reader method, the ThT binding took place in 
situ, at pH 1.6.  
 
Even though histological dyes like ThT and Congo red (CR) have been 
commonly used as indicators of the presence of amyloid fibrils, the relationship 
between fluorescence intensity and amount of amyloid fibril remain unclear 
(LeVine 1999). It has been demonstrated that the ThT fluorescence maximum is 
dependent on the pH, for example, murine senile amyloid protein, amyloid 
protein A (Naiki et al. 1989) and the β-amyloid protein (LeVine 1993) are 
reported to display different maximum fluorescence levels in solutions at 
different pH levels. ThT fluorescence when bound to insulin amyloid fibrils was 
found to be maximal at approximately pH 8, in a 50 mM Tris, 100 mM NaCl 
buffer, close to the pH 7.5 Tris-NaCl used in previous work in the literature 
(Nielsen et al. 2001b, Waterhouse 2003).  
 
The impact of pH and amyloid concentration on fluorescence at 482 nm, was 
determined by investigating the linearity range of concentrations of insulin fibrils 
with ThT fluorescence at 482 nm. 
 
3.2.4 The impact of pH and insulin fibril concentration on ThT 
fluorescence 
Fibrils formed after 4 hr of incubation at 60ºC, pH 1.6 (Figure 3.4) were diluted 
separately in the two different buffers used for each method. Figure 3.5 
illustrates that the fluorescence of the fibril solutions, at both pHs 1.6 and 7.5, 
increased with increasing insulin concentration until reaching a the maximum 
fluorescence reading. Overall, the fluorescence values were higher at pH 7.5 as 
compared to those obtained at pH 1.6. This was expected due to the higher 
binding capacity of insulin fibrils to ThT dye at a higher pH (Nielsen et al. 2001b, 
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Sabaté et al. 2008). However, another study specified that the ThT binding 
capacity is unaffected by pH (Groenning et al. 2007). 
 
At pH 7.5, fluorescence intensity increased rapidly with increasing insulin 
concentration until 0.12 mg/ml, after which it remained at the maximum value of 
the instrument. A linear relationship was found between the insulin 
concentration ranging from 0.004 mg/ml up to 0.10 mg/ml and ThT 
fluorescence, having a correlation coefficient (R2) of 0.99 (Figure 3.5). At pH 
1.6, the linear range extended to 0.8 mg/ml, after which fluorescence remained 
at the maximum value.  
 
 
Figure 3.5 Effect of insulin fibril concentration on ThT fluorescence at 482 nm, in 50 
mM Tris, 100 mM NaCl pH 7.5 (crosses) and 20% acetic acid, 100 mM NaCl, pH 1.6 
(shaded diamonds). Insulin fibrils were initially formed at 5.7 mg/ml pH 1.6, 20% acetic 
acid, 100 NaCl, at 60ºC for 4 hr in plate reader. The data have been corrected for 
background from fluorescence intensity measurements obtained in the absence of ThT. 
Insert: Comparison of insulin linear range for ThT assay conditions, at pH 1.6 (crosses) 
and pH 7.5 (shaded diamonds). Samples were analysed in triplicate. Error bars 
represent the standard error of the mean. 
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3.2.5 The effect of pH on preformed insulin fibrils  
In addition to altering the relative fluorescence of ThT when bound to the 
amyloid fibrils, the effect of pH on the fibrils themselves was investigated. Fibril 
formation was investigated in HCl, since early TEM work revealed that the fibrils 
formed in HCl were more distinctive than those formed in 20% acetic acid. In 
consideration of this, insulin fibrils formed in HCl were intended to be used in 
chapter 4 and 5 of this thesis. To our knowledge, there has not been any study 
that shows the immediate impact of altering the pH on insulin fibrils preformed 
at pH 1.6, in HCl. 
 
Insulin fibrils were prepared at pH 1.6 in HCl (25 mM, 100 m NaCl) on a ~ 400 
mg scale. It was found that adjustment of the fibril pH had a dramatic effect on 
the structure of the fibrils when examined by TEM. It is known that amyloid 
fibrils, when viewed on the TEM, generally share an elongated unbranched 
fibrillar appearance, but they often have a mixture of different morphologies, 
depending on various factors including pH (chapter 1.5, section 1.2).  
 
The characterisation of insulin fibrils at a high concentration of 11.4 mg/ml 
(worked out for bionanomaterial study) via ThT assay showed that no fibrils 
were present in the insulin before fibrillation (Table 3.1) which was in agreement 
with the TEM examination (Figure 3.6 A).  Table 3.1 illustrates that the increase 
in pH had no effect on insulin fibril fluorescence readings. However, the result 
showed a loss in fluorescence when the pH of the fibrils was reduced back to 2 
from 6.5 via dialysis.    
 
Sample ThT 
(+/-) 
Insulin control in 25 mM HCl (100 mM NaCl, pH 1.6), before fibrillation (A) - 
Fibrils prepared in 25 mM HCl (100 mM NaCl, pH 1.6), at 60ºC for 12 hr  (B) + 
Insulin fibrils after dialysis at pH 2 (C) + 
Insulin fibrils after dialysis at pH 3.5 (D) + 
Insulin fibrils after dialysis at pH 4.5  (E) + 
Insulin fibrils after dialysis at pH 6.5  (F) + 
Insulin fibrils after dialysis in pH 6.5, re-dialysed in pH 2 (G) - 
Table 3.1 Effect of dialysing insulin fibrils at different pHs on ThT fluorescence at 482 
nm, in 50 mM Tris, 100 mM NaCl, pH 7.5. Samples were at 11.4 mg/ml. Samples were 
tested in triplicate. 
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Insulin fibrils produced at 11.4 mg/ml (pH 1.6), were short, unbranched rod like 
structures (Figure 3.6 B). The increase in pH from 1.6 to 6.5, led to the loss of 
the distinct, unbranched, rod like fibrils. Figure 3.6 indicates that the fibrils may 
have a tendency to clump together, with increasing pH. 
 
D)                                          E)                                          F) 
 
Figure 3.6 Electron micrographs showing the impact of pH on insulin fibrils. Samples 
were at 11.4 mg/ml: (A) insulin control in 25 mM HCl (100 mM NaCl, pH 1.6) before 
fibrillation, (B) insulin fibrils in 25 mM HCl (100 mM NaCl, pH 1.6) at 60 ºC for 12 hr, (C) 
insulin fibrils after dialysis at pH 2, (D) pH 3.5, (E) pH 4.5, (F) pH 6.5 and (G) insulin 
fibrils after dialysis in pH 6.5, re-dialysed in pH 2. All samples had been frozen at -80°C 
for 24 hr before TEM examination. These images are a representation of triplicate 
samples. Images have been reproduced in larger forms in the Appendix. 
A )                                          B) 
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The loss of fibril morphology demonstrated in Figure 3.6 relates to the early 
findings on insulin fibrils, where treatment with alkali gave a crystalline product 
similar to native insulin (Waugh 1948). The results found in these experiments 
showed that insulin fibrils needed to be kept at pHs below 6, for the large scale 
preparation of fibril in bionanomaterials (chapters 4 and 5).  
 
3.3 Investigation of the Propensity of the Crude Modified Insulin 
to form Fibrils 
 
The following modified insulin samples, as characterised in chapter 2, were 
investigated: 
• crude citraconylated insulin 
• crude acetylated insulin 
• crude reduced insulin 
• crude reduced carboxymethylated insulin 
• crude reduced pyridylethylated insulin precipitate 
• crude reduced pyridylethylated insulin supernatant 
• crude tryptic digest of insulin (partially and total digested) 
• crude chymotryptic digest of insulin 
All samples were initially tested for solubility under native insulin fibrillation 
conditions (Nielsen et al. 2001b). It was found that all of the modified crude 
insulin samples were soluble at pH 1.6, except RCM and RPE supernatant 
which were solubilised at pH 7.4, which provided some constraints on the 
conditions employed for fibrillation. Having examined the preliminary conditions 
for solubility of the modified insulin, they were tested for fibril formation and 
each chemical modification is discussed separately in the next sections.  
 
3.4 The Effect of Acetylation on Insulin Aggregation 
 
Figure 3.7 compares fibrillation patterns of the insulin standard, insulin control 
and crude acetylated insulin, monitored by ThT fluorescence. The insulin control 
was put through all the changes and incubations as the treated sample (chapter 
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2, section 2.3.2), but without the addition of the acetylating agent. The small 
scale incubation method was used to form fibrils due to the unavailability of a 
plate reader at this stage of this project. Analysis of the ThT curves showed that 
the fibrillation of insulin at 5.7 mg/ml, with and without acetylation, is 
characterised by lag times of 2.4 and 7.2 hr, repectively, compared to 1.5 hr in 
the insulin standard. The low yield of fibrils and the reduced rate of fibril 
formation in the modified insulin mixture are evident from Figure 3.7. 
Interestingly, the insulin control had a significantly longer lag time than the 
insulin standard under these conditions. 
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Figure 3.7 Kinetics of fibril formation of insulin standard (black), insulin control (blue) 
and crude acetylated insulin (green). Fibrils were formed at 5.7 mg/ml, in 20% acetic 
acid, 100 mM NaCl, (pH 1.6) at 60°C. For the ThT assay, samples were assayed in 
triplicate Tris buffer (pH 7.5) with ThT, final concentration of protein in the assay was 
0.02 mg/ml. The curves were fitted according to the method of Nielsen et al. (2001c). 
Error bars represent the standard deviation of the mean of three measurements.  
 
It has been shown earlier in this study that the crude acetylated insulin largely 
consists of unmodified insulin (24%) and monoacetyl insulin (37%) (chapter 2, 
section 2.3.4). The ThT data are consistent with fibril formation by the 
Sample Lag time 
(hr) 
Insulin standard 1.5 ± 0.2 
Insulin control 2.4 ± 0.4 
Crude acetylated 
insulin 
7.2 ± 3 
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unmodified insulin present in the insulin-mixture, with the acetylated insulin 
unreactive. The fluorescence intensity units are indicative of 13% of fibrils 
formed by the acetylated insulin mixture. This may be due to the 24% of insulin 
present in mixture leading to its much lower concentration in the assay solution 
(0.005 mg/ml), which led to a lower yield. However, if pure insulin still 
undergoes fibrillation in a heterogeneous sample, this has potential relevance to 
an industrial process, where the presence of impurities in proteins won’t 
necessarily prevent the fibrillating species from forming fibrils. 
 
3.4.1 Identity of the protein in the aggregate 
The ThT assay for crude acetylated insulin was consistent with the possibility 
that the unmodified insulin present in the crude derivatised insulin mixture is 
forming fibrils (Figure 3.7) with the derivatised insulin remaining in solution. An 
additional experiment was performed to determine the content of the soluble 
crude acetylated insulin during the course of its aggregation. Crude acetylated 
insulin solution was subsampled every 30 min during its incubation at 60°C 
under fibril forming conditions. The subsamples of the fibrillating solutions were 
centrifuged and the supernatant analysed for the presence of protein via LC-
ESI-MS (Figure 3.8).  
 
The TIC showed that the intensity of the protein peaks from the fibril 
supernatant reduced during the course of fibrillation, as expected. The results 
obtained demonstrate the loss of crude acetylated insulin from the supernatant 
of its fibril forming solutions (Figure 3.8).  
 
The peak areas of the insulin and monoacetyl insulin component of the crude 
acetylated insulin fibril forming solution were calculated from the TIC profiles. 
Arrows in Figure 3.8 (A) indicate the insulin peak and the monoacetyl insulin 
peak.  The peak areas from both components were plotted against the time 
course of fibrillation to measure the level of the proteins over the course of the 
aggregation (Figure 3.9). 
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A)  
 
 
 
 
 
 
 
B) 
Figure 3.8 Total ion chromatograms (TIC) of crude acetylated insulin solution at pH 1.6 
obtained by LC-ESI-MS in positive ion mode.analysis of: (A) 0 hr incubation, (B) 9 hr of 
incubation, (C) 22 hr of incubation. LC-ESI-MS was performed using an electrospray 
mass spectrometer operated in positive ion mode. Ions were scanned over a range of 
800-2000 m/z [M+H]+ and data were collected in full scan with a secondary dependent 
scan event to select data for ultrazoom mapping.  
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Figure 3.9 LC-ESI-MS of crude acetylated insulin solution over the course of its 
aggregation. Analysis of samples taken out from the 60ºC incubator as a function of 
time: 0 hr to 27.5 hr. Bars represent (green) insulin peak (m/z 1147.9, RT 13.0 min) 
and (blue) monoacetyl insulin peak (m/z 1156.3 RT 13.8 min).      
 
There was no preferential loss of unmodified insulin as compared to derivatised 
insulin. These results suggest that either unmodified insulin was forming fibrils 
whereas the acetylated insulin was forming amorphous aggregate, or that both 
species were forming fibrils and amorphous aggregate. Further work would be 
required to distinguish between these possibilities. 
 
3.4.2 In situ ThT assay of crude citraconylated acetylated insulin and 
crude acetylated insulin 
The in situ ThT assay was used for these experiments, since this required less 
sample compared to the small scale incubation method, enabling tests of both 
the crude citraconylated acetylated insulin and the crude acetylated insulin, plus 
the insulin standard and control samples. There were two types of unmodified 
insulin control samples, one underwent treatment up to the stage of obtaining 
crude citraconylated insulin and the other control was treated under the 
conditions required to obtain the crude acetylated insulin. Due to the limited 
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quantity of modified insulin prepared a lower concentration of 2.9 mg/ml was 
used. Figure 3.10 shows sigmoid curves for all of the samples.  
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Sample Lag time (hr) 
Insulin standard 2 
Insulin control (for citraconylated and acetylated insulin) 6 
Crude citraconylated acetylated insulin 10 
Insulin control (for acetylated insulin) 15 
Crude acetylated insulin 25 
 
Figure 3.10 Time profiles for ThT induced fluorescence of: insulin standard (black 
diamonds), insulin control for crude citraconylated insulin (blue diamonds), insulin 
control for crude acetylated insulin (green diamonds), crude citraconylated insulin 
(unfilled blue diamonds), crude acetylated insulin (unfilled green diamonds) incubated 
at 60ºC. All samples were prepared at a concentration of 2.9 mg/ml in 20% acetic acid 
(100 mM NaCl, pH 1.6). Each reading represents an average of triplicate well readings, 
with the error bars representing standard error. The maximum fluorescence is due to 
instrumental limitations and is not representative of yield. 
 
When compared to the fresh insulin standard fibrillation, both of the insulin 
controls have a longer lag phase (Figure 3.10). Since all protein solution 
concentrations were measured by a Nanodrop (A280) prior to assaying, it can be 
suggested that the controls were affected by the buffer treatments with both 
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having longer lag phases. The buffer treatments undergone by the insulin 
controls may have an impact on their association states, which in turn may have 
affected their oligomerisation.  
 
The crude citraconylated acetylated insulin and the crude acetylated insulin; 
both had a longer lag phase compared to their respective insulin control (Figure 
3.10). This is in accordance with results obtained from the small scale method 
in section 3.5.1. Overall, acetylation led to an increase in the lag phase of 
insulin fibrillation and a decrease in fibril yield when exposed to 20% acetic acid 
(pH 1.6, 100 mM NaCl).  
 
3.4.3 TEM examination of fibrils 
Fibrils formed in section 3.4.2 were examined using TEM to confirm the 
presence of amyloid fibrils and assess if the modification had influenced fibril 
morphology. The fibrils distinguishable by TEM (Figure 3.11) are described in 
Table 3.2. The pictures show that the fibrils are of varying lengths and have 
irregular appearance due to varying degrees of lateral aggregation and twisting 
(Burke and Rougvie 1972).  
 
Treatment Morphology 
(A) None long, twisted, and entangled 
(B) Buffer at pH 8, for 1.5 hr long, twisted, and entangled 
(C) Buffer at pH 8, for 1.5 hr (with 
citraconic acid followed by acetic 
anhydride) 
long, twisted, and entangled 
(D) Buffer at pH 8, for 1.5 hr and dialysed 
in pH 3.5 at 30°C for 48 hr, insulin control 
shorter and less entangled 
(E) Buffer at pH 8, for 1.5 hr (with 
citraconic acid followed by acetic 
anhydride), dialysed in pH 3.5, at 30°C for 
48 hr (deblocking) 
shorter and less entangled 
 
Table 3.2 Effect of buffer and reagent treatment on insulin fibril morphology. 
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A)                                                           B)  
 
 
 
 
 
 
 
 
C)                                                                   D)  
E)  
 
Figure 3.11 Electron micrographs of fibrils obtained from insulin before and after 
modification. These images are a representation of triplicate samples. Small scale 
fibrillation in 20% acetic acid at 5.7 mg/ml, 60ºC in oven: (A) standard insulin, (B) 
insulin control, (C) crude citraconylated acetylated insulin, (D) insulin control, (E) crude 
acetylated insulin.  
0.25 µm
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It is interesting to note that the insulin still forms fibrils in a heterogeneous 
mixture of acetylated insulin, albeit at a slower rate. 
 
3.5 The Effect of Reduction Alkylation on Insulin Aggregation 
 
3.5.1 Previous studies on protein disulfide reduction and fibrillation 
Insulin was reduced and alkylated to determine whether fibril formation is 
facilitated by disruption of disulfide bridges that enhance the structural stability 
for the native protein. Though insulin is amyloidogenic in the wild-type form, 
such enhanced stability conferred by the disulfide bonds is known to delay 
fibrillation in some proteins (Ramirez-Alvarado and Regan 2002). The A and B 
chains of bovine insulin have been found to form fibrils in isolation from each 
other, with unique morphologies in comparison to intact bovine insulin (Devlin et 
al. 2006). Similarly, in reduced human insulin, which has three different amino 
acids to bovine insulin (A-8 Thr, A-10 Ilc, B-30 Ala), both the A and the B chain 
form fibrils at acidic and neutral pHs. The A chain fibrillates without a lag phase, 
whilst the B chain exhibits a pH dependent lag phase (Hong et al. 2006). 
Fibrillation in a mixture of bovine insulin and its B-chain peptide showed that 
mixtures of the two peptides form fibrils in distinctly separate processes (Hong 
and Fink 2005). However, Devlin et al. (2006) also suggested that the impact of 
the insulin chains on fibrillation depends on their physical state, since the 
soluble A and the B chain may inhibit the intact insulin from forming fibrils due to 
a complex formation between insulin and the separate chains. 
 
In β2-macroglobulin, unfolding was achieved by disulfide reduction, which 
destabilised the intermediate state by increasing the flexibility of the molecule 
(Katou et al. 2002) but the intrachain disulfide bond was found to be essential 
for β2-macroglobulin amyloid formation. Similarly, Mait and Surewcz (2001) 
found that the removal of prion peptide disulfide bridge destabilised the native 
protein and resulting in partial unfolding and formation of insoluble aggregates 
(Maiti and Surewicz 2001). 
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Moreover, it was found that disulfide reduction in Bence Jones protein (Klafki et 
al. 1993) and lysozyme (Takase et al. 2002) resulted in fibril formation. These 
findings support the hypothesis that disulfide bond modification of protein can 
have a significant impact on fibril formation. 
 
3.5.2 Investigation of insulin amyloid formation, before and after reduction 
carboxymethylation  
The carboxymethylation reaction was chosen due to the high specificity of 
iodoacetic acid for sulfhydryl cysteine modifications (Hermanson 1996). The 
reduced insulin and reduced carboxymethylated (RCM) insulin were initially 
tested for their solubility under the conditions known to solubilise standard 
insulin, pH 1.6. Both the reduced insulin and RCM insulin were insoluble in 
acidic buffers, but were soluble at pH 7.4, at 5.7 mg/ml, conditions under which 
insulin exists as a hexamer. Since native insulin has a low solubility at neutral 
pHs, solubility tests were carried out at a range of low insulin concentrations, in 
order to find a concentration at which native insulin is soluble. This was 
necessary to enable comparison between unmodified and modified insulin 
samples. All samples were soluble at 1 mg/ml and below, hence in situ ThT 
assay was carried out at 1 mg/ml and 0.1 mg/ml for comparison (Figure 3.12 A 
and B).   
 
Fluorescence measured over time in Figure 3.12 (A) and (B) shows a sigmoid 
curve for crude RCM insulin, indicative of β-sheet formation. At the low 
concentration of 0.1 mg/ml in graph A, there was a lag phase of about 4 hrs 
before an increase in fluorescence. Graph (A) also shows an increase in the 
rate of fibril formation by the insulin standard, after 32 hr of incubation. There 
was no indication of fibril formation with the insulin control and reduced insulin 
at 0.1 mg/ml. The difference between insulin standard and control ThT 
fluorescence, may be due to the low concentration of protein utilised, since 
amyloid formation at pH 7.4 is significantly affected by protein concentration 
(Waterhouse 2003). This result for insulin is consistent with previous studies at 
pH 7.4, where no fibrils were formed within 24 hr without stirring (Nielsen et al. 
2001b). However, RCM insulin behaved differently when compared to 
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unmodified insulin, with amyloid fibril formation apparently occurring at a much 
faster rate than unmodified insulin under the same conditions. 
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Figure 3.12 Influence of reduction carboxymethylation on insulin fibril formation at 
60ºC monitored by ThT fluorescence. Insulin was dissolved in 50 mM potassium 
phosphate buffer and 100 mM NaCl at pH 7.4 at: (A) 0.1 mg/ml and (B) 1 mg/ml. 
Fluorescence measurements were carried out, in situ with ThT (200 µM) in phosphate 
buffer. Graph A and B: black = insulin standard, blue = insulin control, red = crude 
reduced insulin, green = crude RCM insulin.  
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A further fibrillation trial was carried out at 1 mg/ml protein concentration in 
order to determine the effect of concentration on RCM insulin fibril formation 
(Figure 3.12 B). RCM insulin lacked the lag phase, and showed a significant 
increase in fluorescence over the early hours of its incubation.  Insulin standard 
and control, both showed an increase in ThT fluorescence, though the lag 
phase for insulin standard (16 hr) was shorter than for the control (25 hr). The 
reduced insulin showed a reduction in fluorescence over time until it reached a 
plateau, which was not indicative of fibril formation but instead may be due to 
the sample precipitating out of the solution (a white precipitate was observed in 
the plate wells). All insulin samples ThT assayed in Figure 3.12, were examined 
on the TEM (Figure 3.13).  
 
A)                                                                 B)  
 
 
 
 
 
 
 
C)                                                                 D)  
 
 
 
 
 
                
 
Figure 3.13 TEM image of fibrils obtained from: A) insulin standard, B) insulin control, 
C) crude reduced insulin, D) RCM insulin, at pH 7.4 (50 mM phosphate buffer, 100 mM 
NaCl), 0.1 mg/ml, incubated in situ at 60ºC for 72 hr. These images are a 
representative of triplicate samples.  
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The results corroborated the ThT data, showing fibrils present in the insulin 
standard and RCM insulin samples only. The structure of fibrils illustrated in 
Figure 3.13 was very similar in A and D, long, with thin and unbranching 
nanofibres of varying lengths. 
 
From the samples fibrillised at 1 mg/ml in Figure 3.14, insulin standard, control 
and reduced sample all showed the presence of long, unbranched fibrils, 
sparingly scattered around the grids, in addition to the presence of some 
amorphous aggregates (Figure 3.14).  
 
 A)                                                                    B)                                                                   
 
 
 
 
 
 
 
 
C)                                                                    D) 
                                                            
 
 
 
  
   
 
Figure 3.14 TEM image of fibrils obtained from: A) insulin standard, B) insulin control, 
C) crude reduced insulin, D) RCM insulin, at 1 mg/ml, pH 7.4 (50 mM phosphate buffer, 
100 mM NaCl). These images are a representation of triplicate samples.  
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Conversely, the RCM insulin sample revealed straight, distinct fibrils with 
protofilaments twisted around in each other, as well as short wavy fibrils (Figure 
3.14 D). This fibril morphology of RCM insulin at 1 mg/ml is significantly different 
to that obtained at 0.1 mg/ml in Figure 3.13 D. The straight fibrils were also 
wider in diameter (~20 nm) compared to that obtained at 0.1 mg/ml (~10 nm). 
 
The microscopy results confirmed that insulin formed fibrils readily after 
reduction-carboxymethylation at pH 7.4, and the structure of the fibrils was 
dependent on protein concentration. There was a marked acceleration in the 
propensity of bovine insulin to form fibrils without a lag phase post reduction- 
carboxymethylation. This was similar to the results obtained with the fibrillation 
of human insulin A chain, which showed a rapid increase in ThT fluorescence 
without a lag phase at pH 7.2 (Hong et al. 2006). However, the distinctively 
straight, long nanofibres showing twists in its association (Figure 3.14 D) were 
found to be unique in comparison to its control counterparts.  
 
Moreover, fibrillation studies with RCM κ-casein, a milk protein, has shown that 
it forms fibrils much more readily when compared to the native κ-casein (Thorn 
et al. 2005). It was suggested that the loss of disulfide bonds, may have led to 
the increase in the number of dissociated species in solution that is available to 
form fibrils. However, RCM κ-casein fibrils are assumed to form by the 
dissociation of an amyloidogenic precursor from an oligomeric state instead of 
the nucleation-dependent mechanism (Ecroyd et al. 2008). 
 
3.5.3 The impact of reduction pyridylethylation on insulin amyloid 
formation  
As outlined in chapter 2, a precipitate was obtained after insulin reduction and 
pyridylethylation, referred to as RPE insulin.  A quick ThT testing of the 
precipitate obtained showed the presence of β-sheet at pH 1.6, and TEM 
indicated that there were wavy fibrils present. Further tests were done to verify 
these results. 
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Figure 3.15 shows that there is no difference in the fibrillation pattern of insulin 
standard and control under the conditions tested, and an increase in 
fluorescence with time was observed for both. RPE insulin precipitate showed a 
fluorescence of 30000 units at time 0, which suggested the presence of fibrils 
before incubation. Since the RPE insulin precipitate was insoluble in 20% acetic 
acid, and was partially soluble in HCl, fibrillation was carried in 0.025 M HCl. 
The behaviour of insulin standard and control was typical of insulin amyloid 
formation at acidic pHs, forming amyloid in a few hours. The insulin control in 
this section had been treated in Tris-HCl buffer at pH 8 for 1 hr before 
subjected to gel filtration, under similar conditions as the modified insulin. 
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Figure 3.15 Influence of reduction pyridylethylation on insulin fibril formation at 60ºC 
monitored by ThT fluorescence. Insulin (2 mg/ml) was dissolved in 25 mM HCl and 100 
mM NaCl at pH 1.6. Fluorescence measurements were carried out experimentally, in 
situ with ThT (200 µM). Samples are represented as: black= insulin standard, blue = 
insulin control, green = crude RPE insulin precipitate. Crude reduced insulin was not 
tested since it is insoluble in HCl at pH 1.6. 
 
TEM examination of insulin standard and control showed similar structural 
features for the fibrils; narrow long and short tubular structures (Figure 3.16 A 
and B). RPE insulin precipitate was insoluble at 5.7 mg/ml and fibrillation was 
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carried out at the lower concentration of 2 mg/ml, at which it dissolved. The 
insulin fibrils formed at a concentration of 2 mg/ml looked more distinct and 
were not as straight as those obtained at 5.7 mg/ml (Figure 3.23 A and B), 
which may have been due to the differences in concentration. RPE insulin 
precipitate, at 0 hr and at 5 hr of incubation was also examined (Figure 3.16 C 
and D). Examination of RPE insulin precipitate showed that clumps of 
aggregates were present before incubation (Figure 3.16 A), which may have 
been responsible for the positive ThT fluorescence at 0 hr. After RPE insulin 
incubation at 60ºC, it showed fibrils which were well separated and distinctly 
wavy. 
 
 
               B) 
 
 
 
 
 
 
 
C)                                                               D)  
 
 
 
Figure 3.16 Electron micrographs of fibrils obtained from, A) insulin standard, B) insulin 
control, C) precipitated RPE insulin at time 0 hr, D) precipitated insulin after 5 hr of 
incubation, at 2 mg/ml. These images are a representation of triplicate samples. 
A)                                                  
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RPE supernatant also gave a positive test with ThT dye, before incubation at 
60ºC (Figure 3.17). There was an increase in fluorescence over time for about 1 
hr until a plateau was reached. The reduced insulin sample assayed did not 
show any ThT binding, which may have to do with its solubility in the buffer 
since a white precipitate was observed in the sample wells at the end of the 
assay. 
 
 
-10000
0
10000
20000
30000
40000
50000
60000
70000
80000
0 1 2 3 4 5 6 7 8 9 1011121314151617
Time (hr)
R
el
at
iv
e 
flu
or
es
ce
nc
e 
in
te
ns
ity
 (4
82
 n
m
)
 
Figure 3.17 Influence of reduction pyridylethylation on insulin fibril formation at 60ºC 
monitored by ThT fluorescence. RPE insulin supernatant (2 mg/ml) was dissolved in 
pH 7.4 phosphate buffer, 100 mM NaCl. Fluorescence measurements were carried out 
experimentally, in situ with ThT (200 µM). Samples are represented as: green= RPE 
supernatant, red= reduced insulin. Insulin standard and control was not tested since it 
is insoluble at 2 mg/ml in pH 7.4. 
 
 
Figure 3.18 illustrates the presence of wavy fibrils in the RPE insulin 
supernatant, very similar to those observed in the RPE precipitate. However, 
the fibrils obtained from the supernatant had a higher degree of waves within 
them. Insulin fibril morphology (long, unbranched) had changed after 
modification (reduction pyridylethylation). This may have been due to the fact 
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that RPE insulin precipitate and supernatant both have a mixture of insulin and 
A and B chains (chapter 2). The ThT data were indicative of the presence of β-
sheets in the sample at time 0, hence it can be concluded that fibrillation was 
induced during insulin pyridylethylation at pH 8. However, the RPE insulin 
(precipitate and supernatant) showed an increase in fluorescence over time of 
its incubation at 60°C and the fibril morphology examination showed that wavy 
fibrils were formed due to the modification. 
 
 
 
 
 
 
 
 
 
Figure 3.18 Electron micrographs of fibrils obtained from RPE insulin supernatant (2 
mg/ml) was dissolved in pH 7.4 phosphate buffer, 100 mM NaCl , incubated at 60 for 5 
hr. This image is representative of triplicate samples. 
 
3.6 The Effect of Trypsin Digestion on Insulin Aggregation 
The mixture of insulin fragments obtained after trypsin digestion of insulin 
(partial and total digestion) were soluble in 20% acetic acid (pH 1.6). Fibrillation 
tests were performed at 5.7 mg/ml and at 45ºC in situ (Figure 3.19 A). The 
insulin control was found to have a significantly longer lag phase than that of 
insulin standard. Results showed a decrease in the fluorescence intensity of 
insulin after partial digestion and negligible fluorescence after total digestion of 
insulin. This suggested that it is the undigested insulin in the crude digested 
mixture which is responsible for low fluorescence obtained in the partially 
digested insulin fragments. 
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Figure 3.19 Influence of trypsin digestion on insulin fibril formation at: (A) 45ºC  and (B) 
60ºC, monitored by ThT fluorescence. Insulin (5.7 mg/ml) was dissolved in 20% acetic 
acid and 100 mM NaCl at pH 1.6. (A)  In situ fluorescence measurements were taken 
in 20% acetic acid buffer. Samples: black= insulin standard, blue= insulin control, 
green= partially digested insulin, red= totally digested insulin. (B) Fibrillation was 
carried out on small scale incubation in Tris buffer (50 mM, 100 mM NaCl). Samples: 
black= insulin standard, blue= insulin control, green = partially digested insulin.    
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It was found (Figure 3.19 A) that the totally digested insulin (peptide fragments) 
do not form amyloid when present in a mixture at pH 1.6 (20% acetic acid, 100 
mM NaCl). However, fibrillation occurred more readily with insulin in which the 
B-chain C termini were truncated, which confirmed that the B-chain C terminus 
does not have a role in self assembly  (Brange et al. 1997).  
 
Similar results were found when a small scale fibrillation trial was carried out on 
insulin trypsin digest at 60°C, and Figure 3.19 (B) illustrates that the insulin 
standard had a lag time of 1 hr while the insulin control had a longer lag time of 
2 hr with reduced fluorescence. The partially treated insulin also showed a very 
low fluorescence for ThT dye binding over the time of its incubation and the 
totally digested insulin did not show any positive response to ThT dye, in 
agreement with data from in situ studies in Figure 3.19 (B). TEM examination 
was carried out to confirm inhibition of amyloid formation, in crude trypsin 
digested insulin. 
 
TEM observation of insulin samples obtained from the fibril trial (Figure 3.20), 
showed long narrow fibrils present in the insulin standard sample similar to the 
insulin control, except the standard was more densely packed with fibrils. There 
was no indication of fibrils present in the partially digested samples when 
observed on the TEM, although there was a positive fluorescence signal (100 
A.U.) shown by the sample. This could be due to the low concentration of 
unmodified insulin forming fibrils in negligible amounts within the peptide 
fragments. Literature suggests that insulin fibrillation can be inhibited or 
stimulated with polypeptides that are chemically similar to insulin, for example 
the soluble form of the insulin A and B chain form a complex with insulin, 
preventing fibrillation (Devlin et al. 2006).   
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A)                                                                 B) 
 
 
 
 
 
 
 
 
 
 
 
 
C)  
Figure 3.20 Electron micrographs of fibrils obtained from; (A) insulin standard, (B) 
insulin control, (C) partially trypsin treated insulin. Protein at 5.7 mg/ml was dissolved in 
20% acetic acid, 100 mM NaCl at pH 1.6 and incubated at 60ºC. These images are a 
representation of triplicate samples.  
 
 
3.7 The Effect of Chymotrypsin Digestion on Insulin 
Aggregation 
 
ThT assay of insulin digested with chymotrypsin showed that it formed fibrils 
both in acetic acid and HCl (Figure 3.21 A and B). There was no lag phase 
observed for the digest in both acids tested. The high fluorescence intensity at 0 
hr in HCl suggested that fibrils (Figure 3.21 B) were present at the start of the 
assay, and this was confirmed with TEM (Figure 3.23 D).  
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Figure 3.21 Influence of chymotrypsin digestion on insulin fibril formation at 60ºC 
monitored by ThT fluorescence. Insulin (5.7 mg/ml) was dissolved in: (A) 20% acetic 
acid (100 m M NaCl) at pH 1.6, (B) 25 mM HCl (100 mM NaCl) at pH 1.6. Fluorescence 
measurements were carried out experimentally, in situ with ThT (200 µM). Samples in 
graphs A and B are: green= crude chymotryptic digest of insulin, black= insulin 
standard, blue= insulin control.      
 
 131
Chapter 3 The impact of modification on insulin aggregation and fibril 
formation 
 132
The insulin control had a slightly longer lag phase (2 hr) compared to the 
standard (1.5 hr) in acetic acid (Figure 3.21 A), but both showed a similar 
behaviour in HCl (Figure 3.21 B). 
 
TEM examination of the samples after 3 hrs of fibrillation in acetic acid showed 
that both the insulin standard and control had long narrow, unbranched fibrils 
with some twists amongst them (Figure 3.22 A and B). The chymotryptic digest 
of insulin in Figure 3.22 (C) showed similar fibril structure to the standard except 
the fibril edges were not as distinct as the standard.  
 
A)                                                              B)  
 
C)  
 
Figure 3.22 Electron micrographs of fibrils obtained from: A) insulin standard, B) 
insulin control, C) crude chymotryptic digest of insulin, at 3 hr of incubation at 60ºC. 
Protein at 5.7 mg/ml was dissolved in 1.6 (20% acetic acid, 100 mM NaCl).  
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A)                                                                       B) 
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Figure 3.23 Electron micrographs of fibrils obtained from: A) insulin standard at 3 hr, 
B) insulin control at 3 hr, C) i) ii) iii) crude chymotryptic digest of insulin at 3 hr, D) 
crude chymotryptic digest of insulin at 0 hr, of incubation at 60°C. Protein at 5.7 mg/ml 
was dissolved at pH 1.6 (25 mM HCl, 100 mM NaCl).  
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TEM work for the samples fibrillised in the HCl buffer, showed that the insulin 
standard, control and digest (Figure 3.23 A, B and C(i)), contained similar long 
narrow fibrils. Interestingly, the chymotryptic digest revealed fibrils that varied 
from long and narrow to short, thick rod-like structures (Figure 3.24 C (i), (ii), 
(iii)). This heterogeneity in the fibrils was not visible at 0 hr (Figure 3.23 D) 
hence the short thick fibrils had formed after incubation at 60ºC. The different 
types of fibril morphology could be due to the varying peptide fragments 
(section 2.6, chapter 2) present in the crude mixture of insulin digest. However, 
it is known that insulin B chain fibril morphology is concentration dependent, 
and it can contain some monomers that associate to form mature fibrils and 
some soluble oligomers that form protofilaments and not mature fibrils (Hong et 
al. 2006). Thus Figure 3.23 (C) may be indicative of the presence of both 
mature fibrils and thin protofilaments in the insulin digest. 
 
3.8 Discussion 
 
3.8.1 Impact of insulin oligomeric state 
The impact of chemical modifications and buffer treatments on the insulin 
standard was monitored and experiments showed that the behaviour of insulin 
was affected to varying degrees. The lag time for standard insulin fibrillation 
was elevated by some of the buffer treatments, tabulated in Table 3.3. The 
impact of exposing insulin at pH 8 for 1 hr led to an increase in the lag time from 
2 hr to 6 hr, which further increased to 15 hr after treatment at pH 3.5 for 48 hr. 
All data tabulated suggested that exposing insulin to pH 8 caused a delay in the 
time it normally takes to break down to a monomer and form a nucleus for fibril 
formation. As mentioned earlier, insulin exists as a hexamer form at neutral 
pHs. Insulin fibril morphology remained unchanged after the buffer treatments 
except that shorter and less entangled fibrils were noticed in the sample 
designated with an asterisk (Table 3.3). 
 
Under these conditions, the RCM insulin may no longer form a hexamer, and it 
is possible that it exists at a lower oligomeric state than the standard insulin at 
pH 7.5, and is able to form fibrils at faster rate than insulin standard. The 
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fibrillation of the insulin B-chain peptide has been shown to be independent of 
pH, and it assumed that there is no pH-dependent oligomer (e.g. hexamer) 
dissociation involved (Hong and Fink 2005). 
 
 
Table 3.3 Shows the impact of buffer treatment on the lag time of insulin during 
fibrillation.  na= not applicable. * Contained shorter and less entangled fibrils.  
 
 
Buffer/incubation 
history  
Fibrillation of 
insulin control 
at 60 ºC, acetic 
acid buffer, 5.7 
mg/ml 
Fibrillation of 
insulin control 
at 60ºC, acetic 
acid buffer, 2.9 
mg/ml 
Fibrillation of 
insulin control 
45 ºC, acetic 
acid buffer, 5.7 
mg/ml 
None insulin standard 
lag time= 1.7 hr 
insulin standard 
lag time= 2 hr 
insulin standard 
lag time= 7.5 hr  
Potassium phosphate 
buffer at pH 8,  with 
stirring  at 21ºC for 30 
min, followed by 
dialysis at pH 8 for 6 
hr at 0ºC 
na insulin standard 
lag time= 6 hr  
na 
Potassium phosphate 
buffer at pH 8,  with 
stirring  at 21ºC for 30 
min with subsequent 
stirring  at 0ºC for 1 hr, 
followed by  incubation 
at pH 3.5 for 48 hr 
30ºC, and dialysis at 
pH 8 for 6 hr at 0 ºC 
*insulin 
standard lag 
time= 24 hr 
insulin standard 
lag time= 15 hr 
na 
Ammonium 
bicarbonate buffer at 
pH 8.5, 37ºC for 4 hr 
followed by pH 3.5 at -
80ºC for 48 hr 
na na insulin control lag 
time= 21 hr 
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3.8.2 Prediction of the aggregation propensity of proteins by Zagg score 
 
3.8.2.1 Insulin 
The chemical modifications carried out in this study had an impact on the lag 
time for insulin fibril formation, as well as the morphology of insulin fibrils in 
some cases. To explore this phenomenon in more detail, the Zagg score for 
unmodified insulin and modified insulin was calculated and compared (Table 
3.4). The possible relationship between the scores and aggregation 
propensities found in this study was then investigated.  
 
As discussed in chapter 1 (section 1.5), at each position in a polypeptide chain 
we can consider all possible amino acid replacements and determine the 
intrinsic Z-score for aggregation (Zagg). This enables comparisons to be made 
between the aggregation propensities of different polypeptide sequences 
(Pawar et al. 2005). The Zagg scores of known protein and peptide sequences 
show that mutated proteins with a higher score than the wild type correlate with  
an increased propensity to aggregate (Pawar et al. 2005). However, Zagg 
assumes that a completely unfolded protein which may limit the results (Pawar 
et al. 2005). 
 
The algorithm is not designed to explore the impact of chemical modification; 
however, an estimation of the Zagg for the modified insulin was made by 
approximating the modified amino acids with a similar natural amino acid.  
Specifically, the acetylated glycine residue was approximated as alanine, 
leucine, and isoleucine residues in the intact insulin sequence. In insulin A and 
B chains, the cysteines were approximated with glutamic acid and 
phenylalanine residues. The Zagg scores for the wild type and the modified 
(intact insulin, insulin A and B chains) were calculated at pH 1.6 and pH 7. The 
wild type Zagg score were compared to the Zagg scores obtained for the 
modified insulin sequence. 
 
The Zagg score of bovine insulin was found to be 1.38 at pH 1.6, but there was 
an increase in the Zagg score when alanine, leucine and isoleucine were 
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replaced for the glycine in the sequence. This predicts that attachment of a 
residue with more hydrophobic acetyl groups at A1 may induce an increase in 
the aggregation propensity of insulin. This does not agree with the data 
obtained from the acetylation on insulin which slowed down the aggregation.  
 
The Zagg score, predicts that at pH 1.6, the insulin A chain has a higher 
propensity to form fibrils compared to intact insulin and the relative aggregation 
propensity can be ordered as such: A chain>native insulin>B chain. At pH 7, the 
Zagg score of the A chain was higher than both the intact insulin and the B 
chain. When the cysteine residues were replaced with glutamic acid, to mimic 
the RCM insulin, it was found that the Zagg score of the wild type insulin A and 
B chain were higher than the mutated insulin chains. This suggested a lower 
propensity for both the modified insulin A and B chains to aggregate. This does 
not correlate with the experimental results obtained for RCM insulin, which 
readily formed fibrils at a neutral pH.  
 
The Zagg score for the replacement of the cysteines with phenylalanine, to 
mimic RPE insulin was also analysed at both pHs of 1.6 and 7. The Zagg 
scores showed an increase between the wild type (A and B chains) and the 
modified insulin (A and B chains) sequences at both pH 1.6 and 7. This 
correlates with the experimentally observed results for RPE insulin. 
 
According to the Zagg scores obtained in Table 3.4, the tryptic peptide (A1-
A21, B1-B23) has a higher propensity to aggregate compared to native insulin. 
The truncated insulin fragments can be arranged in the order of aggregation 
propensity; tryptic peptide (A1-A21, B1-B23)> tryptic peptide (A1-A21, B1-
B29)> tryptic peptide (B24-B30). The tryptic peptides of insulin showed a 
reduction in observed fibril forming propensity. The Zagg scores of both the 
chymotryptic peptides are higher than the wild type insulin  and this is 
supported by the results obtained in Figure 3.23, which shows that the digests 
formed fibrils readily, suggesting that the algorithm has some value in 
predicting aggregation potential. 
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Modification Primary sequence of bovine insulin after the modification Zagg 
score 
pH 1.6 
Zagg 
score 
pH 7 
Native insulin 
(A1-A21, B1-
B30)  
GIVEQCCASVCSLYQLENYCNFVNQHLCGSHLVEALYLVCGERG
FFYTPKA 
1.38 1.60 
Ala for Gly at 
A1 
AIVEQCCASVCSLYQLENYCNFVNQHLCGSHLVEALYLVCGERG
FFYTPKA 
1.39 na 
Lys for Gly at 
A1 
LIVEQCCASVCSLYQLENYCNFVNQHLCGSHLVEALYLVCGERG
FFYTPKA 
1.45 na 
Ileu for Gly at 
A1 
IIVEQCCASVCSLYQLENYCNFVNQHLCGSHLVEALYLVCGERGF
FYTPKA 
1.48 na 
Insulin A chain GIVEQCCASVCSLYQLENYCN 1.87 1.70 
Insulin B chain FVNQHLCGSHLVEALYLVCGERGFFYTPKA 0.91 1.60 
Glu for Cys 
Insulin A chain 
GIVEQEEASVESLYQLENYEN na -0.64 
Glu for Cys 
Insulin B chain 
FVNQHLEGSHLVEALYLVEGERGFFYTPKA  na 0.60 
Phe for Cys 
Insulin A chain 
GIVEQFFASVFSLYQLENYFN 2.00 1.90 
Phe for Cys 
Insulin B chain 
FVNQHLFGSHLVEALYLVFGERGFFYTPKA 1.00 1.70 
Tryptic peptide 
(A1-A21, B1-
B29) 
GIVEQCCASVCSLYQLENYCNFVNQHLCGSHLVEALYLVCGERG
FFYTPK 
1.38 na 
Tryptic peptide 
(A1-A21, B1-
B23) 
GIVEQCCASVCSLYQLENYCNFVNQHLCGSHLVEALYLVCGER 1.50 na 
Tryptic peptide 
(B24-B30) 
GFFYTPKA 0.82 na 
Chymotryptic 
peptide 
GIVEQCCASVCSLYFVNQHLCGSHLVEALY 1.81 na 
Chymotryptic 
peptide 
QLENYCNLYLVCGERGF 1.37 na 
 
Table 3.4 Effect of mutating amino acids of the insulin chain, separating insulin A and 
B chain and truncating bovine insulin chain, on the aggregation propensity of the 
protein evaluated by Zagg score.  
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3.8.2.2 Bovine eye lens and wheat proteins 
Since the algorithm showed some success in predicting improved aggregation 
propensity in modified insulin, it was applied to two potential large scale sources 
of proteins of interest to the wider research programme: wheat proteins and 
bovine crystallins both of which have been shown to form amyloid proteins from 
crude extracts (Garvey et al. 2008, Mackintosh et al. 2008), to obtain a measure 
of their aggregation propensity in Tables 3.5 and 3.6.  
 
Bovine eye lens is an example of a waste protein, which can be sourced for 
fibrils to be made on a reasonable scale and will be further discussed in chapter 
4 and 5. The α-, β-, and γ- proteins are the major structural proteins in the eye 
lens, which form fibrils under mildly denaturing conditions in vitro (Meehan et al. 
2004). The Zagg scores calculated for bovine eye lens α- and β- sequences 
showed that the α-crystallins are more prone to aggregate when compared to β-
crystallins. This was unexpected since α-crystallins act as chaperones for 
themselves as well as for other crystallins. They also take longer to form fibrils 
in vitro when compared to the β-crystallins (Meehan et al. 2004).   
 
 
Bovine eye lens proteins Zagg score at 
pH 2 
P02470[1-173], Alpha-crystallin A chain -0.29 
P02510[1-175], Alpha-crystallin B chain 0.17 
P02510[1-175], Alpha-crystallin B chain 0.10 
P11843[1-215], Beta-crystallin A3 0.06 
P26444[2-197], Beta-crystallin A2 -0.42 
P11842[2-210], Beta-crystallin A4 -0.41 
P07318[2-253], Beta-crystallin B1 -0.98 
P02522[2-205], Beta-crystallin B2 -1.32 
P19141[2-211], Beta-crystallin B3 -1.74 
P06504[2-178], Beta-crystallin S -0.08 
 
Table3.5 Zagg scores obtained for various crystallins of bovine eye lens. 
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For high molecular weight glutenins (HMW) in wheat (Mackintosh et al. 2008),  
the Zagg scores found were negative, which indicates a low propensity to form 
aggregates. This is consistent with the very long timeframe required to form 
amyloid like structures in this case. 
 
The results obtained show that it may not be possible to utilise the Zyggregator 
to predict the ability of protein to form fibrils in a heterogeneous mixture, as 
Devlin and his co-workers (Devlin et al. 2006) found that the propensity of 
insulin to form fibrils in a mixture of chemically related peptides depends on 
peptide conformation. The impact of buffer treatments on insulin fibril forming 
propensity also suggest that the algorithms are may require further 
development to be of use in these studies. 
 
Wheat high molecular weight (HMW) glutenins Zagg score 
at pH 7 
GLT0_WHEAT(P10387) 
Glutenin, high molecular weight subunit DY10 precursor 
-3.00 
GLT1_WHEAT (P02861)  
Glutenin,high molecular weight subunit PC256 (Fragment) 
-1.20 
GLT2_WHEAT(P02862)         
Glutenin, high molecular weight subunit PC237 (Fragment)  
-0.15 
GLT3_WHEAT(P08488) 
Glutenin, high molecular weight subunit 12 precursor 
-0.30 
GLT4_WHEAT(P08489) 
Glutenin, high molecular weight subunit PW212 precursor 
-3.30 
GLT5_WHEAT(P10388) 
Glutenin, high molecular weight subunit DX5 precursor 
-1.07 
 
Table 3.6 Zagg score obtained for various HMW glutenin sequences. 
 
 
 
 
 
 140
Chapter 3 The impact of modification on insulin aggregation and fibril 
formation 
3.8.3 Fibril morphology, rate and yield 
Results from this chapter suggest that insulin fibril formation is possible in 
heterogeneous matrix, depending on the type of chemical derivatisation. 
 
Acetylation of insulin caused an increase in the lag phase and a reduction in 
the yield of the fibrils. Since the fibrils formed by the acetylated insulin mixture 
were short and straight similar to the insulin control, it was assumed that the 
unmodified insulin in the mixture had formed fibrils and the acetylated 
component of the mixture formed amorphous aggregates.  
 
Reduction carboxymethylation of insulin led to the loss of the lag phase during 
fibrillation and enabled the rapid formation of straight fibrils with twists at pH 
7.4, which also had some small wavy fibrils, unlike the unmodified insulin. The 
method allowed production of fibrils at a faster rate than for the native protein. 
 
Reduction pyridylethylation of insulin led to the formation of wavy fibrils, 
compared to the self assembly of native insulin into non wavy fibrils, suggesting 
that chemical modification may provide a means of manipulating fibril 
morphology. 
 
Enzymatic digestion of insulin had varying effects on its fibrillation. Trypsin 
digests with some undigested insulin, showed an increase in the lag phase and 
a reduction in the yield of fibrils. Straight, long, unbranched fibrils obtained were 
similar to the insulin standard. The trypsin digest without any undigested insulin 
showed no fibrillation. Chymotrypsin digestion of insulin led to the formation of a 
heterogeneous mixture of fibrils. The morphology of fibrils varied from thin, 
straight and long structures to thick, short fibrils.  
 
3.9 Summary  
 
This chapter has demonstrated that bovine insulin forms fibrils in crude 
heterogeneous mixtures of chemically modified insulin. It also showed how the 
various chemical modifications employed affected insulin fibrillation lag phase, 
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rate, yield and fibril morphology. This study also provides evidence that insulin 
can form fibrils of varying morphologies, in heterogeneous mixtures. These 
finding suggests the feasibility of using crude sources of protein such as  bovine 
eye lens in bionanotechnology (Garvey et al. 2008). The ability to control 
morphology of crude mixtures of protein fibrils is a potentially desirable 
characteristic in bionanotechnology, where multiple uses may be required from 
a single crude protein source. 
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The development of a laboratory scale 
method for film manufacture and 
characterisation 
 
4.1 Background 
 
In chapter 1, the background and importance of amyloid fibrils in 
bionanomaterials was discussed. Chapter 2 and 3 investigated and established 
chemical methods to modify bovine insulin and gain control of the morphology 
of bovine insulin nanofibres. In this chapter, a nanocomposite film manufacture 
method was established. The impact of film manufacturing steps and drying 
was characterised. The potential of adding amyloid fibrils to a polymer matrix 
system was also investigated. In chapter 5, proof of principle that amyloid fibrils 
from two different sources of proteins may make a difference to bionanomaterial 
properties was sought.  
 
There has been much interest in the potential application of amyloid fibrils 
(chapter 1, section 1.6) with efforts in the past decade seeking to understand 
protein fibril growth (Dobson 2004, Jahn and Radford 2008, Nielsen et al. 2001, 
Radford 2000, Tycko 2004) and to produce fibrils in an economic way, in 
particular with a view to exploring applications such as nanocomposites (Cherny 
and Gazit 2008, Garvey et al. 2008, Gras 2007, Waterhouse and Gerrard 2004, 
Waterhouse et al. 2003).  
 
Polymers are useful as a matrix to produce nanocomposites with enhanced 
properties (Cadek et al. 2002, Cadek et al. 2004, Calvert 1999, Coleman 2006, 
Guo et al. 2007, Lau et al. 2006, Schadler et al. 1998, Zhang et al. 2003). Of the 
various polymers that serve as a matrix, PVOH was chosen for this study as 
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previously described in chapter 1, section 1.8.2. The primary issues in the 
development of the PVOH + protein fibril composites were the production of 
amyloid fibrils on an appropriate scale, the choice of a polymer as a matrix, the 
choice of method for film manufacture, and the effect of polymer-fibril mixing on 
the stability of the protein fibrils and protein control. 
 
As introduced in chapter 1, bovine insulin is the model protein in this thesis 
hence this chapter is largely based on the use of insulin to develop a film 
manufacture method. However, methods successfully established with bovine 
insulin were applied to crystallins, a cheap, industrial waste material that have 
been shown to form amyloid fibrils (Garvey et al. 2008) and will be discussed in 
part in this chapter and explored further in chapter 5. 
 
4.2 Production of Amyloid Fibrils for Films 
 
As shown in chapter 3, protein fibrils can be produced in a variety of 
morphologies, long, short, twisted, straight and ribbon like, to name a few. In 
this study fibrils were produced from two different protein sources, insulin and 
crystallins. 
 
4.2.1 Insulin fibrils 
The ability of bovine insulin to form fibrils readily under denaturing conditions in 
vitro, was described in detail in chapter 3. For this chapter, insulin fibrils were 
prepared in HCl (25 mM, 100 mM NaCl, pH 1.6). The fibrils prepared in HCl 
were reproducibly unbranched and straight and distinct on the TEM, which 
facilitated its characterisation in films. These nanofibres ranged from 8-30 nm in 
diameter with varying lengths of several micrometers (chapter 3, Figure 3.6).  
 
4.2.2 Crystallin fibrils 
Bovine eye lenses were obtained from Canterbury Meat Packers Seafield Plant 
and stored at -20°C prior to protein extraction in this study. Protein extraction 
and fibril formation was performed using optimised conditions from a recent 
study in our research group (Garvey et al. 2008). Several bovine eye lens were 
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homogenised in a Tris buffer (50 mM, pH 7.2) and centrifuged to obtain a clear 
supernatant which was composed of the crude crystallins.  
The crystallins were diluted to 22 mg/ml in 2,2,2-trifluoroethanol (TFE) (10%, pH 
2) and incubated at 60°C to form fibrils. A NuPAGE gel was run to determine 
the molecular weight of the proteins in the crystallins. Figure 4.1 shows that the 
crystallin control (Lane 1) are 20-28 kDa, which is consistent with the findings of 
Garvey et al. (2008). They are made up of primarily the α-, β- and γ-crystallin 
proteins (Kapphahn et al. 2003). The β- component protein bands were 
identified in Lane 1 at ~26 kDa and the α-, γ-crystallin bands ranged from 17-25 
kDa. After the fibrillation of the crystallins, the fibrils were centrifuged and the 
supernatant was run on NuPAGE (Figure 4.1, Lane 2). The gel shows the loss 
of proteins bands after protein fibrillation.  
                      kDa 
 
Crude crystallin NuPAGE (reducing) analysis on a Bis-Tris 4-12% gel, 5
      M     1      2            
 
                              
Figure 4.1  
μl was loaded at 0.44 mg/ml protein. Lane M = molecular weight marker, Lane 1 = 
native crude crystallin protein, Lane 2 = crude crystallin fibril supernatant.                             
 
Crystallins are known to have high β-sheet content in their structure. The 
crystallins have a relatively high affinity for the ThT dye in their native form 
(Meehan et al. 2004) therefore there is a high ThT background reading in the 
fibrillisation incubation. Time courses on in situ fibrillation incubations were not 
monitored by ThT. However, incubations of crystallins in 10% TFE at pH 2 
260 
 
160 
110 
80 
 
60 
50 
40 
 
30 
20 
 
15 
10 
3.5 
 
 
β 
α/γ 
Chapter 4 Development of a laboratory scale method for film manufacture 
and characterisation 
 149
showed a measurable increase in ThT fluorescence (Figure 4.2 a). The ThT 
assay observations were supported by TEM examination of the crystallin fibrils 
which showed a variety of different morphologies (Figure 4.2 b, c, d).  
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c)                                                       (d) 
Figure 4.2 ThT fluorescence (a) and TEM image (b-d) of crude crystallin fibrils, after 4 
weeks of incubation at 22 mg/ml in 10% TFE (pH 2) at 60°C. For the ThT assay, 
samples were assayed in triplicate, Column 1: crystallin control, Column 2: crystallin 
fibrils. The assay was carried in Tris buffer (pH 7.5) with ThT and the final 
concentration of crystallin in the assay was 7 mg/ml. Error bars represent the standard 
deviation of mean. TEM shows (b) twisted fibril, (c) straight fibrils in sheeted 
conformation and (d) short curly fibril, all obtained from the same sample. Some 
amorphous aggregates were also observed (picture not shown). 
 
 
                                                             
 
 
 
 
 
 
 
 
0.25 µm 0.25 µm
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TEM images in Figure 4.2 (b), (c), (d) show that the fibrils are largely composed 
of straight and curly fibrils. The long straight unbranching fibrils form from the α-
crystallins and short flexible curly fibrils from the β- and γ-crystallin fractions 
(Garvey et al. 2008, Meehan et al. 2004). However, the relative concentration of 
crystallin proteins in crude mixtures may dictate the fibril morphology (Garvey et 
al. 2008). For the purpose of this work, a mixture of morphologies is assumed. 
 
4.2.3 Pre-treatment of fibrils  
All fibrils were dialysed at pH 4 (12 mM HCl) with 3 changes of the solution, at 
room temperature. This was done to minimise the salt in the composites and 
obtain a consistent pH of 4 (12 mM HCl) at which fibrils were stable. It was 
found in chapter 3 that pHs above 4 led to the aggregation of insulin fibrils into 
clumps, which may affect their dispersion in the polymer matrix. Hence all the 
fibril solutions prepared in this composite study were kept at pH 4. TEM 
examination of the crystallin and insulin fibrils at pH 4 showed that the fibrils 
remained unchanged.  
 
Control solutions of the unfibrillised protein were also prepared at 11.4 mg/ml 
(12 mM HCl, pH 4) as a point of comparison to the fibrillised proteins. Since 
insulin is insoluble at pH 4, it was dissolved in a minimum volume of 25 mM HCl 
(pH 2) and made up to volume with pH 4 (12 mM HCl). Crystallin proteins were 
made up at pH 4 (12 mM HCl) without 10% TFE. All unfibrillised protein will be 
referred to as protein (insulin/crystallin) control in this chapter and chapter 5. 
 
Additional controls of buffers used for the 2 different protein fibrillisations, HCl 
and 10% TFE were diluted at pH 4 to obtain control solutions for making control 
films with PVOH. The diluted solutions will be referred to as no protein 
(insulin/crystallin) control in this chapter and chapter 5. 
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4.3 Preparation of Polyvinyl Alcohol for Films 
 
PVOH was chosen to be the polymer matrix for nanocomposite film 
manufacture in this thesis (described in detail in chapter 1, section 1.8.4). The 
polymer contains a unit of chemical structure which is represented by (-
CH2CHOH-) (Sakurada 1985). It is a semicrystalline polymer with hydroxyl 
groups that give rise to intermolecular and intramolecular bonding (Kim et al. 
2007). The PVOH utilised in this project was partially hydrolysed (86.5-89.0%) 
and had a MW of 115 kDa. A PVOH aqueous solution (5% w/v) was prepared in 
water by dissolving PVOH at 80°C. PVOH solutions were used within 3 days of 
its preparation since the solution gradually became turbid upon standing at 
room temperature for longer time periods. The turbidity may be indicative of 
increasing viscosity and secondary bond formation between PVOH chain in the 
aqueous solution (Sakurada 1985) which had to be minimised by using fresh 
PVOH solutions. 
 
 4.4 Incorporating Proteins into PVOH  
 
Development of a PVOH-fibril composite was based on literature examples of 
carbon nanotube (CNT) studies, since the incorporation of CNTs into polymers 
can potentially provide materials with increased modulus and strength (Zhang et 
al. 2003). Polymer-CNT composites can be developed as fibres, films and bulk 
structures, of which films are one of the predominant materials for development 
work (Manocha 2006). Of the several ways to disperse nanostructures in 
polymers (Manocha 2006), a direct mixing of the polymer, PVOH and the 
amyloid fibrils in solution was chosen to minimise agitation and maintain protein 
stability.  
 
Solution casting is a small scale laboratory film production process (Petersson 
and Oksman 2006) which was selected for this study. The method has 
previously been used for the production of nanocomposites with nano-sized 
fillers (Petersson and Oksman 2006). In this thesis, a rectangular gel casting 
tray (7 cm wide x 10 cm length and 1.5 cm in depth) was utilised to obtain an 
 151
Chapter 4 Development of a laboratory scale method for film manufacture 
and characterisation 
 152
appropriate sized film (Figure 4.3) for mechanical characterisation in chapter 5. 
A bubble leveller was used to ensure that all trays were levelled during the 
solvent evaporation stage to minimise variation in the thickness of films.  
 
 
   
Figure 4.3 Gel casting tray used to cast films (7 x10 cm). 
 
 
Protein amyloid fibril solutions were suspended at pH 4 as obtained after 
dialysis. The fibrils were then added to 5% PVOH solution (pH~5.8) to obtain a 
final concentration of 2.5% (w/v) PVOH solution and 0.6% (w/v) fibril. The pH 
was adjusted with dilute NaOH or dilute HCl to pH 4. Control solutions with and 
without protein were also mixed with PVOH in the same way, for comparison. 
The mixtures of PVOH + protein fibrils, PVOH + protein control, PVOH + no 
protein control were swirled gently for 2 min to obtain a uniform dispersion and 
poured into separate casting trays. Care was taken to minimise air bubbles 
during mixing and pouring into casting dishes. The water was then allowed to 
evaporate and a polymer film was formed over 5 days of evaporation at room 
temperature. Films were carefully peeled off the casting trays and left to 
equilibrate at room temperature for 48 hr (Figure 4.4) before further testing. The 
images show that the PVOH + no protein control and PVOH + protein control 
film are clear and transparent in comparison to the opaque PVOH + insulin fibril 
film showing white insulin fibrils dispersed within the film.  
 
Gel casting tray 
 
Gel running tray 
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All films referred to as hydrated films in this chapter and chapter 5, have been 
formed by solvent evaporation method (air drying at room temperature) followed 
by 48 hr equilibration. Any subsequent conditioning or drying of the hydrated 
films will be specified.   
 
 
Figure 4.4 Digital images of 2.5% PVOH composite films: (a) PVOH + no insulin 
control, (b) PVOH + 0.6% insulin control, (c) PVOH + 0.6% insulin fibrils. 
 
 
4.5 Investigating the Impact of Processing Method on Proteins 
in Nanocomposites 
 
Since there had not been any previous literature reports on the incorporation of 
protein fibrils into a polymer matrix, it was important to investigate the impact of 
the polymer-fibril mixing on the protein control and protein fibrils and ensure that 
the fibrils remained intact. ThT assay, TEM and CR staining with polarising light 
microscopy were utilised to ascertain if fibrils were retained in the PVOH + fibril 
films, and whether there was any indication of amyloid formation in the control 
PVOH + protein control films. 
 
 
 
 
 
 
 
 
 
 
                  
                  (a)                                    (b)                                    (c) 
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4.5.1 Characterising insulin fibrils in the nanocomposites by ThT and TEM 
The ThT assay was carried out on PVOH + insulin mixtures to determine the 
impact of processing on the insulin fibrils and insulin control. Figure 4.5 shows 
the intensity of ThT fluorescence and suggests that the dialysis and mixing of 
insulin fibrils with PVOH did not affect the β-sheet content (columns 4 and 5). 
Similarly the insulin control was not affected by the steps involved in preparing a 
PVOH-native insulin mixture, since the ThT fluorescence remained negligible 
(columns 1 and 2), pre and post PVOH mixing.  
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Figure 4.5 ThT assay of casting solutions with insulin control and insulin fibrils, with 
and without PVOH. Lane 1: 0.6% insulin control, Lane 2: 2.5% PVOH + 0.6% insulin 
control, Lane 3: 0.6% insulin fibrils before dialysis, Lane 4: 0.6% insulin fibrils after 
dialysis in 12 mM HCl, Lane 5: 2.5% PVOH + 0.6% insulin fibrils. All PVOH + protein 
solutions were made up with dialysed protein solutions at pH 4. Insulin fibrils were 
prepared in 25 mM HCl (100 mM NaCl, pH 1.6), at 60°C for 24 hr. ThT assay was 
carried out in situ on the plate reader, in triplicates, with 198.4 μl of protein solution and 
1.6 μl of (2.5 mM) ThT in the wells. 
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The TEM micrographs of the two composite solutions from Figure 4.5 (Lane 2 
and 5) prior to casting are shown in Figure 4.6. In the images, observation of 
the proteins and protein nanofibres is made particularly difficult by the presence 
(and thickness) of the PVOH, which strongly reduces the image contrast. Figure 
4.6 (a) shows that native insulin is present in the form of dark globular 
aggregates in the films. Figure 4.6 (b) shows dark contrast, which may have a 
nanofibre network, but the image is not distinct. However, further 
characterisation of the composite solutions was carried out using CR and 
examination of films under cross polarised light. 
 
Figure 4.6 TEM analysis of the 2.5% PVOH composite mixture. (a) PVOH + 0.6%  
insulin control, (b) PVOH + 0.6% insulin fibrils. Insulin control and fibrils had been 
dialysed before mixing with PVOH. 
 
 
4.5.2 Using CR to detect amyloid in PVOH nanocomposites                                       
Further attempts were made to investigate the stability of insulin control and 
insulin fibrils in PVOH films using CR, which has a structure as shown in Figure 
4.7. CR dye is a diazo dye of symmetrical structure (Puchtler et al. 1962) which 
forms hydrophobic interactions with the β-sheets of the fibrils (Westermark et al. 
1999). Light microscopic studies demonstrated that the birefringence of amyloid 
deposits increases intensely after staining with CR (Puchtler and Sweat 1965). 
 
 
 
 
 
 
                    (a)                             
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Figure 4.7 The structure of Congo red. 
 
Insulin (control and fibrils) solutions were stained with CR dye prior to mixing 
with PVOH and casting. Staining was carried out by adding CR at 1 mg/ml to 
the solutions used to make the protein control and protein fibrils respectively. 
The solutions were allowed to equilibrate for 30 min to allow the CR to bind. The 
protein solutions were dialysed to remove any unbound CR. Figure 4.8 shows 
the PVOH films with insulin fibrils at varying levels.  
 
 
             (a)                                 (b)                                (c)                              (d)                        
 
Figure 4.8 2.5% PVOH-insulin fibrils composites with CR in casting dishes, while the 
water was evaporated from the solutions. (a) PVOH + no fibril control, (b) PVOH + 
0.2% insulin fibrils, (c) PVOH + 0.4 % insulin fibrils, (d) PVOH + 0.6% insulin fibrils.  
      
Films composed of PVOH + no protein control, PVOH + insulin control, PVOH + 
insulin fibrils with CR were viewed with a light microscope fitted with a cross 
polarising lens. The CR dye emits a bright yellow-green birefringence under 
polarised light when bound to amyloid fibrils (Puchtler and Sweat 1965) . Figure 
4.9 demonstrates the CR binding on 2.5% PVOH films with and without the 
insulin fibrils and insulin control. PVOH + no protein control films showed no 
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yellow-green birefringence observed in the controls when examined under 
unpolarised light.  
 
The films with insulin fibrils (Figure 4.9 f) showed yellow-green birefringence 
under the cross polarised lens, confirming the presence of amyloid fibrils in the 
films. No yellow-green birefringence was observed for PVOH + insulin control 
films under cross polarised light (Figure 4.9 d). The film manufacture method 
did not induce fibrillation of the insulin control. Similarly the PVOH + no protein 
control film showed no amyloid present (Figure 4.9 b).  
 
            Unpolarised light                             Cross polarised light 
                             
                                 (a)                                                   (b) 
                                   
                   
                                 (c)                                                    (d) 
 
                  
                                (e)                                                     (f) 
Figure 4.9 PVOH films when viewed under unpolarised and cross polarised lens. 
Images are at 40x magnification: (a) and (b) PVOH + no protein control + CR, (c) and 
(d) PVOH + insulin control + CR, (e) and (f) PVOH + insulin fibrils + CR. Fibrils were 
prepared in HCl (25 mM HCl, 100 mM NaCl). Protein solutions were dialysed and the 
buffer was diluted at pH 4. 
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The impact of film manufacture method on crude crystallin protein was also 
assessed by CR. Figure 4.10 shows that the PVOH + crystallin fibrils (Figure 
4.10 d) do not show a yellow-green birefringence similar to the crystallin control 
films. This can be attributed to the low concentration of fibrils in the crystallins 
and CR requires a significant level of amyloid fibrils to be able to bind. However, 
CR served as a diagnostic tool for in vitro detection of amyloid in polymer 
nanocomposites such as PVOH + insulin fibril film method development work.  
 
Unpolarised light                             Cross polarised light 
    
   (a)                                              (b) 
 
    
     (c)                                              (d) 
 
Figure 4.10 2.5% PVOH films when viewed under unpolarised and cross polarised 
lens. Images were taken 10x magnification: (a) and (b) PVOH +  crystallin control + 
CR, (c) and (d) PVOH + crystallin fibrils + CR. Fibrils were prepared in 10% TFE and 
final concentration in the films were 0.6%. Protein solutions were dialysed and the 
buffer was diluted at pH 4. 
. 
 
4.6 Background on Polymer Mechanical Properties  
 
In this thesis, efforts were made to measure the impact of protein nanofibres on 
PVOH mechanical properties since promising results have been found by 
introducing other nanostructures in polymer systems (Aoi et al. 2000a, Aoi et al. 
 
 
Chapter 4 Development of a laboratory scale method for film manufacture 
and characterisation 
 159
2000b, Bhattacharyya et al. 2006, Bhattacharyya et al. 2005, Safadi et al. 2002, 
Zhang et al. 2003). The mechanical properties of interest generally comprise 
the polymer strength, elongation, modulus and toughness, which measure how 
well a material resists deformation. To measure these properties, the composite 
has to be placed under stress and its response to the stress characterised. This 
can be done by tensile strength measurement and thermo-mechanical analysis, 
which are widely employed to measure the mechanical properties of composites 
(Aoi et al. 2000a, Bhattacharyya et al. 2006, Bhattacharyya et al. 2005, Cadek 
et al. 2004, Chang and Kim 2007, Mi et al. 2007, Park et al. 2001, Peng et al. 
2007, Ryan et al. 2006, Safadi et al. 2002, Zhang et al. 2003).  
 
Strength is measured by the force that is needed to break a sample, and more 
specifically tensile strength refers to the force required when the material is 
under tension (Sionkowska 2005). The tensile strength in this study was 
measured on an Instron Universal Testing Machine (UTM) (Figure 4.11), where 
the machine stretches the sample and it measures the amount of force that it is 
exerting and the stress (force/cross sectional area) that the sample is 
experiencing. 
 
 
 
Figure 4.11 Image of Instron (UTM) testing machine showing a film strip attached for 
uniaxial elongation (green arrow). 
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The UTM continues to increase the amount of force, and stress, on the sample 
until it breaks. The force needed to break the sample is the tensile strength of 
the material. The elongation is a type of deformation that a material undergoes 
under stress and the toughness is the amount of energy that is needed to break 
a sample, measured by the area under the stress-strain curves. Figure 4.12 
shows a force-extension curve, normally obtained by an UTM, demonstrating 3 
types of curves with distinctive material properties. The curve shows that a 
strong material can be identified by a large force and a minor extension while a 
strong material may possess a large force and extension. Weak materials are 
signified by a small increase in force with a large extension. Figure 4.12 also 
indicates that the dynamic mechanical analysis (DMA) testing (described below 
and in chapter 5) is done at low force regions.  
 
DMA 
 
 
Figure 4.12 Nominal force-extension plot showing several materials of contrasting 
strength and toughness from (Rosenthal 1999). 
 
The mechanical properties of nanocomposites are dependent on the interface 
between nanostructures and their matrix (Adam and Alan 2001). This is 
because the nanostructures have a high surface area. Studies have shown that 
some types of CNTs provide better nanotube-matrix adhesion than others 
(Manocha 2006). A good adhesion allows effective stress transfer from the 
nanostructures to the polymer, for example in PVOH/CNT composites (Cadek 
et al. 2002). Hence the mechanical properties of bionanocomposites such as 
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the PVOH + protein fibril films may also depend on the extent of stress transfer 
between the PVOH and the protein.  
 
In preliminary experiments, the direct impact of the protein (0.2%-0.6%) on the 
PVOH polymer was evaluated by the tensile strength and strain to failure on an 
UTM. The stress-strain curve provides information on the strength, elongation 
and toughness of the films and forms the preliminary discussion in this chapter 
(sections 4.7.1, 4.9 and 4.10.2) and provides baseline data for the DMA work. 
 
More detailed information about the behaviour of the films was obtained by 
DMA analysis (Figure 4.13). DMA testing is relevant to the initial slope of the 
stress-strain test profile obtained from the UTM (Figure 4.12) (Staiger, pers. 
comm.). The slope of the initial curve represents the elastic modulus of the 
material, which under tension is the Young’s modulus (Nielsen 1974). DMA 
analysis is most useful to study polymer viscoelasticity, because polymers are 
partially elastic and partially viscous (Nielsen 1974). They exist in 2 distinct 
states with different physical properties: at low temperatures they exhibit the 
glass state, the material is hard and rigid, but at high temperatures a rubbery 
state is exhibited, which is flexible and extendible. Thus DMA is carried out over 
a range of temperatures. 
 
 
Figure 4.13 A schematic of a DMA showing the test arrangement in tension mode, 
from (Ehrenstein et al. 2004). 
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During the DMA test, an oscillating force is applied continuously to a sample 
and the resulting displacement of the sample is measured. Sample deformation 
under oscillating load is monitored against time, temperature or frequency of 
oscillation and the sample storage modulus (E′) and loss modulus (E″) and loss 
factor Tan δ are obtained (Figure 4.14). E′ is directly associated with elastic 
response and is a measure of the stiffness of the material  (Yang et al. 2004) 
and E″ measures the energy dissipated per cycle of vibration. The ratio of E″/E′ 
is the loss Tangent (Tan δ), which describes the damping properties of a 
material. A high Tan δ is characteristic of a material with non-elastic behaviour, 
while a low value of Tan δ is characteristic of a more elastic material. Since Tan 
δ measures the ratio of energy dissipated to maximum energy stored, a 
decrease in Tan δ means more energy is stored in the material (Yang et al. 
2004). The maximum value of the Tan δ or E″ modulus is the glass transition 
temperature Tg  (Ehrenstein et al. 2004), which defines the limit between the 
glassy and the rubbery state (Roos and Karel 1991).  
 
 
Figure 4.14 A diagram showing the typical DMA curves for an amorphous polymer, 
from (Ehrenstein et al. 2004). 
 
Thus DMA was used to obtain information as to whether protein addition affects 
the mechanical relaxation processes of the PVOH films. The impact of both 
insulin and crude crystallin proteins was determined at a level of 0.6%, in a 
2.5% PVOH film. Experiments were conducted by increasing the DMA 
temperature at 2°C/min at a constant deformation frequency of 1 Hz, under 
stress in tension (stretching) mode. Initial tests were carried out at a wide 
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temperature range of -150°C to 150°C but were narrowed to 25°C to 150°C 
since the desired PVOH profiles were obtainable within this range. The DMA 
data were supplemented by characterisation with differential scanning 
calorimetry-thermogravimetric analysis (DSC-TGA), X-ray diffraction (XRD) and 
scanning electron microscopy (SEM) imaging.  
 
4.7 Characterisation of PVOH Films 
 
Preliminary studies on PVOH films were based on preparing hydrated PVOH 
films without any additives.  
 
4.7.1 Effect of film thickness on tensile strength 
In the initial studies, a series of experiments were done to develop a reliable film 
casting method. The moisture level (measured by % weight loss on drying) was 
found to be 10 ± 3% for all the hydrated films tested in this section. During the 
method development work, PVOH films were cast at varying thicknesses (0.03-
0.08 mm). Tensile testing of 2.5% PVOH films showed that the thickness of the 
films affected the stress and elongation of the samples (Figure 4.15). As the 
thickness of the films increased, from 0.03 mm to 0.08 mm, the stress values 
decreased while the elongation increased (Figure 4.15 a and b). A decrease in 
stress occurred when the thickness of films was further increased from 0.08 to 
0.12 mm but the elongation increased further (Figure 4.15 a and b). The linear 
increase in % elongation values with increasing film thickness is in agreement 
with the results obtained with whey protein isolate films (Longares et al. 2004). 
 
Film thickness is one of parameters that could affect physicochemical properties 
of the films, such as gas permeability (McCaig and Paul 2000) and mechanical 
properties (Jansson and Thuvander 2004). The data suggested that the thick 
PVOH films were more flexible than the thin films. The decrease in film strength 
with thickness was unexpected since stress is a measure of force per cross 
section area of specimen, which is predicted to be proportional to film thickness. 
However, the results were in agreement with the previous studies (Jansson and 
Thuvander 2004, Pongjanyakul and Puttipipatkhachorn 2008). The higher 
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strength of thin films than the thick films, may have been due to higher 
crystallinity of the thin films (Pongjanyakul and Puttipipatkhachorn 2008).  
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Figure 4.15 Effect of film thickness on the stress (a) and elongation (b) of 2.5 % PVOH 
films. Films were dried for 5 days at ambient conditions and tested in replicates of five; 
Data show average values with % standard error of the mean. 
 
4.7.2 Impact of moisture on the viscoelastic behaviour of PVOH films 
Preliminary testing of hydrated PVOH film without any additive encountered 
reproducibility issues in the UTM and DMA data for replicate samples. This was 
thought to be due to water in the PVOH films. Attempts were therefore made to 
improve reproducibility by vacuum drying the films and measuring the impact on 
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the viscoelastic behaviour. Thus vacuum dried films will be referred to as dried 
films in this chapter and chapter 5. 
 
4.7.2.1 Drying 
Films were dried in a vacuum oven at 60°C for 0 hr to 72 hr to determine the 
loss of moisture over time. Figure 4.16 shows that a plateau is reached after 16 
hr of drying films, after which no further loss of water from the PVOH film was 
observed. Consequently, films were vacuum dried for at least 24 hr at 60°C 
when measuring the mechanical properties for dry films. 
 
91
92
93
94
95
96
97
98
99
100
0 6 12 18 24 30 36 42 48 54 60 66 72
Time (hr)
W
ei
gh
t (
%
) 
 
Figure 4.16 Effect of drying 2.5% PVA films at 60°C in a vacuum oven, over time. 
Samples in triplicate were obtained from three films cast separately and 9 strips of films 
were tested. Error bars represent standard deviation of the 9 measurements. 
 
4.7.2.2 Impact on viscoelasticity 
DMA analysis of hydrated and dried PVOH films without any additives was 
carried out as a function of drying time (Aoi et al. 2000b, Park et al. 2001). 
Figure 4.17 (a), (b) and (c) provide evidence that all the parameters, stiffness, 
loss modulus and the Tan δ profiles of PVOH films are affected by the water 
content. The stiffness (Figure 4.17 a) and the loss modulus (Figure 4.17 b) 
increased with the length of drying and decreasing hydration. The increase in 
Tan δ intensity in Figure 4.17 (c) suggests an increase in molecular slippage 
within the films (Nielsen 1974).  
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Figure 4.17 E′ curve (a) and E” curve (b) and Tan δ (c) of 2.5% PVOH films measured 
by DMA. Graph represents samples which have been dried for 0 hr (black), 5 hr (red), 
16 hr (blue), 24 hr (green) and 48 hr (grey). Films were dried at 60°C in a vacuum 
oven. The Tg is the value indicated by the peaks of E″ curves (b). 
Time (hr) Tg (°C) 
0 23 ± 0.1 
5 23  ± 0.1 
16 64 ± 0.1 
24 73 ± 0.2 
48 73 ± 0.2 
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The Tg was determined from the peak of the E″ curve (Ehrenstein et al. 2004) 
and was found to increase from 23°C in the hydrated films, to 73°C for dried 
PVOH films. Tg increased with the length of drying time to a maximum Tg value 
of 73°C. The Tg values obtained for the dried films in this experiment are similar 
to the literature, where the Tg of PVOH was reported to be between 68-85°C  
(Aoi et al. 2000b, Cassu and Felisberti 1999, Park and Russell 2001, Sakurada 
1985). 
 
Figure 4.17 (c), also shows that moisture/level of hydration affects the shape of 
the DMA (Tan δ) curves. Water can act as a plasticiser and cause the Tg to shift 
to lower temperatures (Ehrenstein et al. 2004). To standardise the effect due to 
differing moisture levels, films were dried prior to mechanical testings. 
 
4.8 Impact of Fibril Forming Solutions on PVOH Films 
 
Since HCl and TFE were utilised in the preparation of the protein fibrils, it was 
necessary to determine the impact of these compounds on PVOH films. The 25 
mM HCl (100 mM NaCl) and 10% TFE solution were diluted with 12 mM HCl 
(pH 4) to simulate the dialysis of the protein fibrils. 
 
4.8.1 Visual examination  
PVOH films prepared were examined to determine the impact of TFE and HCl 
on the visual characteristics of the films. It was found that the PVOH films with 
added water and no protein controls (12 mM HCl) were similar with a uniform 
and clear appearance. The 10% TFE did not affect the appearance of PVOH 
films. However, the addition of undiluted solution used to make insulin fibrils  
(25 mM HCl, 100 mM NaCl, pH 1.6) led to the rough and uneven appearance of 
a film (Table 4.1). This may be due to the low pH or the sodium ions. 
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Film samples Visual 
PVOH + water  Clear, smooth surface   
PVOH + HCl (25 mM HCl, 100 mM 
NaCl) 
Clear, with roughness in mid 
regions on both sides 
 
PVOH + diluted HCl (12 mM HCl) Clear, smooth surface  
PVOH + 10% TFE Clear, smooth surface  
PVOH + diluted TFE (12 mM HCl) Clear, smooth surface  
 
Table 4.1 Comparing the impact of buffers on PVOH film characteristics. 
 
 
4.8.2 Thermal analysis: viscoelastic behaviour 
DMA analysis was performed on dried PVOH films: (1) PVOH + no insulin 
control, (2) PVOH + no crystallin control, (3) PVOH + no insulin with 25 mM HCl 
(100 mM NaCl), and (4) PVOH + no crystallin with 10% TFE. The stiffness, loss 
modulus and the Tan δ profiles are shown in Figure 4.18 (a), (b) and (c). The 
PVOH + no crystallin, and PVOH + no insulin, control films had higher stiffness 
compared to the films with undiluted HCl and TFE. The Tg of both the no protein 
control films were found to be at 72°C.  The 10% TFE, lowered the Tg of PVOH 
to 67°C. Overall, Figure 4.18 confirms that the dialysis of protein solutions is 
ideal to minimise their impact on the viscoelastic behaviour of the PVOH films.  
 
4.8.3 Thermogravimetric analysis  
Another technique that is useful to determine the thermal stability of materials, 
is thermogravimetric analysis (TGA) (Ehrenstein et al. 2004). TGA was carried 
out on all film samples in this study using a simultaneous DSC-TGA. It involved 
a continuous weight measurement as the film sample temperature increased 
from 25°C to 600°C at 10°C/min in an inert nitrogen environment. Preliminary 
TGA was carried out to assess the impact of the solutions used to make protein 
fibrils (25 mM HCl (100 mM NaCl) and 10% TFE) on the thermal stability of the 
nanocomposite system. 
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Figure 4.18 (a) E′ curve, (b) E″ curve and (c) Tan δ of 2.5% PVOH + no protein control 
films and PVOH + no protein with 10% TFE or 25 mM HCl (100 mM NaCl) measured by 
DMA. Sample are: PVOH + no insulin control replicate 1 (black) and replicate 2 (grey), 
PVOH + no insulin with 25 mM HCl (100 mM NaCl) replicate 1 (red), replicate 2 (plum), 
PVOH + no crystallin with 10% TFE replicate 1 (green), replicate 2 (lime green), PVOH + 
no crystallin control replicate 1 (blue), replicate 2 (pale blue).  Samples had been dried at 
60°C in vacuum oven for 24 hr. The Tg is the value indicated by the peaks of E″ curves 
(b). 
Sample Tg (°C) 
PVOH + no insulin 
control 
72 ± 0.2 
PVOH + no crystallin 
control  
72 ± 0.2 
PVOH +  no insulin 
with 25 mM HCl (100 
mM NaCl) 
72 ± 0.2 
PVOH + no crystallin 
with 10% TFE 
    67 ± 0.1 
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The degradation temperature for each sample was determined from the slope of 
the TGA profiles, using the TGA computer software SDT 800 V20. Table 4.2 
shows that PVOH has a degradation temperature from 288 to 293 ± 2°C, in the 
PVOH + water film and PVOH + no insulin control and PVOH + no crystallin 
control films. The solutions used to make protein fibrils in this study did not 
affect the degradation temperature of PVOH films. However, the undiluted 25 
mM HCl (100 mM NaCl) led to a decrease in the thermal stability of the PVOH 
to 280°C. The decomposition temperature of PVOH decreased further on the 
addition of 10% TFE (pH 2).  
 
 
 
Samples 
Degradation 
Temperature 
(°C) 
PVOH + water film 293 ± 1 
PVOH + no insulin with 25 mM HCl (100 mM NaCl) film 280 ± 3 
PVOH + no insulin control  film 290 ± 1 
PVOH + no crystallin with 10% TFE film 240 ± 2 
PVOH + no crystallin control film 288 ± 2 
Table 4.2 Effect of buffers on the thermal degradation temperature of PVOH films. 
 
4.9 Impact of Proteins on the Tensile Properties of Hydrated 
PVOH films  
 
Preliminary tensile studies on the UTM, were based on measuring the impact of 
adding 0.2% fibrils to PVOH films. A low amount of fibrils were used initially to 
observe its impact on the strength of PVOH. 
 
The impact of the incorporation of 0.2% insulin and crystallin into 2.5% PVOH 
films is shown in Figure 4.19. The stress of PVOH films without any protein was 
found to be 133 ± 14 MPa. The stress of the PVOH films was lowered with the 
addition of insulin control. There was no significant change in the stress of the 
PVOH film with the addition of insulin fibrils (Figure 4.19 a). The elongation of 
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the PVOH films was increased with the addition of native insulin as well as 
insulin fibrils (Figure 4.19 b); however the increase conferred by the insulin 
control was substantial compared to insulin fibrils. 
 
 
(a) 
38
141 133
236
382
133
0
50
100
150
200
250
300
350
400
450
500
1 2 3 1 2 3
St
re
ss
 (M
Pa
)
 
 (b) 
27
7
132
7
1721
0
20
40
60
80
100
120
140
160
1 2 3 1 2 3
El
on
ga
tio
n 
(%
)
 
 
Figure 4.19 Effect of 0.2% insulin on 2.5% PVOH films tensile properties (a) stress and 
(b) elongation. In both graphs: unshaded bars = insulin, shaded bars = crystallin 
proteins and the columns represent, PVOH + no insulin/crystallin control (Column 1), 
PVOH + protein control (Column 2), and PVOH + protein fibrils (Column 3). Films were 
0.03 mm in thickness. Error bars represent % standard deviation of mean. 
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In contrast to the impact of insulin on the behaviour of PVOH films, the 
crystallins caused a significant increase in the stress of the films, in both the 
control and fibrillised form with more stress conferred by the fibrillised protein. 
The elongation of the PVOH films was also increased by the addition of the 
crystallin protein, though by a lower amount that the insulin control. 
 
The addition of insulin control caused PVOH films to become more elongated 
than the rest of the composites. The large increase in the stress caused by the 
addition of crystallin fibrils is a promising result and suggests that crystallins 
may increase the strength of PVOH films. 
 
4.10 The Impact of Insulin Addition on PVOH Films by DMA 
 
Insulin was added at a higher concentration of 0.6%, to determine its impact on 
the PVOH film mechanical properties. The level of insulin fibrils in the PVOH 
matrix was increased from 0.2% in the preliminary study (section 4.9) to 0.6% 
since nanocomposite studies with CNTs show incorporation of CNTs at 
significantly higher levels for investigations on their effect on PVOH films 
(Safadi et al. 2002, Zhang et al. 2003). The costs associated with bovine insulin 
allowed a maximum of 0.6% to be incorporated into the PVOH films for this 
study. The viscoelastic properties were measured in both the hydrated and 
dried states of the films. 
 
4.10.1 Viscoelastic properties of hydrated films 
Figure 4.20 a and b show that the stiffness and the loss modulus, E″ profile of 
PVOH shift toward a higher temperature region, due to the addition of the 
insulin, in both the control and the fibril form. This is indicative of an increase in 
the Tg of PVOH (Figure 4.20 b) and suggested that the PVOH required a higher 
temperature to transit from a glassy to a rubbery polymer, due to the presence 
of insulin in the films. The decrease in stiffness due to the insulin addition 
(Figure 4.20 a) shows that the insulin is making the PVOH films less stiff 
compared to the PVOH without insulin.  
(a) 
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Figure 4.20 (a) E′ curve, (b) E″ curve and (c) Tan δ curve of 2.5% PVOH films with and 
without insulin measured by DMA. Graph represents hydrated film samples, PVOH + 
no insulin control (black and grey), PVOH + 0.6% insulin control (blue and pale blue) 
and PVOH + 0.6% insulin fibrils (red and plum). The E′ values at 30°C (a), Tg values 
from E″ peak (b) and the Tan δ intensities (c) are tabulated at the respective curves. 
 
Sample E′ at  30°C 
(x109) Pa 
PVOH + no insulin 
control 
6.3 ± 1.3 
PVOH + 0.6% insulin 
control 
4.0 ±  1.8 
PVOH + 0.6% insulin 
fibrils 
2.0 ± 0.4 
Sample Tg (°C) 
PVOH + no insulin 
control 
30 ± 3 
PVOH + 0.6% insulin 
control 
42 ± 0.3 
PVOH + 0.6% insulin 
fibrils 
42 ±  1 
Sample Tan δ at 
57°C 
PVOH + no insulin 
control 
0.17 ± 0.5 
PVOH + 0.6% insulin 
control 
0.58 ± 0.1 
PVOH + 0.6% insulin 
fibrils 
0.45 ± 0.1 
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The effect of insulin control and insulin fibrils on the value of Tan δ is shown in 
figure 4.20 c. The Tan δ peaks observed for PVOH + insulin control/fibril films 
show that their Tan δ intensities are higher (40°C-77°C) than those obtained for 
PVOH + no insulin control. This suggested that the hydrated PVOH + insulin 
films had more molecular slipping than PVOH + no insulin control films. 
However, PVOH + insulin fibril films had a lower Tan δ when compared to the 
PVOH + insulin control, which suggested that the PVOH with insulin fibrils may 
possess a lower extent of molecular slipping than PVOH with insulin control. 
 
4.10.2 Dried films 
 
The results obtained earlier in Figure 4.17 suggested that the moisture in the 
films were having an effect on thermal analysis, hence the PVOH films with 
insulin were also dried under vacuum prior to analysis. The hydrated films were 
cut into 60 mm x 7 mm rectangular strips, dried in a vacuum oven at 60°C for 24 
hr before tensile testing.  
 
4.10.2.1 Effect on tensile strength 
 
Figure 4.21 (a) and (b) show data on the effect of insulin (control and fibrils) on 
the dried PVOH film tensile properties. The stress was increased with the 
addition of insulin control to the dry PVOH film but was reduced with the fibril 
addition (Figure 4.21 a) in contrast to the results obtained with the hydrated 
films with 0.2% insulin (Figure 4.19). This suggested that the insulin fibril 
addition reduced the strength of the PVOH films. The PVOH film elongation was 
markedly reduced upon insulin addition (Figure 4.21 b).  
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Figure 4.21 Effect of 0.6% insulin on 2.5% PVOH films tensile properties: (a) stress 
and (b) elongation. Graph (a) and (b) show: (Lane 1) PVOH + no insulin control, (Lane 
2) PVOH + insulin control, (Lane 3) PVOH + insulin fibrils. Data values are an average 
of triplicate measurements and error bars represent standard deviation of the mean. 
Samples had been dried at 60°C in vacuum oven for 24 hr. 
 
Interestingly, the PVOH film behaviour changed from a tough hydrated film 
(Figure 4.19) to a brittle dried film (Figure 4.21). These findings suggest that 
water may affect the elongation properties of the PVOH + insulin control/fibril 
film. 
 
4.10.2.2 Effect on viscoelastic properties 
PVOH + no insulin control, PVOH + insulin control and PVOH + insulin fibrils 
films were tested on the DMA to analyse the impact of 0.6% insulin on dried 
PVOH films. Figure 4.22 (a) shows the storage moduli of PVOH and various 
composites. The stiffness of the PVOH + no protein control film (< Tg) was 
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reduced by the addition of the insulin. The Tg of the PVOH + no protein control 
films did not change with the addition of insulin (Figure 4.22 b). The Tan δ of 
PVOH + no protein control film (>Tg) was reduced with the addition of insulin in 
Figure 4.22 (c). This suggested that the PVOH + insulin (control/fibril) films have 
a lower extent of molecular slippage within the films. Compared to the PVOH + 
insulin control film, the decrease in the mobility was more significant for PVOH + 
insulin fibril films. 
 
4.11 Impact of Insulin on Hydrated PVOH Film Structure  
 
Since film mechanical behaviour is related to its structure, the PVOH films with 
insulin were examined visually and by SEM to further understand the impact of 
addition of insulin to the films 
 
4.11.1 Visual examination  
The addition of insulin to PVOH caused a difference in the appearance of the 
PVOH control films (Table 4.3). Native insulin caused the films to be opaque. 
Insulin fibrils contributed to the rough top surface of the PVOH films, which 
suggests that the PVOH settled to the bottom of the tray and fibrils remained on 
the surface during the drying process. In addition, a close examination by a 
trained eye suggested the presence of voids in the PVOH + insulin fibril films 
(Staiger, per. comm.) Microscopy examination was therefore undertaken. 
 
Film samples Visual 
PVOH + no insulin control Clear, smooth surface  
PVOH + 0.6% insulin control Opaque film,  smooth surface 
PVOH + 0.6% insulin fibrils Roughness on top with white 
aggregates, smooth bottom surface 
 
Table 4.3 Comparing the impact of buffers and proteins on PVOH film: qualitative 
attributes. 
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Figure 4.22 E′ curve (a), E″ curve (b) and Tan δ curve (c) of 2.5% PVOH films with and 
without 0.6% insulin measured by DMA. Sample: PVOH + no insulin control replicate 1 
(black), replicate 2 (grey), PVOH + insulin control replicate 1 (blue), replicate 2 (pale 
blue), PVOH + insulin fibrils replicate 1 (red), replicate 2 (plum). Samples had been 
dried at 60°C in vacuum oven for 24 hr. The E′ values at 36°C (a), Tg values from E″ 
peak (b) and the Tan δ intensities (c) are tabulated for each profile. 
 
Sample E′ at  
36°C 
(x109) 
Pa 
PVOH + no insulin 
control 
9.9 ± 1 
PVOH + 0.6% insulin 
control 
6.7 ± 1 
PVOH + 0.6% insulin 
fibrils 
3.0 ± 0.2
Sample Tg (°C) 
PVOH + no insulin 
control 
70 ± 0.1 
PVOH + 0.6% insulin 
control 
70 ± 0.1 
PVOH + 0.6% insulin 
fibrils 
70 ± 0.1 
Sample Tan δ at 
80°C 
PVOH + no insulin 
control 
0.65 ± 0.05 
PVOH + 0.6% insulin 
control 
0.46 ±  0.01 
PVOH + 0.6% insulin 
fibrils 
0.36 ±  0.01 
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4.11.2 Examination of film microstructure by SEM 
Film microstructural characteristics are closely related to the mechanical 
properties of the films (Hernandez-Izquierdo and Krochta 2008, Roohani et al. 
2008). Thus the morphology of the PVOH + insulin films was examined by 
surface examination of cast films (Figure 4.23) and freeze-fractured films 
(Figure 4.24) using scanning electron microscopy (SEM). The surface of the 
pure PVOH film appeared smooth and uniform at both magnifications (Figure 
4.23 a and b). The PVOH + insulin control film showed some unevenness on its 
surface (Figure 4.23 c), which at a higher magnification revealed the presence 
of grainy-like structures (Figure 4.23 d). It was found that these structures were 
evenly distributed on the surface of the PVOH + insulin control films. The PVOH 
+ insulin fibril films (Figure 4.23 e and f) showed a rough and uneven surface 
with voids in some places. The roughness was uniformly distributed but the 
voids (< 10 μm) were found to be present in some places on the surface. 
 
The grainy-like structures present in the PVOH + insulin control films may be 
aggregated insulin formed as water evaporated during the film formation. Since 
insulin dissolved at low pHs only (pH 2) and the casting solution is at pH 4, 
insulin may have formed precipitates.  
 
Further characterisation of the interior of the films involved field emission (FE)-
SEM examination of their fractured surfaces. Figure 4.24 shows the full 
fractured surface of the films, with the arrow indicating the direction in which the 
fracture took place. The PVOH + no protein control films have a smooth glassy 
morphology. Films containing native insulin show some slight roughness, 
maybe due to the grainy-like structures. Films with insulin fibrils in them show 
ridges and roughness in their fractured surface. 
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(a)                                                               (b) 
                                                                              
(c)                                                              (d)  
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Figure 4.23 SEM images of the surface of cast PVOH film samples: (a and b) PVOH + 
no protein control, (c and d) PVOH + insulin control, (e and f) PVOH + insulin fibrils. 
 
 
A composite material is expected to show a smooth fractured surface if its 
components are adhered well (Staiger, pers. comm.). Figure 4.24 (a), (b) and 
(c) illustrate that greater unevenness is conferred by the slow initiation of the 
fracture (Staiger, pers. comm.), indicated by the arrow. The greatest level of 
unevenness is present in Figure 4.24 (c) suggesting that the presence of insulin 
fibrils posed hindrance to the fracture. 
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Figure 4.24 FE-SEM images of fractured surfaces, of a) PVOH + no insulin control, b) 
PVOH + insulin control and c) PVOH + insulin fibril films. Images reveal that the 
fracture was initiated from top end (Staiger, pers. comm.). Arrow indicates direction of 
fracture. 
 
Further examination of the fractured surface of the films at a much higher 
magnification revealed more structural detail (Figure 4.25 a, b and c). 
Interestingly, the interior of the PVOH + insulin control film also showed that 
grains were present, similar to the film surface in Figure 4.23 (b). This 
observation confirmed that the insulin is distributed evenly in the film. 
 
                (a)                                          (b)                                      (c) 
 
Figure 4.25 FE-SEM images of freeze fractured surfaces of (a) PVOH + no insulin 
control, (b) PVOH + insulin control and (c) PVOH + insulin fibrils, films. 
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The SEM examinations suggested that in PVOH + insulin control films, there is 
poor bonding between the insulin and the PVOH. This structural information 
correlates to the DMA findings in section 4.10.2.2, since poor interfacial bonding 
leads to a reduction in the stiffness which is manifested in reduced storage 
modulus (decreased E′ of the PVOH +  insulin control/fibril film at < Tg in Figure 
4.22 a).  
 
The presence of voids in the PVOH + insulin fibril films were only visible in 
some places on the film surface and not in the interior (Figure 4.25 c). The SEM 
studies suggested that the PVOH + insulin fibril film mechanical behaviour was 
affected by the presence of some porosity and possible voids. Hence, PVOH + 
insulin fibrils films were treated with a hot pressing technique (section 5.1) to 
minimise the contributions of voids on the mechanical behaviour of the films. 
 
4.11.3 Film crystallinity  
Measurement of the degree crystallinity is important since crystallinity affects 
the physical properties of polymers (Sakurada 1985). An increase in polymer 
crystallinity may lead to a reduction in its damping peak intensity (Nielsen 1974) 
which was found in the PVOH + insulin (control/fibril) films. X-ray diffraction was 
undertaken to determine in the crystallinity in PVOH films as a function of added 
insulin, both control and after fibrillisation. 
 
An X-ray diffraction equatorial scan of the PVOH films is shown in Figure 4.26. 
A quantitative evaluation was undertaken since the breadth of the peak can be 
related to the crystallization of the material by the Scherrer equation, where the 
peak width is inversely proportional to crystal size. In 1918, Scherrer first 
observed that small crystallite size could give rise to line broadening (Patterson 
1939). A well known equation (Hammond 1997) for relating the crystallite size to 
the peak broadening is called the Scherrer formula, t = Kλ/(β cos θ) where: 
t = crystal depth/thickness (Å) 
K = Scherrer consTant, arbitrary factor related to crystal size and value that falls 
constant in the range 0.87-1.0, in this case assumed as K = 0.9 
λ = 1.54 Å, the wavelength of the radiation  
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β = The integral breadth of a reflection (in radians 2θ) located at 2θ, calculated 
as FWHM (full width at half maximum height) 
θ = scattering angle 
The Scherrer formula was used to calculate crystal size of PVOH films in this 
experiment. 
 
The diffraction patterns of the films were overlapped as shown in Figure 4.26. 
Peaks were observed at 2θ=19.6° for PVOH, 19.7° for PVOH with native insulin 
and 19.4° for PVOH with insulin fibrils. The data correlate to the literature, 
where  the PVOH XRD peak was found at 19.4° (Yu et al. 2003). Peak positions 
are sensitive to the intermolecular bonding which draws the molecules together. 
The intensity of the peaks can be arranged in a decreasing order as such; 
PVOH + insulin fibril > PVOH + insulin control > PVOH + no insulin control, 
which suggests that the protein addition may have led to a small increase in the 
average crystallinity of the films.  
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Figure 4.26   X-ray diffractometer scan of PVOH films with and without protein fibrils. 
Graph represent PVOH + no insulin control (red), PVOH with 0.6% insulin control 
(blue) and PVOH with 0.6% insulin fibrils (black).These were not replicated. 
 
The calculated crystal size of the films is shown in Table 4.4. The data suggest 
that insulin control and insulin fibril addition may have had a small effect on the 
crystal size in the films.  
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Sample PVOH  + no 
insulin control 
PVOH + insulin 
control 
PVOH + insulin 
fibrils 
 
Crystal size (nm) 
 
7.3 
 
7.1 
 
7.0 
Table 4.4 Effect of insulin addition on crystal size of PVOH films. 
 
4.12 Summary  
 
A reliable film manufacture method has been developed. The impact of the film 
manufacturing method on native protein and protein fibrils was determined to 
ensure that both control and fibrillated proteins were stable to the procedures 
involved. The results suggest that the solution casting method for small scale 
manufacture of films with fibrils was successfully accomplished. However, films 
prepared with insulin fibrils required an additional hot pressing step to process 
the films to minimise defects from voids in the films.  
 
Film mechanical properties were obtained from UTM and DMA analysis. The 
effect of the solution components on mechanical properties was minimised by 
dialysing the proteins. The impact of water as a plasticiser was found to affect 
the viscoelastic behaviour of the films, including the Tg. The impact of water was 
minimised by vaccum drying the films.  
 
The method developed with the model protein, bovine insulin, was applied on 
proteins from crystallins which is discussed in chapter 5. The thermomechanical 
impact of fibrils on PVOH films using the optimised film manufacture method 
developed in this chapter will be assessed in chapter 5.  
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Chapter 5 Fibrils in films 
 
 
 
Fibrils in Films 
 
Chapter 4 established a method for the manufacture of PVOH + protein fibril 
films and provided preliminary evidence that adding fibrils from two different 
proteins: insulin and bovine crystallins into PVOH films had different impacts on 
their properties. In this chapter, a rigorous characterisation of films containing 
the two proteins was carried out. Characterisation of both the PVOH + insulin 
and PVOH + crystallin films were carried out using DMA, DSC-TGA, SEM and 
TEM to compare the impact of the 2 proteins on the PVOH films manufactured 
using the method developed in chapter 4.   
 
 
5.1 The Impact of Hot Pressing on PVOH Film Viscoelastic 
Behaviour 
 
In chapter 4 (section 4.11), it was observed that PVOH + insulin fibril films 
contained some voids. It was thought that voids may affect the mechanical 
properties of the films. To minimise the impact of voids on the viscoelastic 
properties of the films, the PVOH + no insulin control, PVOH + insulin control 
and PVOH + insulin fibril films were hot pressed (Watts et al. 2002). Films were 
cut into rectangular sizes of 60 mm x 7 mm and dried at 60°C for 24 hr. The 
dried films were hot pressed at 180°C, for 20 min. The selection of the hot press 
temperature required the PVOH to melt without any degradation effects. A 
DSC-TGA test was done, which provided a simultaneous measure of sample 
weight loss/heat flow over increasing temperature. The weight loss vs 
temperature, as described in section 4.8.3, provided the degradation 
temperature of samples. The heat flow vs temperature profiles can be used to 
obtain the melting points and it was found that the PVOH had a melting point of 
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194°C (Figure 5.1). The graph shows that PVOH started to melt at 174°C, thus 
a temperature higher than 174°C and lower than 194°C was used to hot press 
the PVOH composite films. 
 
According to the standard practice of treating plastics, they should be 
conditioned under an appropriate relative humidity (RH) and temperature 
(Staiger, pers. comm.) In attempts to apply the standard practice on PVOH 
films, the hot pressed films were conditioned at 50% relative humidity (RH) 
under ambient temperature for 72 hr in accordance with the ASTM standard 
(ASTM Standard, 2005) prior to DMA testing.  
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Figure 5.1 Profile showing the onset and the end, of PVOH melting. Samples were 
analysed in duplicates by the DSC-TGA, SDT Q600, which simultaneously provides 
heat flow measurement and weight change. 
 
The PVOH + insulin fibril films in Figure 5.2 (a and b) show that a smoother less 
flaky appearance of the hot pressed films compared to the pre-hot pressed 
films. However, some voids were still present in some areas of the film. The hot 
pressed PVOH + insulin control films did not have the grainy structures which 
were visible prior to hot pressing the films (image not shown). 
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(a)                                                              (b)                 
                                                          
50μm
 
Figure 5.2 SEM images of the surface of cast 2.5% PVOH + 0.6% insulin fibrils films: 
(a) before hot pressing and (b) after hot pressing. The PVOH + no insulin control film 
and PVOH + insulin control film showed an even surface (image not shown). 
  
 
After hot pressing and standard conditioning of the PVOH films with insulin, the 
DMA tests were carried out. Figure 5.3 (a) shows that there was no observable 
change in the stiffness (E′) of the PVOH with the addition of insulin fibrils. 
However, a decrease in the Tg of the films was observed with the addition of 
insulin (Figure 5.3 b). This means that the PVOH transformed from the glassy to 
rubbery state at a lower temperature when insulin was present, suggesting that 
insulin reduced the thermomechanical properties of PVOH. At temperatures 
above Tg, Figure 5.3 (c) demonstrates that shows a decrease in Tan δ with the 
addition of insulin, which provides evidence that there is a lesser extent of 
molecular slippage in the insulin containing films (Menard 1999, Nielsen 1974). 
The results obtained in Figure 5.3 were not directly compared to the pre-hot 
pressed films (section 4.10), since they differ in the standard conditioning step. 
However, the result obtained in Figure 5.3 (c) is consistent with the pre-hot 
pressed data (chapter 4, Figure 4.22 c). 
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Sample E′ at  30°C, 
x109 
Pa 
PVOH + no insulin 
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5.5  ± 0.4 
PVOH + 0.6% insulin 
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6.3  ± 0.5 
PVOH + 0.6% insulin 
fibrils 
6.5 ± 0.5 
(b) 
Sample Tg (°C) 
 
PVOH + no insulin 
control 
74 ± 0.1 
PVOH + 0.6% insulin 
control 
70 ± 0.1 
PVOH + 0.6% insulin 
fibrils 
52 ± 0.1  
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Sample Tan (δ) 
PVOH + no  insulin 
control 
0.47 ± 0.01 
PVOH + 0.6%  insulin 
control 
0.35 ± 0.01 
PVOH + 0.6% insulin  
fibrils 
0.27 ± 0.01 
Figure 5.3 E′ curve (a), E″ curve (b) and Tan δ curve (c) of 2.5% PVOH films with and 
without 0.6% insulin measured by DMA. Sample are: PVOH + no insulin control 
replicate 1 (black) and replicate 2 (grey), PVOH + with 0.6% insulin control replicate 1 
(blue), replicate 2 (pale blue), PVOH + insulin fibrils replicate 1 (red), replicate 2 (plum). 
Samples had been hot pressed at 180°C and conditioned at 50% (RH), at 23°C for 72 
hr. The E′ values at 30°C (a), Tg values from E″ peak (b) and the Tan δ intensities (c) 
are tabulated for each profile. Errors represent standard deviation of the mean. 
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5.2 The Potential of Crystallins in PVOH Films 
In this section, addition of fibrils from crystallin proteins on the viscoelastic 
properties of PVOH films will be discussed. Section 4.9 showed some 
preliminary data on the increase in the tensile strength of PVOH films with 
added crystallins. Having optimised the methods for testing film viscoelastic 
properties with insulin in the previous sections, the methods were applied to 
crystallin proteins. 
 
5.2.1 Visual and microstructural  examination 
Table 5.1 provides a comparison of the impact of crystallin addition on PVOH 
film visual attributes after vacuum drying. The PVOH films with crystallin protein 
were smooth, similar to the PVOH control. However, the addition of crystallin 
fibrils caused films to become opaque. Although the films with crystallin controls 
had small aggregate particles distributed in them, the particles did not affect the 
smoothness of the films.  
 
The SEM examination of the surface of the films, showed no voids in the films 
with crystallins (Figure 5.4). PVOH + no crystallin control images were the same 
as previously reported with no unevenness observed (picture not shown). The 
films remained smooth with the crystallin fibril addition, unlike PVOH + insulin 
fibril films (chapter 4, Figure 4.23 e), there was no flakiness observed. 
 
Film samples Visual 
PVOH + no crystallin control Clear, smooth surface  
PVOH + 0.6% crystallin control White aggregates  visible within the 
film otherwise clear film, smooth 
surface  
PVOH + 0.6% crystallin fibrils Opaque,  smooth surface 
 
Table 5.1 Comparing the impact of crystallin proteins on PVOH film qualitative 
attributes. 
 
The SEM examination of PVOH with crystallins, confirmed that these films did 
not require the added step of hot pressing. Thus the dry films with crystallins 
were tested on the DMA without any additional processing. 
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Figure 5.4 SEM images of the surface of cast PVOH film samples: (a and b) PVOH + 
no crystallin control, (c and d) PVOH + crystallin control, (e and f) PVOH + crystallin 
fibrils. 
 
5.2.2 The Impact of crystallins on the viscoelastic properties of dry PVOH 
film  
Crystallins were incorporated into PVOH films and dried for 24 hr in a vacuum 
oven at 60°C before testing on the DMA. This experiment is analogous to the 
PVOH with insulin films in section 4.10.2.2. The addition of crystallin fibrils 
caused an increase in the stiffness (E′) of the PVOH films, at temperatures 
below the below the Tg (Figure 5.5 a). The Tg of PVOH films remained 
unchanged with the addition of the crystallin control but there was small 
reduction with the addition of the crystallin fibrils. At temperatures above Tg, 
there was a decrease in Tan δ with the addition of the crystallins (control/ fibrils) 
(Figure 5.5 c). This is consistent with the results obtained for PVOH + insulin 
(control/fibrils) films (Figure 4.22 c) and further suggested that the molecular 
slippage was reduced by the addition of the proteins (control/ fibrils) to the 
PVOH films. Literature confirms that reduction in Tan δ (less damping) occurs 
when the polymer chain mobility is decreased in the nanocomposites (Nielsen 
1974, Suhr et al. 2005). 
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 (a) 
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Sample Tg (°C) 
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Sample Tan δ at 80°C 
PVOH + no crystallin 
control 
0.70 ± 0.01 
PVOH + 0.6%   
crystallin control 
0.47 ± 0.04 
PVOH + 0.6%  
crystallin fibrils 
0.62 ± 0.01 
Figure 5.5 E’ curve (a), E″ curve (b) and Tan δ curve (c) of 2.5% PVOH films with and 
without 0.6% crystallin measured on the DMA. Sample are: PVOH + no crystallin 
control replicate 1 (black) and replicate 2 (grey), PVOH + crystallin control replicate 1 
(blue) and replicate 2 (pale blue), PVOH + crystallin fibrils replicate 1 (red) and 
replicate 2 (plum). Samples had been dried at 60°C for 24 hr. 
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5.3 Comparison of Protein Properties 
 
Table 5.2 compares various characteristics of insulin and the crystallins in their 
native state. There are differences between the two in terms of size, since 
insulin is about 5 times smaller than the crystallins and their solubility profile, 
reflecting differing isoelectric points (insulin = 5.3, crystallins = 5.8-7.0) (Bours 
1973, Conway-Jacobs and Lewin 1971, Spector et al. 1985). Crystallins have a 
lower degradation temperature in comparison to insulin. Microstructural study 
was carried out by TEM to further probe these differences in film properties. 
 
Property PVOH (86.5-89 % 
hydrolysed) 
Bovine insulin Bovine crystallins 
MW (kDa) 115 ~5.7 ~20-28 
Solubilising conditions  80°C (50 mg/ml)) pH 2 (11.4 mg/ml) pH 7 (11.4 mg/ml) 
Source commercial commercial waste protein 
Degradability biodegradable biodegradable biodegradable 
Purity, Cost pure, reasonable pure, expensive crude, cheap,  
Degradation 
temperature (°C) 
290 ± 1  268 ± 3 256 ± 3 
 
Table 5.2 Comparison of properties of proteins and the PVOH. 
 
5.4 Film Microstructure Examination by TEM 
 
 
TEM images were collected for microtomed transverse cross-sections of the 
PVOH composites, containing insulin and crystallins, (control/fibrils). TEM 
samples for PVOH + no protein control film could not be examined by this 
method since the film disintegrated in the preparation media.  
 
Examination by TEM of the insulin control (Figure 5.6 a) shows an amorphous 
matrix indicative of insulin control scattered throughout the film. Figure 5.6 (b) 
illustrates that the PVOH + insulin fibril film had a network of nanofibres which 
were entangled with each other.  
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The crystallin control yielded a network-like structure, which may have formed 
amongst the native crystallin proteins (Figure 5.6 c). Interestingly, their 
distribution is similar to insulin fibrils and not to the native insulin structure. The 
PVOH + crystallin fibril films revealed large clusters of nanofibres which were 
not entangled, in contrast to the insulin fibril film (Figure 5.6 d). The image 
observed in Figure 5.6 (d) also shows that the PVOH + crystallin fibril films had 
structures which were larger in size than the PVOH + insulin fibrils films. 
 
 
a)                                                               b) 
 
0.25 µm
 
 
 
 
 
 
 
 
0.25 µm
c)                                                                d) 
 
 
 
 
 
 
 
 
 
0.25 µm 0.25 µm
 
Figure 5.6 TEM  images of the cross-sections of PVOH cast films with and without 
proteins,  A) PVOH + insulin control, B) PVOH + insulin fibrils, C) PVOH + crystallin 
control, D) PVOH + crystallin fibrils. Images are representative of more than five 
images. 
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The images obtained in Figure 5.6, suggested that there is a difference in the 
way in which the insulin and the crystallin fibrils exist in the PVOH matrix. This 
may suggest that is also a difference in the interaction of the fibrils between 
themselves when mixed with PVOH. However, both protein fibrils have been 
shown to decrease the interfacial slip between nanofibres and PVOH.  
 
The structural findings in this section provide evidence that fibrils entangle to 
form networks with potential applications as reinforcing agents for 
multicomponent mixtures and templates for functional nanostructures. However, 
future work should investigate methods to improve interaction between the 
fibrils and the matrix, for example by the use of compatibilisers (Chapleau et al. 
1998, Xie et al. 2005). 
 
5.5 Thermal Stability of Films 
 
DSC-TGA analysis (Tang et al. 2005) of PVOH film nanocomposites was 
performed to gain a more detailed information about the impact of the protein 
nanofibres on the thermal stability of the PVOH. The real time characteristic 
TGA curves were generated using the Universal Analysis Data Acquisition 
System. The representative TGA curves for the PVOH (powder) control, insulin 
(powder) control and the crystallin (extract) control as well as the PVOH + 
insulin (control/fibril) and PVOH + crystallin (control/fibril) films are shown in 
Figure 5.7. The initial drop in weight is the loss of moisture from the samples. 
The graph shows that the thermal stability of pure PVOH is higher than the 
proteins.  The introduction of proteins lowered the onset of the degradation 
temperature for PVOH.  
 
Data from a typical TGA of the PVOH control and the nanocomposites are 
shown in Table 5.3. Bovine insulin had a higher degradation temperature 
compared to the crystallins. Both proteins indicated a slightly elevated thermal 
stability after fibrillisation. Table 5.3 also shows that the thermal stability of 
PVOH composites decreased with protein addition, and this may be due to the 
effect of the low thermal stability of the protein controls compared to its polymer 
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counterpart, PVOH. The extent of interaction between the protein and the 
PVOH may also contribute to the lowering of the thermal stability, since 
immiscibility between additives have shown to lower the thermal stability of 
composites (Aoi et al. 2000). 
At temperatures higher than 500°C, the TGA curves level off. The weight % loss 
was the highest for composites with insulin fibrils compared to the PVOH 
without insulin fibrils. The weight % loss was lowest for the insulin powder. 
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Figure 5.7 TGA profiles for PVOH, proteins and PVOH-protein composites. Graph 
represents curves for: bovine insulin from the jar (dark blue), PVOH from the jar 
(brown), PVOH + no insulin control (green), PVOH + insulin control film (red), PVOH + 
insulin fibrils film (purple), PVOH + no crystallin control (black), PVOH + crystallin 
control film (blue), PVOH + crystallin fibrils film (pink), crystallin extract (teal). Samples 
were tested in duplicates. Graph shows one profile representative of each sample. 
Note: native crystallin testing was limited to about 4.5 mg since the protein has a large volume 
to weight ratio and the size of testing pans restricted the amount protein.  
 
Interestingly, in this section, it was found that although the thermal stability of 
the crystallins is lower than the insulin, its thermal stability rises much more 
prominently than insulin, when incorporated in the PVOH. This finding suggests 
that the PVOH is more compatible with the crystallins than the insulin and the 
strong interaction with PVOH is responsible for the increase in the thermal 
stability of the PVOH + crystallin (control/fibrils) nanocomposites. 
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Samples 
Degradation 
Temperature (°C) 
PVOH from the jar 293 ± 2 
Insulin from the jar 265 ± 1 
Insulin fibrils  268 ± 3 
Crystallin extract 256 ± 3 
Crystallin fibrils 252 ± 4 
PVOH + 0.6% insulin control film 261 ± 3 
PVOH + 0.6% insulin fibril film 262 ± 3 
PVOH + 0.6% crystallin control film 280 ± 3 
PVOH + 0.6% crystallin fibril film 278 ± 3 
 
Table 5.3 Shows the degradation temperature of the proteins before and after 
fibrillation and PVOH composites which were tested for their mechanical properties. 
The data represents an average of the duplicates analysis. Errors represent standard 
deviation of the mean. 
 
Although nanostructures have been thought to increase the thermal stability of 
polymers, some have reduced the thermal stability of polymers (Naebe et al. 
2007)  which is consistent with the findings in this section. 
 
5.6 Summary 
 
In this chapter, a TEM study of PVOH composites with insulin fibrils and 
crystallin fibrils showed that the manner in which the fibrils are distributed within 
the composites vary. Insulin fibrils had a network-like structure composed of 
narrow strands compared to crystallin fibrils which had larger aggregates in its 
structure. It was found that the bovine insulin fibril was distributed in a similar 
manner to the crude crystallin control.  
 
The structural characterisation can be related to the mechanical behaviour of 
the films, since crystallin fibrils behaved in a different manner to insulin fibrils 
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and below the Tg the stiffness of the dry PVOH composite film containing 0.6% 
of crystallin fibrils increased in comparison PVOH + insulin fibril films.  
 
The structural information was supplemented by the analysis of the thermal 
stability, which revealed a reduction in the degradation conferred by the 
proteins. However, the addition of crystallins reduced the degradation 
temperature for PVOH but the PVOH in turn stabilised the thermal degradation 
of the crystallins protein, which was not found with insulin. 
 
The findings in this chapter also suggest that for PVOH + protein 
bionanomaterials, crystallins were more compatible than insulin. Thus fibrils 
formed from different source materials may be compatible with different 
polymers and optimisation will be required in each case. PVOH films with 
varying properties can be obtained by incorporation of fibrils from different 
protein sources. These results suggest that the protein source provides new 
options for processing and control. For example, the crystallins contain a 
mixture of proteins which form straight and curly fibrils in a heterogeneous 
mixture (section 4.1.2), and opens up the possibility of their multifunctional role 
in the bionanomaterial. Such an approach may consequently lead to the 
fabrication of cheap and readily available protein based nanostructures. 
 
This chapter has demonstrated that a relatively small quantity of protein fibrils 
(0.6%) in a PVOH matrix is capable of changing its visual, microstructural and 
mechanical properties. Both the protein fibrils were found to reduce the 
molecular slipping within the PVOH films, which may be of interest to some 
applications. Although considerable development work will be required prior to 
commercial application, this work provides proof of principle that amyloid fibrils 
can be incorporated into a nanocomposite material and change its mechanical 
properties. 
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Summary and Conclusions  
 
Amyloid fibrils have considerable potential as bionanomaterials. If they are to be 
employed as such on a commercial scale then a means of manufacturing them 
from crude sources of readily available materials is required. This thesis aimed 
to explore whether amyloid fibrils could be prepared from crude mixtures and 
whether chemical modification influenced the rate of fibril formation. It also 
explored the use of amyloid fibrils as components of a model nanocomposite 
material. Using PVOH as a model polymer, the mechanical and thermal impacts 
of these nanofibres produced from both, insulin and an industrial waste 
material, bovine eye lenses as novel additives in PVOH films were evaluated.  
 
Initially, the impact of chemical modification on the propensity of a model 
protein, bovine insulin, to form amyloid fibrils was investigated. It was 
demonstrated that insulin can be modified via acetylation, reduction 
carboxymethylation, reduction pyridylethylation, trypsin cleavage and 
chymotrypsin cleavage to obtain crude mixtures of modified insulin. The crude 
modified insulin mixtures were assessed for their propensity to form fibrils at a 
range of temperatures; fibril formation was confirmed by the ThT assay and 
TEM. 
 
Most of the modifications led to a decrease in the rate of formation and yield of 
amyloid fibrils. However, certain modifications increased the rate of formation 
and led to distinct changes in morphology when compared to fibrils formed from 
unmodified insulin. For example, reduction carboxymethylation of insulin 
resulted in the formation of straight, twisted fibrils compared to the straight and 
narrow fibrils formed in the insulin standard at pH 7.4. In contrast, the crude 
reduced pyridylethylated insulin formed wavy fibrils at pH 1.6, a very different 
morphology to the standard insulin fibrils.  
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Exposure to neutral and slightly alkaline buffer reduced the rate of insulin fibril 
formation even in the absence of chemical modification. This perhaps reflects 
that the oligomeric state can slow down amyloid formation under certain 
conditions. 
 
The effect of enzymatic digestion on fibril formation of insulin was investigated 
by treatment of trypsin and chymotrypsin. It was found that the intact insulin in 
the partially trypsin digested insulin mixture formed long narrow and 
unbranched fibrils, which were similar to the insulin control at pH 1.6. However, 
the fully digested insulin peptides did not form any fibrils, under the same 
conditions. Chymotryptic digest of insulin formed a heterogeneous mixture of 
fibril structures, ranging from long, thin, and straight, as well as short and thick 
fibrils, at pH 1.6.  
 
The successful formation of protein nanofibres from unpurified mixtures of 
modified insulin indicates that bovine insulin has the ability to form into 
nanofibres while still in the presence of other, derivatised polypeptides and 
peptides. Chemical modification of insulin showed that varying morphologies of 
fibrils can be prepared and the fibril structure was specific to the modification. 
These findings add to the enormous interest in the potential utility of amyloid 
fibrils as structural templates in nanomaterials science (Cherny and Gazit 2008, 
Gras 2007a, Gras 2007b, Gras et al. 2006) which requires the capacity to 
manipulate the fibril structure for such applications. Studies continue to 
determine ways of controlling peptide and proteins self-assembly to obtain 
amyloid fibrils  (Griffin et al. 2008, Hong and Fink 2005, Hong et al. 2003) and 
these results suggest that simple chemical modifications can provide 
considerable control over higher order assembly processes. 
 
Insulin fibrils have an “elastic modulus of 3.3 ± 0.4 GPa which ranks fibrils 
amongst the stiff polymers such as nylon” (Welland 2007). Insulin and crystallin 
amyloid fibrils were therefore trialled in a polymer model system of PVOH. 
PVOH nanocomposite films were manufactured with the addition of insulin fibrils 
or crude crystallin fibrils using a solution casting method. TEM studies showed 
that the solution casting method achieved fibrils dispersion. Congo red was 
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added to the casting solutions to confirm the presence of fibrils in the films, as 
well as to ensure the absence of fibrils in protein control films with added native 
protein. PVOH + insulin fibrils showed yellow-green birefringence in the films 
which was consistent with amyloid fibrils being present, while there was no 
yellow-green birefringence detected in the PVOH + insulin control films, 
confirming that the film manufacture method did not induce fibrillation in the 
native proteins.  
 
Insulin fibril addition produced a rough film, in contrast to crystallin fibrils which 
led to the production of a smooth film. The film manufacture method was 
optimised for insulin fibril added composites to minimise voids in the PVOH + 
insulin (fibril/control) films via hot pressing. This step was not required for the 
crystallin fibril containing films, which did not contain voids. 
 
Preliminary studies on hydrated films showed that insulin did not change the 
strength of the PVOH films, but increased their elongation. However, crystallin 
fibrils caused an increase in the tensile strength of the PVOH films, which was 
20% higher than the crystallin control. DMA showed that both insulin and 
crystallin fibrils altered the mechanical properties of the polymer in a manner 
consistent with a decrease in molecular slippage within the polymer (Nielsen 
1974). These changes suggested better compatibility of the crude crystallin 
fibrils with the PVOH than the insulin fibrils. 
 
It has thus been shown that PVOH nanocomposite films with improved 
reinforcement of the PVOH matrix can be prepared using protein nanofibres 
assembled from a crude source. An enhancement of the tensile strength and 
elastic modulus of the PVOH films was obtained at low nanofibre loading 
(0.6%), which indicates efficient load transfer between the fibrils and the matrix. 
As a representative example, a 21% improvement of the stiffness was achieved 
by the additions of 0.6% crude crystallin fibrils, in the glassy region (<Tg) of the 
PVOH system. The potential for interfacial bond tailoring by the side chain 
amino acid of protein nanofibres makes protein nanofibres attractive as effective 
reinforcing agents of bionanocomposites. 
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Results show that nanofibres assembled from proteins affected the mechanical 
behaviour of the PVOH films to some extent. The pure insulin fibrils are 
morphologically long, straight and unbranching compared to the crude mixture 
of short, curly and long straight fibrils assembled from crude crystallins. Insulin 
and crystallins differed in their mechanical behaviour. It has thus been 
demonstrated that protein nanofibres affected the PVOH thermo-mechanical 
properties in a protein dependent manner. 
 
With proof of concept now established, future work on the addition of protein 
nanofibres in PVOH should include the addition of crosslinkers such as 
glutaraldehyde and transglutaminase to act as a binder between the nanofibres. 
Moreover, compatibilisers can be added to enhance the interfacial bonding 
between nanostructures and polymers (Xie et al. 2005). Other polymers, such 
as epoxy resins, can also be used as a matrix to assess the effect of protein 
fibres on their mechanical properties. 
 
The partial biodegradability of the amyloid fibrils is increasingly recognised in 
recently published work on composites of amyloid and commercial plastics 
(Arnold 2008). Protein nanofibre composites may have potential in products like 
food packaging or wrapping, filter membranes with selective adsorption 
properties conferred by functionalised nanofibres. Since protein nanofibres have 
been shown to confer changes in polymer strength, the availability of side chain 
amino acids in protein nanofibres offer better scope for their functionalisation 
than carbon nanotubes. Thus amyloid fibrils offer a complementary technology 
to carbon nanotubes for a wide range of potential applications. 
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Exposure to neutral and slightly alkaline buffer reduced the rate of insulin fibril 
formation even in the absence of chemical modification. This perhaps reflects 
that the oligomeric state can slow down amyloid formation under certain 
conditions. 
 
The effect of enzymatic digestion on fibril formation of insulin was investigated 
by treatment of trypsin and chymotrypsin. It was found that the intact insulin in 
the partially trypsin digested insulin mixture formed long narrow and 
unbranched fibrils, which were similar to the insulin control at pH 1.6. However, 
the fully digested insulin peptides did not form any fibrils, under the same 
conditions. Chymotryptic digest of insulin formed a heterogeneous mixture of 
fibril structures, ranging from long, thin, and straight, as well as short and thick 
fibrils, at pH 1.6.  
 
The successful formation of protein nanofibres from unpurified mixtures of 
modified insulin indicates that bovine insulin has the ability to form into 
nanofibres while still in the presence of other, derivatised polypeptides and 
peptides. Chemical modification of insulin showed that varying morphologies of 
fibrils can be prepared and the fibril structure was specific to the modification. 
These findings add to the enormous interest in the potential utility of amyloid 
fibrils as structural templates in nanomaterials science (Cherny and Gazit 2008, 
Gras 2007a, Gras 2007b, Gras et al. 2006) which requires the capacity to 
manipulate the fibril structure for such applications. Studies continue to 
determine ways of controlling peptide and proteins self-assembly to obtain 
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these results suggest that simple chemical modifications can provide 
considerable control over higher order assembly processes. 
 
Insulin fibrils have an “elastic modulus of 3.3 ± 0.4 GPa which ranks fibrils 
amongst the stiff polymers such as nylon” (Welland 2007). Insulin and crystallin 
amyloid fibrils were therefore trialled in a polymer model system of PVOH. 
PVOH nanocomposite films were manufactured with the addition of insulin fibrils 
or crude crystallin fibrils using a solution casting method. TEM studies showed 
that the solution casting method achieved fibrils dispersion. Congo red was 
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added to the casting solutions to confirm the presence of fibrils in the films, as 
well as to ensure the absence of fibrils in protein control films with added native 
protein. PVOH + insulin fibrils showed yellow-green birefringence in the films 
which was consistent with amyloid fibrils being present, while there was no 
yellow-green birefringence detected in the PVOH + insulin control films, 
confirming that the film manufacture method did not induce fibrillation in the 
native proteins.  
 
Insulin fibril addition produced a rough film, in contrast to crystallin fibrils which 
led to the production of a smooth film. The film manufacture method was 
optimised for insulin fibril added composites to minimise voids in the PVOH + 
insulin (fibril/control) films via hot pressing. This step was not required for the 
crystallin fibril containing films, which did not contain voids. 
 
Preliminary studies on hydrated films showed that insulin did not change the 
strength of the PVOH films, but increased their elongation. However, crystallin 
fibrils caused an increase in the tensile strength of the PVOH films, which was 
20% higher than the crystallin control. DMA showed that both insulin and 
crystallin fibrils altered the mechanical properties of the polymer in a manner 
consistent with a decrease in molecular slippage within the polymer (Nielsen 
1974). These changes suggested better compatibility of the crude crystallin 
fibrils with the PVOH than the insulin fibrils. 
 
It has thus been shown that PVOH nanocomposite films with improved 
reinforcement of the PVOH matrix can be prepared using protein nanofibres 
assembled from a crude source. An enhancement of the tensile strength and 
elastic modulus of the PVOH films was obtained at low nanofibre loading 
(0.6%), which indicates efficient load transfer between the fibrils and the matrix. 
As a representative example, a 21% improvement of the stiffness was achieved 
by the additions of 0.6% crude crystallin fibrils, in the glassy region (<Tg) of the 
PVOH system. The potential for interfacial bond tailoring by the side chain 
amino acid of protein nanofibres makes protein nanofibres attractive as effective 
reinforcing agents of bionanocomposites. 
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Results show that nanofibres assembled from proteins affected the mechanical 
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morphologically long, straight and unbranching compared to the crude mixture 
of short, curly and long straight fibrils assembled from crude crystallins. Insulin 
and crystallins differed in their mechanical behaviour. It has thus been 
demonstrated that protein nanofibres affected the PVOH thermo-mechanical 
properties in a protein dependent manner. 
 
With proof of concept now established, future work on the addition of protein 
nanofibres in PVOH should include the addition of crosslinkers such as 
glutaraldehyde and transglutaminase to act as a binder between the nanofibres. 
Moreover, compatibilisers can be added to enhance the interfacial bonding 
between nanostructures and polymers (Xie et al. 2005). Other polymers, such 
as epoxy resins, can also be used as a matrix to assess the effect of protein 
fibres on their mechanical properties. 
 
The partial biodegradability of the amyloid fibrils is increasingly recognised in 
recently published work on composites of amyloid and commercial plastics 
(Arnold 2008). Protein nanofibre composites may have potential in products like 
food packaging or wrapping, filter membranes with selective adsorption 
properties conferred by functionalised nanofibres. Since protein nanofibres have 
been shown to confer changes in polymer strength, the availability of side chain 
amino acids in protein nanofibres offer better scope for their functionalisation 
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Experimental 
 
7.1 General Methods and Materials 
 
Unless otherwise stated, all chemicals, reagents and solvents were purchased 
from Sigma-Aldrich New Zealand Ltd., or BDH Laboratory Supplies, and were of 
analytical grade. 
 
Bovine eye lenses were supplied by local abattoirs (CMP Canterbury Ltd, 
Seafield Road, Ashburton, New Zealand).  
 
pH measurements were obtained using an UltraBasic UB10 pH meter 
purchased from Denver Instrument Co. and fitted with a high-performance glass 
body pH/Tris electrode. The electrode was calibrated against standard buffers 
at pH 4.0, 7.0 and 9.0, purchased from BDH Laboratory Supplies. 
 
Dialysis was undertaken using Thermo Scientific SnakeSkin pleated dialysis 
tubing, 3.5 kDa molecular weight cut off (MWCO) or Pierce Slide-A-Lyzer MINI 
dialysis unit, 3.5 kDa MWCO, prepared as per instructions on packaging. 
 
Polyacrylamide gel electrophoresis was routinely run using a NuPAGE system 
from Invitrogen with pre-cast NuPAGE Novex 4-12% Bis-Tris gels 1.0 mm 
(Invitrogen New Zealand Limited, Auckland, New Zealand). The gel images 
were captured using a BioImaging System, Syngene, A Division of the 
Synoptics Group equipped with Gene Snap from Gene Snap software.  
 
Citraconylation and acetylation was carried out using the pH stat, 718 Stat 
Titrino, Metrohm Swiss Made, John Morris Scientific Pty Ltd. with 728 Stirrer-
Metrohm. 
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For the measurement of protein concentrations, the Thermo Scientific 
NanoDrop 1000 Spectrophotometer was used (Thermo Fischer Scientific, 
Nanodrop Technologies Inc., Wilmington, Delaware, USA).  
 
Freeze drying of samples was performed in an Edwards “Speedivac” Model 
30P2 Centrifugal freeze drier. 
 
Fluorescence spectroscopy assays were carried out using:  
(1) Cary Eclipse Varian Fluorescence Spectrophotometer interfaced with Cary 
Eclipse version 2 operating software. It was equipped with a 450-5 nm 
excitation filter and emission spectra were recorded over a range from 460-560 
nm. All cuvettes used with the Cary Eclipse Varian fluorescence 
spectrophotometer were 1 cm path length quartz cuvettes.  
(2) Plate reader, Fluostar Optima, BMG Labtech (Alphatech Systems Limited, 
Auckland, New Zealand) with a set of 520-10/450-10 nm emission/excitation 
filters and gain set at 1444. For fluorometric measurements, on the plate reader, 
NuncTM 96 well optical bottom plates were used with NuncTM 236707 sealing 
tape, 130 x 78.32 mm. NuncTM products were supplied by In Vitro Technologies, 
Auckland, New Zealand. 
 
For the ThT assays, fresh solutions of ThT were filtered through a 0.2 μm filter 
immediately before use. The filter cartridge was a Millex GP filter unit 0.2 µm, 
supplied by Millipore, and the 10 ml syringe was supplied by Bectn Dickinson. 
The LC-MS system utilised in this thesis consisted of a Thermo Electron 
Corporation (San Jose, CA, USA) Finnigan Surveyor MS pump, Finnigan 
MicroAS auto-sampler, Finnigan Surveyor PDA detector and a ThermaSphere 
TS-130 column heater (Phenomenex, Torrance, CA, USA). A PDA detector was 
used which scanned from 190-350 nm and spectral anaysis was performed at 
276-280 nm.  
 
Microscopy: Optical microscopy imaging was carried out using a J Swift & Son 
optical microscope fitted with a cross-polarising lens. Electron micrographs 
were obtained using Hitachi H600 TEM operating at 80 kV. SEMs were carried 
out on a JEOL JSM 6100 SEM and a JEOL JSM-7000F FE-SEM. 
 209
Chapter 7   Experimental 
Centrifugations were carried out on the Eppendorf Centrifuge 5810R (maximum 
speed 12 000 rpm) with fixed-angle rotor: F-34-6-38 (>1.5 ml) and F45-30-11 
(<1.5 ml) with adapters in the fixed-angle rotor. 
 
PVOH was supplied by BDH Laboratory Supplies (MW= 115 kDa, degree of 
hydrolysis= 86.5-89.0%). 
 
Falcon tubes (50 ml) and Eppendorfs (1.5 ml) were utilised for reactions, 
storage of insulin derivatives and for making polymer solution for film 
manufacture. 
 
The mechanical properties of the films were measured on: 
(1) UTM, Model 1011 with an installed computer programme at New Zealand 
Institute of Crop and Food Research. 
(2) DMA (Perkin Elmer, Diamond DMA, Distributed by New Zealand Scientific). 
(3) DSC-TGA, SDT Q600 V20.5 Build 15, TA Universal Analysis, (Alphatech 
Systems Ltd., Auckland, New Zealand). 
 
Hot pressing of films was carried out on a laboratory press, with an automatic 
press control (from Gibitre Instruments). 
 
7.2 Protein Analysis 
 
7.2.1 Protein concentration 
The protein concentration of unknown solutions were determined on the 
Thermo Scientific NanoDrop 1000 Spectrophotometer using the nanodrop 1000 
protein A280 application. Analyses of 1-3 µl samples were carried out in 
triplicates against a blank of distilled water (dH2O) or the respective buffer. 
 
7.2.2 Characterisation of proteins by NuPAGE 
The procedure was adapted from Invitrogen supplies (Invitrogen 2003, 
Invitrogen 2007). Samples were prepared by mixing with NuPAGE lithium salt 
of dodecyl sulphate (LDS) sample buffer (4x) and sample reducing agent 
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(10x). The samples were placed in a water bath set at 70°C for 10 min to aid the 
reduction of disulfide bonds. Protein samples were run against wide range 
molecular weight marker Mark12™ (stained with Coomassie® R-250) 
purchased from Invitrogen (3.5-200 kDa). Each of the heated protein samples 
and the marker were loaded into separate wells in the polyacrylamide gel 
(NuPAGE Novex 4-12% Bis-Tris Gel 1.0 mm, 10 well). Samples were 
electrophoresed at a constant voltage of 200 V in running buffer (NuPAGE 2-(N-
morpholino)ethanesulfonic acid (MES) –sodium dodecyl sulphate (SDS) at 
room temperature for 35 min. The MES-SDS running buffer was made up of 50 
mM MES, 50 mM Tris base, 0.1% SDS, 1 mM ethylenediaminetetraacetic acid 
(EDTA) at pH 7.4. The proteins in the resultant polyacrylamide gel were stained 
in a solution of Coomassie brilliant blue stain (0.1% Coomassie brilliant blue 
(10% v/v), glacial acetic acid (50% v/v), methanol, dH2O (40% v/v), pre-filtered 
at room temperature). After two hours of staining the gel was transferred into a 
destaining solution (glacial acetic acid (10% v/v), methanol (5% v/v), dH2O 
(85% v/v)) at room temperature.  
 
7.3 Insulin Acetylation Procedure  
 
The procedures for insulin citraconylation and acetylation was modified from the 
literature (Blundell et al. 1972). 
 
7.3.1 N-Terminal group protection 
Bovine insulin solution was prepared at a concentration of 1 mg/ml in potassium 
phosphate buffer (50 mM, pH 8). Insulin was dissolved in a minimum volume of 
12 mM HCl solution (pH 2) and then made up to the required concentration with 
the phosphate buffer. The pH of the protein solution was monitored after dilution 
using the pH meter and adjusted to pH 8 with dilute NaOH. 
 
The insulin solution (1mg/ml, 20 ml) was placed in the pH stat vessel and the 
pH stat was started with a runtime of 1800 min containing 0.5 M NaOH and set 
to maintain a pH of 8. At 100 sec on the pH stat, a 25 times excess of citraconic 
acid anhydride (to all amino groups except lysine) was added to the protein 
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solution. Citraconic anhydride was added slowly ensuring that pH did not drop 
below 7.5.  The solution was left to react while stirring for 30 min at pH 8.  
 
To determine the impact of pH, the above reaction was carried out at pH 7 as 
well. Both the samples (pH 7 and pH 8) were analysed on ESI-MS. Insulin 
controls were reacted under the same buffer conditions as the citraconylated 
insulin, without any reagents and analysed. 
 
One half of the citraconylated insulin (pH 8) was acetylated as described in the 
next section.  
 
7.3.2 Acetylation 
Citraconylation was followed by acetylation of the insulin amino group as 
previously described. The citraconylated insulin (1 mg/ml) was acetylated with 
the addition of 10-fold molar excess of acetic anhydride per lysine group. The 
reaction was carried out for 1 hr at 4°C at pH 8.0, maintained by the addition of 
0.5 M NaOH on a pH stat that was utilised in section 7.3.1. The insulin standard 
was treated under the conditions above without the reagents and provided the 
controls for this experiment.  
 
All samples were dialysed (3.5 kDa MWCO) at 4°C in 50 mM ammonium 
bicarbonate buffer and lyophilised. The samples were stored at -80°C and the 
reaction was subsequently analysed by LC-MS. 
 
7.4 Reduction Carboxymethylation of Insulin 
 
The reduction alkylation procedure used in this study was adapted from the 
literature (Shechter et al. 1973) and is described below. 
 
7.4.1 Reduction 
Bovine insulin (50 mg) was dissolved in 5 ml of 1 M Tris-hydrochloride buffer, 8 
M urea (pH 8.0) containing 0.01% EDTA. DTE (30 mg) was added and the 
reduction proceeded for 1 hr at room temperature. An insulin control was also 
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treated with the same buffer, without the reducing agent. The reduced insulin 
was subsequently carboxymethylated and pyridylethylated separately. 
 
7.4.2 Carboxymethylation 
IAA (150 mg) was added to the reduced insulin reaction mixture and the 
reaction further proceeded for 20 min at room temperature. The RCM insulin 
obtained was gel filtered as described below. 
 
7.4.3 Pyridylethylation 
4-VP (150 mg) was added to the reduced insulin mixture and was left to react 
for 20 min under nitrogen bubbling into the solution, at room temperature (in 
fumehood). The mixture obtained was centrifuged at 10000 rpm for 10 min at 
4°C. The pellet and supernatant obtained were subjected to gel filtration as 
described below. 
7.4.4 Gel filtration chromatography 
RCM and RPE insulin samples were subjected to gel filtration (Shechter et al. 
1973) using AKTA fast performance liquid chromatography (FPLC), from 
Amersham Biosciences in conjunction with a pump (UPC-900), detector (P-920) 
and a fraction collector (Frac-950). Sephadex G-25 resin was prepared for 
column chromatography as per the instruction of the supplier, Amersham 
Biosciences. The resin was filled into a column (100 cm x 2.5 cm) and 
equilibrated with 50 mM ammonium bicarbonate buffer (pH 7.85). The insulin 
sample were loaded at 2-10 mg/ml and eluted using 50 mM ammonium 
bicarbonate at a flow rate of 4 ml/min. Fractions were collected at 10 ml/per 
tube. The fractions corresponding to the protein peak as judged by UV 
absorbance at 280 nm were pooled and lyophilised. 
 
7.5 Procedure for Enzymatic Cleavage of Insulin 
 
7.5.1 Trypsin digestion of insulin 
The trypsin utilised was from bovine pancreas (L-1-tosylamide-2-phenylethyl 
chloromethyl ketone (TPCK) treated, salt-free, lyophilised powder and obtained 
form Sigma-Aldrich). The Sigma technical bulletin for trypsin digestion of 
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peptides and proteins was used for insulin digestion (Sigma-Aldrich 2007). A 
ratio of 1:50 (w/w) of enzyme to substrate was used in this experiment. Insulin 
(5 mg/ml) was dissolved in 100 mM ammonium bicarbonate pH 8.5. The trypsin 
was dissolved in 1 mM HCl to a concentration of 1 mg/ml. Trypsin solution was 
added to the protein solution and incubated for 4 hr at 37°C in a water bath. 
This provided a partially digested insulin sample which was stored at -80°C. 
 
Half of the partially digested insulin was treated further with trypsin to obtain 
total digestion of the insulin. An aliquot of trypsin was added to the insulin every 
4 hr over a 12 hr period to adjust the final trypsin to insulin molar ratio to 1:6 
(total trypsin to insulin). After the 12 hr sequential digestion, the sample was 
stored at -80°C.  
 
An insulin standard was treated under the same buffer conditions, without the 
enzyme and was referred to as the insulin control. Samples were stored at  
-80°C and lyophilised. 
 
7.5.2 Chymotrypsin digestion of Insulin 
α-Chymotrypsin (Type II, lyophilised powder) from bovine pancreas  was used 
to cleave insulin (Sigma-Aldrich 2007). Insulin (5 mg/ml) was digested with 
chymotrypsin at 1:50, enzyme to protein ratio, in 100 mM ammonium 
bicarbonate buffer at pH 8.5. Solutions were incubated in a water bath at 37°C 
for 4 hr. Samples were digested in 500 µl fractions, in Eppendorfs. An insulin 
standard was treated under the same buffer conditions, without the enzyme and 
was referred to as the insulin control.  
 
The general strategy to analyse the chymotrypsin digested fragments of insulin 
via LC-ESI-MS/MS involved the following steps (Yen et al. 2002): (1) 
chymotrypsin digestion of insulin was carried out at pH 8.5 to obtain peptides; 
(2) complete reduction was carried out with DTE and carboxymethylation by IAA 
as detailed in section 7.4.1 and 7.4.2; (3) LC-ESI-MS/MS analysis of the 
resulting peptides was carried out as described in section 7.6.3 and section 
7.6.4 to identify the fragments. Treatment with DTE and IAA was necessary 
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because it was difficult to analyse fragments for disulfide-bonded peptides than 
those completely reduced and alkylated. 
 
7.6 Mass Spectrometry  
 
Mass spectrometry conditions were selected with advice from Nigel Joyce, New 
Zealand Institute of Crop and Food Research. Insulin solutions from the 
respective experiments were retained and stored at -80°C for mass 
spectrometry. All MS methods were based on the Finnigan™ LTQ™ manual 
(Thermo Electron Corporation, 2003).  
 
7.6.1 ESI-MS 
Electrospray ionisation-mass spectrometry (ESI-MS) was used to screen the 
degree of insulin citraconylation at pH 7 and pH 8 (section 2.3.1). Insulin sample 
that had or had not been treated with citraconic acid at pH 7 and 8 were also 
analysed, for comparison. 
 
Insulin samples at a concentration of 0.1 mg/ml were injected via an ESI 
source. The ionised peptides were scanned by API-MS (LTQ, 2D linear ion-trap, 
Thermo-Finnigan, San Jose, CA, USA) with ESI in the positive mode. Data 
were acquired for relevant parent masses up to 2000 amu. Spectral scans were 
obtained at normal (16700 amu/sec) resolution for full scan followed by zoom 
(1100 amu/sec) or ultra-zoom (27 amu/sec) for charge state calculation. 
Appropriate parent masses based on charge states were selected for MS2 
fragmentation with an applied collision energy of 35 arbitrary units. Data were 
processed with the aid of Xcalibur1.4 (Thermo Electron Corporation). 
 
7.6.2 LC-ESI-MS of insulin and modified insulin 
The following samples were anaylsed by liquid chromatography-electrospray 
ionisation-mass spectrometry (LC-ESI-MS): insulin standard (section 2.2.4), 
citraconylated acetylated insulin with unmodified insulin (section 2.3.2), 
acetylated insulin (section 2.3.4), reduced alkylated insulin (sections 2.4.4 and 
2.4.5), trypsin treated insulin (section 2.5) and the supernatant of the 
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aggregated crude acetylated insulin (section 3.4.1). LC-ESI-MS analysis of 0.1 
mg/ml insulin solutions was carried out by injecting 10 μl samples. Insulin was 
resolved on a Zorbex 2 column with mobile phase A and B (A: 0.2% formic acid 
in distilled H2O, B: 0.2% formic acid in acetonitrile) and pumped via a Surveyor 
MS pump at a flow rate of 300 μl/min, the eluent was introduced to mass 
spectrometer via electrospray. Ions were scanned over a range of 800-2000 
m/z [M+H]+ at an orifice potential of 4.2 kV, with an activation time of 30 msec. 
The mass spectra corresponding to the insulin LC peak present in the TIC 
chromatogram were averaged in order to improve the ion statistics, leading to a 
better molecular weight determination. Data were collected in full scan with a 
secondary dependent scan event to select data for ultrazoom mapping. LC-ESI-
MS data were analysed using Xcalibur software.  
 
7.6.3 Identifcation of insulin site of acetylation, by LC-ESI-MS/MS 
The acetylated insulin described in section 2.3.5 was analysed for the site of 
acetyl attachment on the insulin chain by mass sequencing as described below. 
The chymotrypsin treated insulin was also reduced and carboxymethylated 
before trypsin digestion and the fragments were identified by LC-ESI-MS/MS. 
 
7.6.3.1 Reduction carboxymethylation 
The crude acetylated insulin sample was denatured prior to any digestion with 
protease so that the protease will have as much access to the recognised 
amino acid sequence as possible. To help achieve this, the crude protein was 
reduced and carboxymethylated as per section 7.4.1 and 7.4.2, on a smaller 
scale volume of 200 μl, at 5 mg/ml. The insulin control was also reduced and 
carboxymethylated in a similar manner. 
 
7.6.3.2 Protease digestion 
The reduced carboxymethylated insulin sample was digested with trypsin as 
described in section 7.5.1. A 10 μl aliquot of the proteolytic digest was loaded 
onto the LC column and separation was performed on a Zorbax-300SB-C8, 5 
µm, 150 x 4.6 mm column with a guard cartridge (Agilent, p/n883995-906) with 
a mobile flow rate of 300 µl/min at 25°C. The mobile phase consisted of dH2O 
(A) and acetonitrile (B) both containing 0.2% formic acid. An elution gradient of 
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95% A held for 5 min then switched to 70% A with a linear gradient to 20% A 
over 45 min was applied. The column was then washed with 5% A for 5 min 
before being re-equilibrated with 95% (A). The eluent was dispersed with ESI in 
the positive mode to assist ionisation of the peptides into the ion-trap mass 
analyser scanning from 400-2000 m/z. Full scan normal/zoom data were 
automatically filtered to select M+2H and M+3H peptide states for MS2 
fragmentation to produce fragments expected. 
 
7.6.3.3 MS/MS analysis of peptide ions 
X-calibur software provided with the mass spectrometer enabled the acquisition 
of mass spectra in a non-redundant manner so that as many peptides as 
possible were surveyed from the complex mixture. During this process, an 
experimental method was set up in which one full range MS scan (400-2000 
m/z) was acquired followed by the acquisition of MS/MS scans.  
 
7.6.3.4 Peptide sequence identification using SEQUEST 
SEQUEST compares experimental MS/MS spectra to theoretical MS/MS 
spectra from database proteins and calculates a correlation value, which can be 
examined in order to determine how well a particular experimental spectrum 
matches the corresponding theoretical spectrum (Eng et al. 1994). The acquired 
MS/MS spectra for each sample were searched using the SEQUEST algorithm 
(BioWorks 3.1 SR1, Thermo Electron) against the UniProt database (5.26.05 
download; 125,244 entries). Searches were performed, with trypsin specified as 
the enzyme, with an allowance for up to two missed cleavage sites. Searches 
from multiple fractions or replicates within an experiment were combined in 
BioWorks using a MultiConsensus report to generate a comprehensive list of 
peptides and proteins identified in a particular experiment. 
 
Data were filtered and scored against the database consisting of bovine insulin 
A and B chains and trypsin with the expected variable amino acid modifications 
of carboxymethylated (+58) on cysteine (C) and acetylation (+42) on N-terminal 
amines and lysine (K). In addition, a missed cleavage of one amino acid was 
allowed for potential steric hindrance to cleavage of the acetylated lysine B29. 
Possible peptide combinations were then filtered to show only matches with 
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greater than 30% Y and B ion confirmation and a preliminary score of greater 
than 200.  
 
SEQUEST performs two types of scoring. After finding all peptides that match 
within your mass tolerance, SEQUEST does a preliminary scoring of these 
candidates to weed the list down to 500 for the final correlation analysis. The 
scoring is based on the number of ions in the MS/MS spectrum that match with 
the experimental data. Larger peptides will have bigger Sp values. A 20 residue 
peptide will usually have an Sp value of over 1000, while a 6 residue peptide 
will likely be below 500. 
 
7.6.4 Identification of insulin chymotryptic digest, by LC-ESI-MS/MS 
The chymotrypsin treated insulin and the untreated insulin (control) were 
reduced, alkylated and analysed by the liquid chromatography-electrospray 
ionization-mass spectrometry/mass spectrometry (LC-ESI-MS/MS) method 
described in section 7.6.3 except that the MS/MS data obtained with the insulin 
chymotryptic digest was searched against chymotrypsin specified as the 
enzyme on SEQUEST. Two missed cleavages were allowed for chymotrypsin 
during the search and several insulin fragments matching the expected 
fragments obtained theoretically was found (section 2.6). 
 
7.7 Procedures for Insulin Amyloid Formation and ThT assay  
 
Insulin fibrils were initially prepared by the small scale method and 
subsequently in situ on the plate reader with modifications from the literature 
(Nielsen et al. 2001). Fibrils were analysed by the ThT fluorescence assay 
(LeVine 1999).  
 
7.7.1 Small scale fibrillation and ThT assay  
Solutions of insulin were prepared in duplicate to the required concentration, 
ranging from 0.57 to 5.7 mg/ml in buffers with pHs ranging from 1.6 to 7.4, 
before and after the chemical modifications (listed in Table 7.1). These samples 
were aliquoted (50 µl) into sealed Eppendorf tubes and placed in an incubating 
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oven set at 60°C. The aliquoted samples were removed from the incubation 
ovens every 15 min or 30 min. The samples were frozen immediately (-80°C) 
until required for analysis. An insulin control (0 hr) was immediately stored at 
 -80°C for each treatment condition for the duration of the experiment.  
 
Derivatised insulin pH Buffer (mg/ml) 
Insulin standard 1.6 20% acetic acid, 100 mM NaCl 5.7 
Insulin control 
Crude acetylated insulin 
1.6 20% acetic acid, 100 mM NaCl 5.7 
Insulin control 
Tryptic digest of insulin 
1.6 20% acetic acid, 100 mM NaCl 5.7 
Table 7.1 The modified insulin samples used to assess the influence of chemical 
modification on the formation of insulin amyloid. 
 
For the ThT assay, the fibril solution was diluted in a Tris buffer (50 mM Tris, 
100 mM NaCl, pH 7.5) containing ThT (5 to 10 µM) in a cuvette. The final 
concentration of protein in the cuvette was 20 µg/ml. The resulting, (protein + 
ThT + buffer) solution was mixed for 3 min to allow binding between the dye 
and protein to equilibrate, before the emission spectra were recorded from 450 
to 560 nm. Optimum fluorescence at 482 nm was monitored for amyloid 
detection. 
 
7.7.2 In situ fibrillation and ThT assay 
In the subsequent part of this study, a plate reader was available for in situ 
insulin fibrillation. This procedure allowed a large number of samples to be 
assayed using small reaction volumes. Solutions of insulin were prepared in 
triplicate to the required concentration ranging from 0.57 to 5.7 mg/ml in buffers 
with pHs ranging from 1.6 to 7.4 (listed in Table 7.2). These samples were 
aliquoted (200 μl) into 96 well, clear bottomed NuncTM fluorescence well plates. 
ThT (1 mM) was added directly to the wells to give a final concentration of 5 μM. 
As controls, insulin samples without ThT were also incubated in the well plates.  
 219
Chapter 7   Experimental 
Derivatised insulin pH Buffer (mg/ml) 
Crude acetylated insulin 1.6 20% acetic acid, 100 mM NaCl 2.9 
Crude reduced 
carboxymethylated insulin 
7.4 50 mM potassium phosphate 
buffer, 100 mM NaCl 
0.1, 1 
Crude reduced 
pyridylethylated insulin pellet 
1.6 25 mM HCl buffer, 100 mM NaCl 2 
Crude reduced 
pyridylethylated insulin 
supernatant 
7.4 50 mM potassium phosphate 
buffer, 100 mM NaCl 
5.7 
Tryptic digest of insulin 1.6 20% acetic acid, 100 mM NaCl 5.7 
1.6 20% acetic acid, 100 mM NaCl 5.7 Chymotryptic digest of 
insulin 
1.6 25 mM HCl buffer, 100 mM NaCl 5.7 
Table 7.2 The modified insulin samples used to assess the influence chemical 
modification on the formation of insulin amyloid. 
 
The well plates were sealed with NuncTM 236707 sealing tape, to minimise 
evaporation, and incubated at temperature of 60°C (except for trypsin digest 
which was analysed at 45°C). Fluorescence at 482 nm was recorded over time 
until maximum fluorescence of 65000 was reached.  
 
7.7.3 Procedure for determining the impact of pH and insulin fibril 
concentration on ThT fluorescence 
Insulin fibrils were formed by incubation of an insulin solution (5.8 mg/ml in 20% 
acetic acid buffer, 100 mM NaCl, pH 1.6) at 60°C in an oven for 4 hr, as 
discussed in section 3.2.5. The fibril solution was diluted separately in (1) 50 
mM Tris, 100 mM NaCl, pH 7.5 and (2) 20% acetic acid. Fibrils were diluted at a 
range of 0 to 0.04 mg/ml at pH 7.5 and 0 to 2.9 mg/ml in 20% acetic acid. All 
dilutions were done in triplicate. The solutions were pipetted into 96 well plates. 
ThT was added directly to the wells to give a final concentration of 5 µM and 
fluorescence was read 482 nm. A fresh solution of insulin was prepared in 
acetic acid buffer and ThT was added to correct for any fluorescence from 
native insulin and ThT dye. 
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7.7.4 The impact of pH on insulin fibrils assessed by ThT 
Insulin solution prepared in 25 mM HCl (100 mM NaCl, pH 1.6) at 11.4 mg/ml, 
was incubated at 60°C in an oven for 24 hr, to form fibrils. The fibrils mixtures 
(100 µl) were dialysed using the Slide-A-Lyzer MINI dialysis unit (MWCO 3.5 
kDa) against 1 l of the different buffers (Table 7.3) for 3 hr. Insulin fibrils 
dialysed at pH 6.5, was redialysed at pH 2 (12 mM HCl) to determine the impact 
of acidification of the fibrils. The dialysed fibrils were frozen at -80°C and 
analysed by ThT assay and TEM. A fresh insulin control solution was prepared 
in HCl (12 mM, pH 2) and analysed. 
 
Buffer  pH 
12 mM HCl  pH 2.0 
50 mM citrate buffer pH 3.5 
50 mM sodium acetate pH 4.5 
50 mM potassium phosphate pH 6.5 
 
Table 7.3 Insulin fibrils dialysed in the different buffers and pHs. 
 
The ThT assay was carried out on the plate reader. Fibril solutions were 
defrosted at room temperature and diluted separately in 50 mM Tris buffer (pH 
7.5, 100 mM NaCl) to obtain 5-20 μm protein solution in the wells of a 96 well 
plate reader. Fluorescence emission intensity of the samples was measured at 
482 nm using the Fluostar Optima plate reader. Fluorescence was measured in 
triplicate and averaged.  
 
TEM was carried out on the samples to determine the impact of pH on 
preformed insulin fibrils (section 3.2.6). 
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7.8 Extraction and Fibrillation of Crude Bovine Eye Lens 
Proteins 
 
7.8.1 Extraction of crystallin proteins 
The crystallin protein extraction method was adapted from (Garvey et al. 2008). 
Bovine lenses were homogenised in 50 mM Tris at pH 7.2 (1 mM DTE and 
0.04% NaN3, with 2 mM phenylmethylsulphonyl fluoride) using a magic bullet 
blender.  The homogenate was centrifuged at 12,000 rpm for 60 min at 4°C. 
The supernatant was removed (centrifugation was repeated whenever a clear 
supernatant was not obtained) and analysed for protein concentration using the 
Nanodrop (A280). The crystallin stock solution was freshly utilised for fibril 
studies and stored at -80°C for any other experiments. 
 
7.8.2 Formation of fibrils from crystallins 
Amyloid fibrils were formed directly from crude mixtures of bovine eye lens 
proteins using methods adapted from Garvey et al. (2008). The crude protein 
sample was diluted at 22 mg/ml into a solution 10% TFE v/v (pH 2). The pH of 
the protein solution was adjusted with dilute NaOH or HCl to pH 2 and samples 
were fibrillated by incubation at 60°C for 4 weeks.  
 
7.8.3 ThT assay 
Crystallin control and fibril solutions were assessed for ThT dye binding 
capacity, using a method adapted from (Thorn et al. 2005). Protein solutions 
were assayed at 50 μg/ml in 50 mM Tris buffer at pH 7.5, with 5μm ThT. 
Fluorescence emission intensity of the samples was measured at 482 nm using 
the Fluostar Optima plate reader. Fluorescence was measured in triplicate and 
averaged.  
 
7.9 TEM Imaging of Amyloid 
 
Insulin and crude bovine eye lens fibril formation and morphology were 
assessed by TEM, as described in the literature (Burke and Rougvie 1972, 
Whittingham et al. 2002), to confirm the presence of fibrils. TEM samples were 
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prepared by placing small aliquots (2 µl) of protein fibril samples (0.5-1.0 mg/ml) 
on carbon-coated copper grids covered with plastic films. The grid was then 
rinsed once with 3 µl of dH2O, negatively stained with 2 µl of uranyl acetate (2% 
w/v) and dried with filter paper. Samples were analysed under magnifications of 
60 000 to 100 000x, on a TEM. 
 
7.10 Film Manufacture  
 
7.10.1 PVOH solution 
PVOH was prepared at a concentration of 5% w/v with dH2O as the solvent. 
The PVOH powder was dispersed in dH2O and full salvation was obtained by 
stirring with a glass rod with heating at 80°C in a water bath for 4 hr. The 
solution was left to settle for 24 hr to allow air bubbles to float out of the solution 
prior to casting.  
 
7.10.2 Preparation of protein fibrils for films 
Protein solutions were prepared as follows:  
Insulin control solution was prepared by dissolving insulin in a small volume of 
12 mM HCl (pH 2) and making up to volume with 12 mM HCl (pH 4). Insulin 
fibril solution was obtained by dissolving insulin in HCl (pH 1.6, 25 mM HCl, 100 
mM NaCl) and incubating at 60°C for 24 hr.   
 
Crystallin fibril solution was prepared by diluting the fresh protein extract in 10% 
TFE (pH 2) to 11.4 mg/ml and incubating at 60°C for 4 weeks. The crystallin 
control solution was prepared at pH 2 without TFE. 
 
Both the protein fibril solutions were dialysed (SnakeSkin  pleated dialysis 
tubing with a MWCO 3.5 kDa) in 12 mM HCl (pH 4) to remove salts. The 
presence of fibrils was detected by ThT and TEM. Fibrils were stored at -80°C 
and used for film casting the next day. 
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Both buffers used to make protein fibrils, HCl buffer (25 mM HCl, 100 mM NaCl) 
and 10% TFE were diluted separately in 12 mM HCl (pH 4), similar to the 
proteins. 
 
All dialysis was carried out with a 3.5 kDa MWCO dialysis tubing in 2 l of 12 mM 
HCl (pH 4). 
 
7.10.3 PVOH + protein (control/fibril) solution 
Protein fibrils, as detailed in section 7.8.2, were prepared for addition to the 
PVOH solution. The desired volume of fibrils was added to the PVOH solution 
and gently swirled to obtain uniform fibril dispersion. The solutions were mixed 
and poured into casting trays for film formation. The preparation process was as 
follows:  
 
A Schott bottle containing 1 l of 5% w/v PVOH in dH2O was produced and 
utilised for the entire batch of films prepared for DMA, DSC-TGA, and 
microscopy work. 50 g PVOH powder was dissolved into 1 l of dH2O and stored 
at room temperature as described in section 7.10.1. 
 
A 24 ml of 0.6% w/v protein fibril + 2.5% PVOH film composite was produced by 
mixing 12 ml of 1.2% fibril solution with 12 ml of 5% w/v PVOH solution, without 
introducing bubbles. However, in the preliminary studies, 0.2% protein was 
utilised. Before casting, each solution was left standing for 30 min to displace 
any air trapped in the solution by giving time for the bubbles to rise to the 
surface.  
 
PVOH + no protein control, PVOH + protein control and PVOH + protein fibrils 
composite solutions were prepared in triplicate to produce 3 films per sample. 
 
7.10.4 Solution casting  
Film casting method was adapted from the literature with some modifications 
(Aoi et al. 2000, Kim et al. 2007, Park et al. 2001, Wang and Sain 2007). Films 
were prepared by solution casting into a rectangular gel casting tray, with a 
length of 10 cm and a width of 7 cm and depth of 1.5 cm. The casting tray was, 
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HE 47-10 casting kit composed of a gel running tray inserted into a gel casting 
tray (generally used for Hoefer HE 33 Horizontal Agraose Unit), supplied by 
Amersham Biosciences (Figure 4.3). The solution was poured into the middle of 
the tray and allowed to spread out to cover the tray. Air bubbles were avoided 
but in some cases a thin glass pipette was gently used to remove any air bubble 
in the solution. A bubble level with dual axis (supplied by the workshop, School 
of Biological Sciences, University of Canterbury), was utilised to check the 
flatness of the trays on the bench. 
 
Each film comprised of 24 ml of solution with solvent evaporation under ambient 
conditions for 5 days. The film was removed by carefully peeling from the trays. 
This was achieved by lifting the edge with thin tweezers and peeling the film by 
hand while wearing protective gloves. These steps produced a film of 9 cm in 
length and 6 cm in width, with an average thickness of 0.07 ± 0.02 µm, 
measured using an electronic digital caliper. The films were then cut into strips 
7±1 mm wide using a razor blade and a steel chopping block scored with 
parallel lines, which acted as a template. 
 
7.10.5 Determination of moisture content 
The moisture content of films was determined by air oven drying at 60°C for 72 
hr. The loss of film weight over time was monitored until there was no change in 
weight. Ten film samples were analysed and moisture was determined by the % 
weight loss.  
 
7.11 Treatment of Films Prior to Mechanical Testing 
 
All films were prepared by solvent evaporation for 5 days after casting and 
equilibration under ambient conditions for 48 hr (after peeling from the trays). 
These have been referred to as the hydrated films. 
 
7.11.1 Vacuum drying 
The hydrated films were initially dried in a vacuum oven (Vacuum drying oven, 
with an end vacuum of 10-2 mbar) at 60°C from 0 hr to 72 hr to determine the 
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length of time required to dry the films. Seven replicates of the films samples 
were analysed and the weight loss measured over the length of drying time. 
 
The hydrated films were subsequently dried for 24 hr at 60°C in the vacuum 
oven for UTM and DMA testing of dry films. The dried films were cooled inside a 
desiccator (Secador auto-dessicator cabinet with 280 V automatic electronic 
dryer) for 2 hr before testing. 
 
7.11.2 Hot pressing the PVOH + insulin composite 
Dried films were cut into samples of 7 mm in width and 60 mm in length 
avoiding any edge effects. A sample was then wrapped in a smooth piece of Al 
foil that had been coated with a release wax (silicone FMG spray from ITW 
Polymers and Fluids, New Zealand). The foil wrapped film was then placed in a 
mould for hot pressing. The films were hot pressed at a temperature of 180°C, a 
pressure of 2.5-3 MPa using a processing time of 20 min. The hot pressed 
samples were then conditioned at 50% RH at 23°C. Samples were hot pressed 
in duplicate. 
 
Conditioning at a equilibrium of 50% (RH) at 25°C, was obtained over saturated 
aqueous of the following alkalis: potassium carbonate 42.8%, calcium nitrate 
50.0%, magnesium nitrate 52.9%, sodium bromide 57.7% (Staiger, pers. 
comm.) The humidity in the chamber was maintained by a Thermometer 
Hygrometer (Mason’s wet and dry bulb hygrometer). 
 
7.12 Procedure for Testing the Presence of Fibril in Films, using 
Congo Red 
 
Samples were stained for amyloid following the procedure in literature with 
some modifications (Westermark et al. 1999). CR solution (1 mg/ml) was 
prepared in dH2O and filtered using 0.2 µm filter cartridges. CR staining of the 
casting solution was done by adding CR to: the protein (control, fibril) solution 
and to the no insulin control solution at 0.08 mg/ml prior to mixing with PVOH 
solution. The solutions were allowed to stain for 30 min on a shaker. The 
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stained solution was dialysed in pH 4 (12 mM HCl) to remove excess dye and 
the salts. 
 
After dialysis the dyed solutions were mixed with PVOH and films were cast. All 
films were cast at 2.5% PVOH. Insulin concentrations were 0.2, 0.4 and 0.6% in 
the PVOH + insulin (control/fibril) films. Crystallins were at 0.6% in the PVOH + 
crystallin films. Triplicate specimens from each film were examined under 
polarising light microscopy. 
 
7.13 Characterisation of Nanocomposite Films 
 
7.13.1 Tensile testing  
Preliminary mechanical testing of the PVOH films with and without protein 
involved the tensile testing of films on the Instron UTM, Model 1011 with an 
installed computer programme. The procedure was based on the in house 
methods for testing films at NZ Institute for Crop and Food Research. A 100 N 
load cell with a crosshead speed of 50 mm/min was utilised. Tensile tests were 
performed on a hydrated PVOH + insulin (control/fibril) (0.2%) and PVOH + 
crystallin (control/fibril) films (0.2%), and dry PVOH + insulin (control/fibril) 
(0.6%) films only. 
 
Strips were cut from the central region of the films to the dimensions 60 (± 1) 
mm x 7 (± 1) mm. Before testing, the sample dimensions were recorded using a 
digital caliper. The manner in which the films were attached to the Instron varied 
between the hydrated and the dry films described below. 
 
7.13.1.1 Hydrated films 
In the preliminary study, hydrated films were tested after 48 hr of equilibration at 
room temperature. Samples were stored in a desiccator during the testing 
period. Film strips were mounted using tapes and hooks as shown in the image 
in chapter 4, Figure 4.11. A straight hook was mounted into the Perspex base 
plate of the Instron and an extensigraph cradle was mounted into the cross-
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head load cell. Film strips were taped on both ends and stuck to the hook at the 
base and the cradle hook on the crosshead, and the tensile test was activated. 
 
 7.13.1.2 Dried films  
PVOH + insulin (control/fibril) films were dried for 24 hr at 60°C and 
subsequently stored in a desiccator in the laboratory until measurements 
commenced. Testing was performed by holding the test sample at each end 
with mechanical grips which were constructed (by Department of Mechanical 
Engineering, University of Canterbury) for the tensile testing. The screw wedged 
grips were attached to the base of the UTM and on the load cell. Each end of 
the film strip was inserted into the grips of the sample holder and screwed to 
avoid slippage.   
 
7.13.1.3 Tensile testing on the UTM 
Films were uniaxially stretched at 50 mm/min until they broke and a stress vs 
strain graph was recorded on the computer. The stress, strain data obtained 
from the tensile test were analysed (using the in house method for New Zealand 
Institute for Crop and Food Research) and the % elongation and stress (MPa) 
of the films were determined. Three films were prepared and 3 strips per film 
were tested and the data was averaged. 
 
7.13.2 X-ray diffraction  
XRD components utilised were: Philips PW1729 X-ray generator, Philips copper 
anode Long Fine Focus X-ray tube (wavelength 1.54 Å) operating at 50 kV/40 
mA (primary beam filter was nickel), Philips PW1820 Goniometer (stepping 
motor assembly), Philips PW1752 Monochromator, Philips PW1711 X-ray 
Proportional Detector, Philips PW1710 diffractometer control linked to a PC 
running VisualXRD control software and Traces Version 4 Search/Match 
processing software. The scan speed was 0.02° 2θ/sec with a step size of 0.02° 
2θ. 
 
The PVOH + no insulin control, PVOH + insulin control, PVOH + insulin fibril 
films were analysed on the XRD with assistance from Stephen Brown, 
Department of Geology, University of Canterbury. A glass slide (3.5 cm x 2.5 
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cm) was placed in the XRD chamber to support the free-standing film. A small 
section of the film was laid on the glass slide which was clamped inside the 
chamber. The films were scanned through 2θ values ranging from 2 to 30°. 
 
7.13.3 Microscopy 
Polarising microscope, TEM and SEM were used to image the films: 
 
7.13.3.1 Polarising microscopy  
A Leica DMRE light microscope (Leica, Wetzlar, Germany), with a cross 
polarising lens, interfaced to a computer was used to detect the presence of 
amyloid in the PVOH + protein film. The protein control, fibrillised protein and 
the no protein control solutions were CR stained prior to film casting and pink 
coloured films were obtained.  
 
A small specimen of the cast film was placed on a microscope glass slide and a 
drop of water was added to moisten the specimen. The sample was covered 
with a cover slip and examined under the microscope. Samples were initially 
examined with a non polarising lens followed by the polarising lens.  
 
7.13.3.2 TEM of films 
 
Film casting solution 
TEM grids of the casting solutions composed of 2.5% PVOH + 0.6% insulin 
control and 2.5% PVOH + 0.6% insulin fibrils were prepared as per section 7.9, 
to assess insulin fibril morphology. 
 
Film cross-section (microtomed) 
The transverse section of films was studies using a Hitachi H600 transmission 
electron microscope. The PVOH + insulin composites (control and fibrils) and 
PVOH + crystallin composite (control and fibrils) were examined by TEM. 
Composites were fixed in 2.5% glutaraldehyde in 0.075% phosphate buffer for 
one hour.  After three buffer washes, samples were post fixed in 1% osmium 
tetroxide in water for 30 min. Sample were washed in buffer again and 
dehydrated in a series of 60%, 80% (acetone in water) and then 2 changes of 
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100% acetone. Infiltration was carried out overnight with two changes of Spurr 
resin/acetone mixture, followed by embedding in Spurr resin at 65°C. PVOH 
control was difficult to handle due to its solubility and fragmentation in the 
solvent. It was not fixed and was placed directly in 60% acetone. Sections 
approximately 100 nm thick were cut on an LKB Ultrotome, and stained with 
uranyl acetate and lead citrate to distinguish the protein and the matrix.  
 
7.13.3.3 SEM 
PVOH + insulin films were studied using the SEM and FE-SEM (with assistance 
from Mike Flaws, Senior Technician, Department of Mechanical Engineering, 
University of Canterbury). Imaging was carried out at an accelerating voltage of 
7 kV. The morphologies of freeze fractured surface (in liquid nitrogen) of PVOH 
+ no insulin control, PVOH + insulin control, PVOH +insulin fibrils film were 
studied using a FE-SEM. The morphologies of the cast surface of PVOH + no 
insulin control, PVOH + insulin control, PVOH +insulin fibrils film, PVOH + no 
crystallin control, PVOH + crystallin control, PVOH + crystallin fibrils films were 
examined on an SEM. Specimens were prepared by sputter coating with gold 
for both SEM and FE-SEM.  
 
7.13.4 DMA 
The viscoelastic properties of the films were studied using a Perkin Elmer 
Instruments Inc Diamond DMA (with assistance from Dr. Mark Staiger, 
Department of Mechanical Engineering, University of Canterbury). The DMA 
was operated in tension mode with nitrogen as the furnace purge gas and liquid 
nitrogen for controlled cooling. Samples were dynamically tested in tension 
mode using a frequency of 1 Hz, amplitude of 10 μm and a minimum tension 
force 300 mN, and force amplitude initial value of 4000 mN. Samples of 0.05-
0.08 mm in thickness were prepared with a gauge length of 60 mm and a width 
of 7-8 mm. The storage of modulus (E″), loss modulus (E') and tan δ (E"/E') 
were measured over the range of 0-150°C using a heating rate of 2°C/min.  
 
7.13.5 DSC-TGA 
DSC-TGA was performed on a SDT Q600 (from Alphatech Systems Ltd., 
Auckland, New Zealand) under flowing nitrogen (100 ml/min) atmosphere at 
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10°C/min (with assistance from Kelvin Walst, Department of Chemistry, 
University of Canterbury) to determine the melting point and decomposition 
temperature. Samples of more than 8 mg were placed into platinum pans 
except for crystallins, which was tested at less than 5 mg. The temperature was 
increased from ambient conditions to 600°C during the test.  
 
For the films, disk shaped specimens which were 4-5 mm in diameter were cut 
with scissors from the central regions of the cast films. The integral balance on 
the DSC-TGA measured the exact sample mass. Samples were tested in 
duplicate: PVOH from the jar, bovine insulin from the jar, crystallin extract, and 
the PVOH + protein (control/fibril) films including PVOH + no protein control 
films. Data analysis was performed on the TA Universal Analysis software, 
available on the computer attached to the DSC-TGA.  
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Figure 3.6 Electron micrographs showing the impact of pH on insulin fibrils. Samples 
were at 11.4 mg/ml: (A) insulin control in 25 mM HCl (100 mM NaCl, pH 1.6) before 
fibrillation, (B) insulin fibrils in 25 mM HCl (100 mM NaCl, pH 1.6) at 60 ºC for 12 hr, (C) 
insulin fibrils after dialysis at pH 2, (D) pH 3.5, (E) pH 4.5, (F) pH 6.5 and (G) insulin 
fibrils after dialysis in pH 6.5, re-dialysed in pH 2. All samples had been frozen at -80°C 
for 24 hr before TEM examination. These images are a representation of triplicate 
samples.  
 
 
 
 
 
 
 
 
 
 
